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Abstract 
 
DISCOVERY AND CHARACTERIZATION OF BILE ACID AND STEROID METABOLISM 
PATHWAYS IN GUT-ASSOCIATED MICROBES 
 
Spencer Harris, B.S. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2017 
 
Major Director:  Phillip Hylemon, Ph.D. 
Professor, Department of Microbiology and Immunology 
 
The human gut microbiome is a complex microbial ecosystem residing in the lumen of our 
gastrointestinal tract.  The type and amounts of microbes present in this ecosystem varies based 
on numerous factors, including host genetics, diet, and environmental factors.  The human gut 
microbiome plays an important role in normal host physiological functions, including providing 
energy to colonocytes in the form of short-chain fatty acids.  However, gut microbial metabolites 
have also been associated with numerous disease states.  Current tools for analyzing the gut 
microbiome, such as high-throughput sequencing techniques, are limited in their predictive 
ability.  Additionally, “-omic” approaches of studying the complex array of molecules, such as 
transcriptomics (RNA), proteomics (proteins), and metabolomics (previously identified 
physiologically active molecules), give important insight as to the levels of these molecules but 
do not provide adequate explanations for their production in a complex environment.  With a 
 xix 
better physiological understanding of why specific metabolites are produced by the gut 
microbiome, more directed therapies could be developed to target their production.  Therefore, it 
is immensely important to study the specific bacteria that reside within the gut microbiome to 
gain a better understanding of how their metabolic actions might impact the host.  Within this 
framework, this study aimed to better understand the production of secondary bile acid 
metabolites by bacterial in the gut microbiome.  High levels of secondary bile acids are 
associated with numerous pathophysiological disorders including colon cancer, liver cancer, and 
cholesterol gallstone disease.  In the current study, three bile acid metabolizing strains of bacteria 
that are known members of the gut microbiome were studied.  A novel strain of Eggerthella 
lenta was identified and characterized, along with the type strain, for its ability to modulate bile 
acid and steroid metabolism based on the atmospheric gas composition.  Additionally, it was 
shown that the oxidation of hydroxyl groups on primary bile acids by E. lenta C592 inhibited 
subsequent 7α-dehydroxylation by Clostridium scindens. The gene involved in the production of 
a Δ4,6-reductase enzyme, responsible for catalyzing two of the final reductive steps in the 7α-
dehydroxylation pathway, was putatively identified and characterized in Clostridium scindens 
ATCC 35704.  Lastly, the transcriptomic profile of Clostridium scindens VPI 12708 in the 
presence of numerous bile acids and steroid molecules was studied.  These studies contribute 
significantly to the understanding of why specific bile acid metabolites are made by members of 
the gut microbiome and suggest ways of modulating their production. 
 
 1 
Chapter 1:  Introduction 
 
Introduction to the human gut microbiome 
 
The human body can be thought of as a vehicle used by trillions of microscopic passengers.  In 
fact, the number of prokayotic cells associated with our bodies outnumbers our own eukaryotic 
cells by an order of magnitude (1). The overall conglomeration of microbes making up the 
“human microbiome” varies based on numerous factors including:  diet, environment, and host 
genetics, among others (2). There has been significant effort by scientists to better understand 
this complex microbial community.  Next generation nucleic acid sequencing, along with 
advances in both computational and bioinformatic analysis, allows for whole-genomic 
sequencing from both isolated strains in culture and those isolated via single-cell sorting (3) as 
well as reconstruction of these individual genomes in more complex microbial communities (4) 
and even modeling bacterial metabolic potentials (5). In tandem with these high-throughput 
analyses, the assignment of bacterial strains into operational taxonomic units (OTUs) is 
accomplished via comparison against 16S sequencing data.  The utilization of OTU classification 
has important implications, as it is used to predict metabolic potential of complex microbial 
ecosystems.  It is on the basis of OTU assignment that the observation was made that in spite of 
vast variation of microbial constituents, there is maintenance of metabolic potential across 
different individuals (2). 
 
Within this association between humans and microbes, a large amount of attention has been paid 
to the lumen of the large intestine. The anaerobic environment here harbors the highest 
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concentration of microbes in the human body, as well as a vast host mucosal layer allowing for 
direct interaction with the microbes. With over 1013 prokaryotic cells (6), the number of 
microbial genes eclipses our own by over 100-fold.  The “human gut microbiome” refers to this 
incredibly diverse microbial ecosystem and under normal physiological conditions it establishes 
a symbiotic relationship with us.  The gut microbiome has important, established roles in 
producing energy sources for gut epithelial cells (7), modulating host immunity (8, 9), and 
preventing colonization by harmful pathogens (9).  This, however, is only the beginning of our 
understanding of the complex interplay between gut-associated microbes and their hosts. 
 
Microbial fermentation of complex carbohydrates in the large intestine 
 
As with many niches in symbiotic ecosystems, there is usually an evolutionary “opening” that 
allows for abundant but otherwise unused byproducts and nutrients to be exploited for energy 
production, respiration, or used for other cellular processes.  The most quantitatively important 
example of this phenomenon in the large intestine is the plant-derived complex carbohydrates 
that escape absorption and metabolism in the small intestine. Resistant starches undergo 
anaerobic fermentation by bacteria, forming short chain fatty acids (SCFAs) (10). The three 
major SCFAs produced in human large intestine include acetate, propionate, and butyrate (11). 
Figure 1.1 depicts the structure of these three major SCFAs. SCFAs are present at a 
concentration of 13-130mM in the lumen of the gut (12), and are rapidly absorbed by the 
surrounding epithelial cells.  Buryrate is favored by the colonic epithelial cells as an energy 
source (12), but all SCFAs are an important source of energy for intestinal epithelial cells, 
contributing to an estimated 3-9% of our calorie intake per day (7). 
 3 
Figure 1.1:  Chemical structure of major short chain fatty acids produced by gut-associated 
microbes 
  
 4 
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Both propionate and acetate are detected in portal circulation (12, 13), but propionate is mostly 
metabolized by the liver, leaving acetate as the major SCFA reaching systemic circulation (13). 
It is important to note that SCFA production varies widely and is impacted by bacterial species 
present, gut transit time, pH, hydrogen partial pressure, and the availability of complex 
carbohydrate substrates (14-16). 
 
Landmark studies have been performed comparing the contributions of genetics, environmental, 
and dietary factors towards predisposition to colorectal cancer (CRC).  Native Africans eating a 
diet rich in complex carbohydrates and low in animal protein had a significantly lower rate of 
CRC compared to African Americans eating a “Western diet” low in complex carbohydrates but 
high in fats and animal protein (17, 18). The mechanism by which increased complex 
carbohydrates play into prevention of CRC has been a topic that has received a lot of attention.   
 
Both butyrate and propionate have been shown to have beneficial effects on colonocytes and gut-
associated immune cells, and also impact colorectal tumor growth.  On normal colonic epithelial 
cells, SCFAs aid in the maintenance of normal physiological functions by sustaining the integrity 
of the mucosal barrier (19, 20), regulating inflammatory responses (9, 21), and cell 
growth/differentiation (22, 23). Butyrate and propionate are inhibitors of histone deacetylases 
(HDACs), leading to induction of apoptosis in CRC cell lines (24, 25).  SCFAs also impact 
peripheral regulatory T cells (Treg) through the same HDAC inhibition, leading to an 
upregulation of forkhead box P3 (FOXP3) and enhancement of the Treg population and anti-
inflammatory function, under normal conditions (26).  Because of the dual functionality of 
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preventing CRC cell proliferation and maintaining homeostatic conditions, the production of 
SCFAs in the colon has been suggested as a means of reducing the occurrence of CRC.   
 
Microbial production of hydrogen gas in the large intestine 
 
SCFAs are not the only end products of the fermentative actions of gut microbes on 
carbohydrates in the colon.  Both carbon dioxide (CO2) and hydrogen gas (H2), found in 
abundance in the colon, are byproducts of anaerobic bacterial fermentation (27).  The majority of 
CO2 produced by gut-associated microbes is either absorbed into circulation through the 
enterocytes or is immediately utilized by other microbes in the vicinity (28).  On the other hand, 
approximately 60-70% of H2 produced remains after utilization by other microbes to be excreted 
via breath or flatus (28).  Upwards of 13L per day of H2 can be produced in the human colon 
(29), while germ-free animal studies show negligible hydrogen gas production until introduced 
to fecal slurries containing gut microbes (30).  The amount of H2 found in the lumen of the large 
intestine varies based on numerous factors, but is mainly impacted by the rate of production 
versus the rate of utilization of H2 by various members of the gut microbiota (14, 28, 29). 
 
H2 producers are relatively abundant in the gut microbiota.  Hydrogen production is common 
within the Firmicutes and Bacteroidetes phylum, the two major constituents colonizing the colon. 
In vitro studies have shown that members of the genera Roseburia (31), Ruminococcus (32), 
Eubacterium (33-35) generate H2.  Another means of microbial H2 production is through the 
oxidation of ferredoxin, pyridine nucleotides, and formate by microbial hydrogenases.  Through 
this process, anaerobic bacteria are able to rid their cells of reducing equivalents and maintain 
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intracellular redox balance.  Genes encoding various hydrogenases are widespread throughout 
bacteria known to inhabit the colon, especially in the Bacteroidetes phylum (36). 
 
Hydrogen gas utilization by microbes in the large intestine 
 
Because H2 is a major byproduct produced by many gut bacteria, microbes able to utilize it as a 
substrate would have an evolutionary advantage in the gut microbiota.  One such group of H2 
utilizers is methanogens, a group of archaea that are able to reduce CO2, methanol, or acetate to 
methane gas (CH4), using H2 as an electron donor (37).  CH4 is an entirely microbial-derived 
product, as it is neither made nor utilized by our own cells (38). The reduction of CO2 to CH4 is 
carried out by a series of dehydrogenases and reductases, forming an electron transport chain 
(38).  CO2 is first reduced and attached to methanofuran as a formyl group, then affixed to 
tetrahydromethanopterin, undergoes a dehydration followed by two reductive steps, is transferred 
to its next carrier sulfhydryl-coenzyme M along with the generation of a Na+ gradient, and 
undergoes a final reduction resulting in CH4 (39, 40) (Figure 1.2).   
 
This process is energetically favorable, the resulting change in free energy (ΔGº’) = -131 kJ/mol 
and leads to approximately one mol ATP generated for each mol CH4 formed (41).  
Methanobrevibacter smithii is the most numerically prominent methanogen found in the gut 
microbiome and can be present in up to 1010 CFU/g in stool (42).  Presence of methanogens in 
the gut microbiome is impacted by diet (17, 38), host genetics (43), and environmental factors 
(17).  Early studies on methanogens in humans used breath assays to determine presence of CH4
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Figure 1.2:  Biochemistry of the methanogenesis pathway in archaea from CO2 
 
Conversion of CO2 and H2 to methane via methanogenesis in Methanobrevibacter species starts 
by the fixation of CO2 with H2 to methanofuran.  The resulting formyl group is then transferred 
to tetrahydromethanopterin.  After a dehydration step, the resulting molecule undergoes two 
successive reductive steps (requiring additional H2).  The resulting methyl group is then 
transferred to reduced coenzyme M.  The last step requires reduced coenzyme B and the nickel-
containing porphinoid F430, and results in the production of methane.
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producers (45).  Detection of CH4 in a breath assay is indicative of relative activity of methane 
producers, although the lack of CH4 detection was not necessarily indicative of their absence 
(46).  More modern molecular techniques have been developed to screen for a highly conserved 
methanogenic gene, i.e. coenzyme M reductase (mcrA) (47, 48).  Studies have shown that 
methanogens are found in colonic samples at rates ranging from less than 103 to over 109 CFU/g 
stool (49). 
 
Methanogens have been implicated to have various effects on human health.  For instance, 
patients with terminal ileal disease, Crohn’s disease, and ulcerative colitis (UC) have been shown 
to have significantly lower amounts of CH4 excretion compared to healthy controls (50-54).  
Moreover, gene copy number of mcrA is significantly reduced in patients with UC (47).   
Whether the lack of methanogens contributes to or is merely a symptom of these disorders 
remains to be elucidated, although the reduced gut microbial diversity found in these disorders 
may contribute to the reduction in methanogenesis.  There is less definitive data surrounding the 
effects methanogens may play on CRC, and the data that exists is mixed.  Older reports indicate 
increased amounts of CH4 in patients with CRC versus control patients (55, 56), while newer 
ones show no difference or less methanogens in patients with CRC versus control patients (57, 
58).   
 
In the colon, methanogens are not the only group of microbes that are able to utilize H2.   
Sulfate reducing bacteria, are able to reduce sulfate (SO42-) as their terminal electron acceptor, 
forming hydrogen sulfide gas (H2S or HS-).  This reaction is able to utilize reducing equivalents 
from numerous electon donors, including lactate, pyruvate, ethanol, formate, SCFAs, and amino 
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acids (59, 60), although H2 appears to be the preferred electron donor for the most prevalent 
sulfate reducing bacteria found in the gut microbiome (61).  Similar to methanogenesis, 
reduction of sulfate to hydrogen sulfide gas is carried out through an electron transport chain 
(62) (Figure 1.3). Sulfate and ATP are first linked via an ATP-sulfurylase to form adenosine-5’-
phosphosulfate, which then undergoes reduction via APS-reductase leading AMP and sulfite 
(SO3--) (62). Sulfite then undergoes three successive reductive steps leading to H2S (63).  This 
process is even more energetically favorable under physiological conditions than 
methanogenesis, resulting in ΔGº’ = -152.2 kJ/mol, although the overall ATP generation is 
estimated to still be 1 mol ATP per mol H2S formed (41).   
 
Sulfate reducing bacteria with the highest activity and affinity for H2 are found within the genus 
Desulfovibrio (59) and are known members of the gut microbiome at a level of 104 to 1011 CFU/g 
wet weight (46, 64).  Newer molecular techniques screening for genes conserved in sulfate 
reduction have confirmed sulfate-reducing bacteria are relatively ubiquitous in the human gut 
microbiome (65, 66).  In addition to using numerous electron donors, sulfate can come from 
numerous sources both endogenous and exogenous, including secreted mucin, non-absorbed 
proteins, sulphur-containing amino acids, and taurine (a source of sulfite) (63, 64, 67).  Since 
both sulfate-reducing bacteria and methanogens in the gut microbiota compete for the same pool 
of H2, the deciding factor is the availability of sulfate for hydrogen sulfide production.  
Energetically, hydrogen sulfide generation is a more favorable reaction than methanogenesis.  
While presence of one strain is not mutually exclusive of the other, screening tests of human 
fecal samples have shown that patients usually harbor either methanogens or sulfate-reducing 
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Figure 1.3:  Biochemistry of sulfidogenesis in gut microbes from sulfate and taurine 
 
In the process of hydrogen sulfidogenesis from sulfate, adenosine triphosphate is first linked to 
sulfate via ATP sulfurylase.  This molecule is then reduced, forming AMP and sulfite.  Sulfite 
can also be liberated from bile acid conjugate taurine via bacteria such as B. wadsworthia (68).  
Sulfite then undergoes three successive reductions (via dissimilatory sulfite reductases) to 
ultimately produce hydrogen sulfide.  
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bacteria (46), although in situations of abundant H2 there are reports of both being present and 
active (59, 60, 69).  In vivo studies comparing methanogenesis and H2S production in mouse 
models confirm that when both methanogens and H2S producers are present and available sulfate 
is abundant, H2S production dominates and methanogenesis along with viable methanogens are 
below the limits of detection (70, 71).  By reducing the amount of sulfate available, 
methanogenesis has been shown to recover (71), suggesting a direct inverse link between H2S 
production and methanogenesis and confirming that sulfate-reducing bacteria out-compete 
methanogens for utilization of H2. 
 
High levels of H2S have been reported to have deleterious effects on human health. Several 
studies have suggested a link between ulcerative colitis and gut microbial H2S production (72, 
73) while others have refuted this claim (74).  There is a demonstrated link between UC and a 
western diet high in protein and sulfur-containing amino acids (75, 76). Similarly, removal of 
such foods from the diet of UC patients results in an improved outcome (76). Another source of 
sulfite, taurine from conjugated bile salts, has been shown to be increased in the lumen of the 
large intestine in individuals eating a western diet (77, 78).  Studies have also suggested a link 
between bacteria able to liberate sulfate from conjugated bile acids and the development of 
colitis in mice (68).  In addition to ulcerative colitis, H2S production has been associated with 
CRC.  In a mouse model of colonic dysplasia, mice given a source of sulfate had significantly 
more colonic dysplasia than those treated with a source of sulfate plus metronidazole, suggesting 
both H2S is formed by gut microbes and that it is associated with dysplasia (79).  Stool H2S 
levels in CRC cancer patients have been shown to be increased (80).  However, a concurrent 
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increase in H2S producing bacteria was not significant, suggesting that H2S producing activity 
instead of presence of H2S producing bacteria is more predictive for CRC (81, 82). 
 
One suggested link between H2S and CRC is the H2S-mediated inhibition of acyl-CoA 
dehydrogenase in colonocytes, the enzyme responsible for butyrate oxidation (83, 84).  
Inhibition of butyrate oxidation leads to increased epithelial permeability, decreased absorption 
of ions, as well as membrane lipid and mucus formation (85).  Even at physiological 
concentrations, H2S has been shown to be cause DNA damage in colonocytes, at least partially 
via stimulation of reactive oxygen species (ROS) (86, 87).  In addition to direct DNA damage, 
H2S can induce inflammatory and DNA damage repair pathways in human intestinal cells (88).  
Levels of the enzyme thiosulphate sulphotransferase, responsible for detoxifying H2S, are 
significantly reduced in patients with CRC (89).  Taken as a whole, H2S is a likely culprit for 
creating and maintaining an environment that can, over time, lead to the formation of CRC in 
individuals that have sufficient substrates promoting H2S formation in the colon. 
 
A third mechanism of utilizing H2 produced by gut microbial fermentation is through 
acetogenesis.  Acetogenesis is the process by which bacteria fix CO2 and molecular H2 to form 
acetate.  The study of acetogenesis takes its roots in the study of gas metabolism by anaerobic 
soil bacterium, as one of the first reports of this “new type of glucose fermentation” was found in 
a strain of Clostridium thermoaceticum isolated from manure (90).  Subsequent studies by 
Harland Wood and Lars Ljungdahl elucidated enzymatic pathway responsible for autotrophic 
synthesis of acetate from CO2 known as the Wood-Ljungdahl pathway (WLP) (91). The WLP is 
a multi-step enzymatic pathway that utilizes eight reducing equivalents and two CO2 to form 
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acetate (Figure 1.4).  The overall reaction yields even less energy than methanogenesis or 
sulfidogenesis, with a Gº’ = -95kJ/mol (41).  ATP is generated from ADP during the final 
substrate-level phosphorylation of acetyl-CoA to acetate (92). However, more recently it has 
been suggested that instead of acetogenesis being a pathway of energy production, it is a means 
of regenerating oxidized pyridine nucleotides and ferredoxin to maintain intracellular redox 
equilibrium (93).  As many of these bacteria are found in anaerobic environments and electron 
acceptors are at a premium, the ability of acetogens to use CO2 as an electron acceptor via the 
WLP gives them an evolutionary advantage.  In addition, the majority of acetogens are able to 
use a multitude of different electron acceptors and electron donors, making them good at 
adapting to the energy and redox requirements of their environment (94). 
 
In addition to harboring the genes for the WLP, most acetogens additionally have membrane 
bound hydrogenases that are able to interconvert their reducing equivalents in an electron 
transport chain.  One of the best-characterized examples of this is the Rhodocbacter nitrogen 
fixation (RNF) complex originally characterized in an electron transporter associated with 
nitrogenases (95-97).  The RNF complex, found in numerous strains of acetogens, couples the 
oxidation of ferredoxin (Fd) to the reduction of pyridine nucleotides and the generation of either 
a Na+ or H+ membrane gradient (98) (Figure 1.5).  This process is reversible and can help cycle 
reducing equivalents between various electron carriers (99, 100).  The gradient produced by the 
RNF complex can then be utilized to generate additional ATP, coupling acetogenesis to an ATP-
generating process in the cell in addition to regenerating oxidized electron carriers (93, 98).  Not 
all acetogens harbor RNF complexes, although those that do not usually encode some 
membrane-bound energy conserving hydrogenase system capable of interconverting reducing 
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Figure 1.4:  Diagram of acetate formation via the Wood-Ljungdahl Pathway 
 
The multistep process of CO2 fixation to acetate starts with the fixation of carbon dioxide by 
formade dehydrogenase.  Formate is then linked to tetrahydrofolate (requiring ATP) via formyl-
tetrahydrofolate synthetase.  Formyl-tetrahydrofolate is then recognized by a cyclohydrolase, 
forming methenyl-THF.  This molecule undergoes two successive reductive steps by methylene-
THF dehydrogenase and methylene-THF reductase, respectively. The resulting methyl-group is 
transferred to a corrinoid/iron sulfur protein via a methyltransferase.  Then, along with CoA and 
carbon monoxide (from reduction of CO2 by a carbon monoxide dehydrogenase), the methyl 
group is used to generate acetyl CoA via acetyl-CoA synthase.  This acetyl-CoA then undergoes 
substrate-level phosphorylation, ultimately leading in the production of acetate and the 
generation of ATP.  This process is energy-neutral (1 mol ATP used/1 mol ATP generated per 
mol acetate), but requires a significant amount of reducing equivalents (four reducing 
equivalents/mol acetate) (101).  
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Figure 1.5:  Schematic of RNF Complex and ATP Synthase in Acetogens 
 
RNF complex is a multi-subunit NADH/ferredoxin oxidoreductase capable of reversibly 
oxidizing reduced ferredoxin forming reduced NADH and generating a proton or Na+ gradient.  
Other transmembrane machinery can utilize this gradient for transport or for energy generation, 
such as an ATP synthase.  
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equivalents whilst generating an ion gradient (98, 102, 103).  More recently, acetogenesis has 
begun to garner interest as an alternative pathway of H2 elimination in the lumen of the large 
intestine.  Due to the contributions of CH4 production of livestock to global warming (104), 
acetogens have been suggested as a potential alternative probiotic in the rumen of cattle (105). 
The largest group of characterized acetogens present in mammalian gut microbiomes is from the 
Firmicutes phylum (106). However, unlike the methanogenesis and sulfidogenesis, the 
acetogenesis phenotype has also been identified in other phyla, making acetogens a more diverse 
group of H2 utilizers (107).  Studies have shown that in humans, acetogenesis during glucose 
fermentation by gut microbes contributes to up to a third of the total amount of acetate produced 
(11).  Much less is known about contributions acetogens may have on human health.  Since 
acetogens, in contrast with methanogens and sulfidogens, are a more heterogenous group of 
organisms, traditional means of molecular screening testing are less effective, though some 
studies that have screened genes from the acetogenic pathways in stool samples have found them 
at rates of 103 – 107 genes/g stool (49).  Based on the energetics, acetogenesis is the least 
energetically favorable reaction behind methanogenesis and sulfidogenesis.  However, in vivo 
data suggests acetogens are the most quantitative potential H2 utilizers present in the gut 
microbiome (11, 106). Taken together, this suggests that acetogenic utilization of H2 in the colon 
may be the prevalent method in humans that harbor neither active methanogens nor active H2S 
producers.  Ultimately, acetogenesis in the human colon can be influenced by numerous factors 
that impact microbial fermentation, the levels of available CO2 and H2, the presence of 
methanogens or sulfidogens, and presence of sulfate or sulfite for reduction. 
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Bile acid formation and enterohepatic circulation 
 
Under normal physiological conditions, microbial fermentation of complex carbohydrates and 
amino acids in the colon is quantitatively the most prevalent reaction occurring.  However, other 
exogenous and endogenous molecules also enter the lumen of the large intestine where they 
become substrates for microbial conversion.  One such group of molecules is bile acids, sterol 
molecules synthesized by hepatocytes from cholesterol.  The two major bile acids produced in 
humans are cholic acid (3α, 7α, 12α-trihydroxy-5β-cholan-24-oic acid; CA) and 
chenodeoxycholic acid (3α, 7α-dihydroxy-5β-cholen-24-oic acid, CDCA) (Figure 1.6).  Bile 
acids are conjugated to either taurine or glycine forming bile salts, resulting in their characteristic 
amphipathic nature.  Bile salts are actively secreted across the canalicular membrane of 
hepatocytes via the bile salt export pump (BSEP) (108), and subsequently stored and 
concentrated in the gallbladder during the interdigestive phase.  Upon the arrival of fatty acids 
and/or amino acids reaching the duodenum, enteroendocrine cells in the mucosal lining of the 
duodenum secrete cholecystokinin (CCK).  CCK stimulates release of pancreatic enzymes, 
inhibits gastric emptying, and induces the gallbladder to constrict (109).  This constriction causes 
the stored bile salts through the cystic duct, common bile duct, ampulla of Vater, and finally 
through the relaxed sphincter of Oddi into the lumen of the duodenum (110).  Once in the lumen 
of the small intestine, bile salts serve to aid in the sequestration and absorption of lipids and lipid 
soluble vitamins (A,D,E,K) via the formation of micelles (111).  Bile salts activate pancreatic 
lipase, producing monoglycerides and free fatty acids, which become key components of the 
mixed micelles (112).  Due to their high concentration and detergent-like actions, bile salts also 
help to prevent overgrowth of bacteria in the small 
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Figure 1.6:  Chemical structure of primary bile acids and their conjugates  
 24 
  
 25 
intestine (113).  Once the bile salts reach the terminal ileum they are actively transported across 
the apical membrane of ileal enterocytes via the apical sodium-codependent bile acid transporter 
(ASBT) (108).  They are then transported across the apical membrane of enterocytes via the 
OSTα/OSTβ transporter (114) and enter portal circulation.  When they reach the liver, bile salts 
are highly efficiently taken up through active transport across the sinusoidal membrane of 
hepatocytes via Na+ taurocholate cotransporting polypeptide (NTCP) and returned to the pool of 
bile salts (115), thus completing a process known as enterohepatic circulation.  Enterohepatic 
circulation of bile salts is only approximately 95% effective, allowing 400-800mg/day of bile 
salts to escape into the large intestine where they become substrates for numerous microbial 
biotransformations (113). 
 
Bile acid metabolism by gut microbes 
 
Beginning in the ileum and occurring in earnest once in the large intestine, the first reaction bile 
salts undergo is deconjugation of bile acids from their taurine or glycine conjugate via bile salt 
hydrolases (BSH) (116).  Typically the ratio of glycine:taurine conjugation in humans is 3:1, 
however this is impacted by diet. It has been shown that individuals on a “Western diet” have 
predominantly taurine conjugation, while individuals on a vegetarian diet shift towards glycine 
conjugation (77, 78).  BSH activity is widely present in the microbes populating both the large 
and small intestines.  Gram-positive commensal bacteria with BSH activity include Clostridium 
(117, 118)), Enterococcus (119), Bifidobacterium (120, 121), and Lactobacillus (122, 123).  
BSH activity is less widespread in commensal Gram-negative bacteria, but include members of 
Bacteroides genus (124).  Gut-associated archaea Methanobrevibacter smithii and 
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Methanosphera stadmanae have also been found to have BSH activity (116).  BSH enzymes 
specifically hydrolyze the N-acyl bond on the 24th carbon that is responsible for linking the 
amino acid conjugate to the bile acid (Figure 1.7) (125).  Studies that have characterized BSH 
activity from purified enzymes show that their pH sensitivities tend to be between 5-6, are 
located intracellularly, and have higher activity on glycine-conjugated bile salts (121, 126-128).   
 
Once bile acids are liberated from their conjugate, they become substrates for numerous 
microbial biotransformations.  7α-dehydroxylation is a process by which a small group of 
bacteria within the Clostridia genus are able to remove the hydroxyl group from the seventh 
carbon of both CA and CDCA forming secondary bile acids deoxycholic acid (3α, 12α-
dihydroxy-5β-cholen-24-oic acid; DCA) and lithocholic acid (3α-monohydroxy-5β-cholen-24-
oic acid; LCA), respectively (113) (Figure 1.7).  This process is unique to gut microbes, as 
hepatocytes do not produce secondary bile acids nor are they found in fecal samples of germ free 
animals (129, 130). Studies measuring fecal bile acid composition show that secondary bile acids 
form the major constituency (113), suggesting that even though only approximately 0.0001% of 
gut microbes harbor the 7α-dehydroxylation pathway (131), it is the most quantitatively 
significant biotransformation of primary bile acids by gut microbes after BSH.  In metagenomic 
analyses, C. scindens, a well-characterized 7α-dehydroxylating species, has been shown to be a 
member of the “core gut microbiome” in humans, due to its high rate of prevalence in human 
fecal samples (132).  DCA, and to a smaller degree LCA, both passively diffuse across the 
epithelial barrier and enter portal circulation, where they are reabsorbed by the liver and  
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Figure 1.7: Diagram of bile salt biotransformations by gut bacteria 
 
Endogenous bile salts are produced by the liver and then undergo biotransformation by gut 
microbes.  Bile acids are liberated from their conjugates by microbial bile salt hydrolases.  
Primary bile acids then undergo numerous further reactions, such as oxidation and epimerization 
(bottom) or 7α-dehydroxylation (right).    
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accumulate in the bile acid pool, since human hepatocytes cannot perform 7α-hydroxylation 
(133).   
 
While bile acids had seen usage as “liver tonics and laxatives” earlier, contemporary scientific 
interest in both primary bile acids and secondary bile acids began after determination of their 
chemical structure in 1932 (134).   In 1946, an effective method for developing cortisone from 
DCA was developed (135). Three years later the use of cortisone in patients was shown to cause 
significant improvement in patients dealing with rheumatoid arthritis (136).  However, since at 
the time the only source for DCA was from bile isolates from livestock, pharmaceuticals began 
to worry there would not be enough supply to cover the demand for cortisone (134), and as a 
result plant sterols became used as a more widespread and effective precursor to cortisone (137). 
As such, interest in bile acids dwindled but for a few dedicated laboratories.  However, work on 
bile acids continued in a Swedish laboratory run by Sune Bergström where means of tracking H3 
and 14C incorporation into bile acids (138), as well as GC and MS techniques for measurements 
of bile acids were developed (139).  Bergstrom and colleagues were the first to distinguish 
primary bile acids, made by the host, and secondary bile acids, made by commensal intestinal 
microbes (140, 141).  In this earliest work of determining the pathway for microbial conversion 
of primary bile acids to secondary bile acids, it was proposed that the mechanism was a two-step 
process with a single intermediate, cholen-6-oic acid (142). However, subsequent work by 
Hylemon et al. of CA-induced conversion of [24-14C]-CA by Clostridium scindens showed the 
formation of numerous bile acid metabolites (143). MS identification of the metabolites and 
chemical synthesis and introduction to CA-induced Clostridium scindens showed DCA was the 
major end product, suggesting these were intermediates in the formation of DCA (143).  Taken 
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together, it was suggested that the formation of secondary bile acids by 7α-dehydroxylating 
bacteria was an inducible, multi-enzymatic process. 
 
Although 7α-dehydroxylation of primary bile acids leads to the most abundant end products, 
there are several other biotransformations that bile acids can undergo in the large intestine.  
Members of the intestinal microbiota have genes that encode a variety of pyridine nucleotide-
dependent hydroxysteroid dehydrogenases (HSDH).  HSDHs are widely distributed throughout 
various members of the gut microbiota (113).  Gut microbes are known to be capable of 
oxidation and reduction of the hydroxyl groups on the 3-, 7-, and 12- carbons of bile acids 
(Figure 1.7).  The epimerization of bile acid hydroxyl groups (α ↔ β) requires two position-
specific bile acid α- and β- HSDHs, which generate a stable oxo-bile acid intermediate i.e., 7α-
hydroxy ↔ 7-oxo ↔ 7β-hydroxy.  Bacterial bile acid HSDHs differ in their pH optima, pyridine 
nucleotide specificity (NAD(H), NADP(H), or both), subunit molecular weight, and gene 
regulation (113).  Amino acid sequence analysis suggests that most bacterial HSDHs in the gut 
microbiota belong to the short-chain alcohol/polyol dehydrogenase family (113). Bile acid 
HSDHs have been found and characterized in numerous genera inhabiting the lumen of the 
colon, including Bacteroides (144, 145), Clostridium (146-148), Escherichia (149), Eggerthella 
(150), Eubacterium (151-154)), Peptostreptococcus (155), and Ruminococcus (156, 157). 
 
Bile acids with oxidized hydroxyl groups (oxo-bile acids) have been shown to be present in fecal 
bile acids (158-160), portal circulation (161, 162), and human serum (163).  Interestingly, the 
hydroxyl groups on dihydroxy-bile acids (DCA, CDCA) have been shown to be more sensitive 
to microbial oxidoreduction than trihydroxy-bile acids (CA) (164).  Also, cholecystectomised 
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patients have been shown to have increased levels of oxo-bile acid derivatives in enterohepatic 
circulation (165).  This observation is likely that due to the increased levels of bile acids being 
seen by the gut microbes in cholecystectomised patients leading to increased microbial 
biotransformation.  The extent of epimerization and the accumulation of oxo-bile acids appears 
to be influenced by the oxidation/reduction potential of the local cellular environment.  For 
example, the formation of oxo-bile acids may be more favorable in bacteria associated closer to 
the mucosal edges, where there is a higher redox potential than further inside the lumen of the 
intestines (125). 
 
Consequences of bile acid metabolism on microbial and host physiology 
 
To understand the effects of microbial biotransformations of bile acids on host and microbial 
physiology, it is important to first discuss the effects that bile acids have on normal host 
physiology.  Near the turn of the millennium, it was discovered that endogenous bile acids were 
ligands for the orphan nuclear receptor farsenoid X receptor (FXR) (166, 167).  Under normal 
physiological conditions, primary bile acids CA and CDCA activate FXR in enterocytes, leading 
to expression of fibroblast growth factor 15/19 (FGF15/19) (168).  FGF15/19 then acts on the 
hepatic FGFR4 receptor in hepatocytes and, among other effects, leads to a down-regulation of 
CYP7A1, the rate-limiting enzyme of bile acid synthesis (169).  Through this pathway, bile acids 
are able to effectively inhibit their own synthesis. 
 
Soon after the discovery of FXR activation by bile acids, it was shown that transmembrane G-
coupled protein receptor 5 (TGR-5), a widely distributed receptor throughout human cells, is 
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activated by bile acids (170, 171).  TGR-5 is a Gαs receptor that leads to an increase in 
intracellular c-AMP (172).  It has been reported that activation of TGR-5 can lead to the release 
of glucagon-like peptide 1 (GLP-1), which has roles in glucose homeostasis as well as appetite 
suppression (173).  Subsequent work also showed bile acids as ligands for pregnane-activated 
receptor (PXR) (174), vitamin D receptor (VDR) (175), sphingosine-1 phosphate receptor 2 
(S1PR2) (176), and some muscarinic receptors (M2,3) (177).   
 
While primary bile acids have been shown to be agonists for many different receptors, the 
potency of their activation differs based on their substituents.  In addition, secondary bile acids 
produced by gut microbes have differing and sometimes more potent agonist properties than 
primary bile acids.  In the case of FXR, primary bile acid CDCA appears to be the most potent 
activator, but both secondary bile acids LCA and DCA are more potent than CA (167).  
Similarly, PXR appears to be most potently activated by LCA (174), VDR by 3-oxo-LCA (175), 
and TGR-5 by DCA and LCA (170).  Taken together, this suggests that not only can bile acids 
modulate the structure of the gut microbiome, but the microbes can also modulate host 
physiology by the creation of secondary bile acid “hormones” (178).   
 
In addition to modulating normal host physiology, bacterial bile acid metabolites such as DCA 
and LCA also have roles in pathophysiological disorders.  There is a body of evidence 
suggesting a link between secondary bile acids (DCA and LCA) and numerous gastrointestinal 
diseases, including colon cancer (67), liver cancer (179), and cholesterol gallstone disease (131).  
Both LCA and DCA levels are increased in fecal samples of CRC patients compared to control 
(180).  In African Americans, when compared to rural, native Africans, a high-fat diet is 
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correlated with increased levels of DCA/LCA as well as an increased rate of CRC (18).  DCA 
and LCA have been shown to be effective enhancers of mutagenesis (181, 182), and in rats 
endogenous levels of secondary bile acids led to increased CRC tumor numbers and invasiveness 
(183).  In addition, rats supplemented with DCA show decreased production of protective 
SCFAs when compared to control, along with significant changes to the makeup of the gut 
microbiota away from SCFA-producing bacterial species (184).   
 
The mechanism by which DCA and LCA may contribute to the formation of CRC is an area of 
significant study.  Based on their hydrophobicity, DCA and LCA can cause membrane 
pertubations in colonocytes (185).  Chronic exposure to secondary bile acids has been shown to 
lead to resistance to apoptosis and enhanced cell proliferation in many epithelial cell lines (186, 
187).  Secondary bile acids have been shown to generate reactive oxygen and reactive nitrogen 
species, can cause DNA double-stranded breaks, and inhibit DNA repair mechanisms (188, 189).  
They also cause NF-κB activation in intestinal epithelial cells, which can promote CRC 
development (126, 188, 190-192).  It has been suggested that DCA may directly stimulate CRC 
progression through activation of protein kinase C, which effects growth regulation, 
differentiation, and apoptosis (193).  DCA has also been shown to cause hypomethelation of 
DNA, leading to increased transcription of proto-oncogenes (194).  In CRC cells, DCA has been 
shown to phosphorylate β-catenin, causing increased invasiveness (195).  DCA can also prevent 
apoptosis in CRC cells via activation of EGFR, NF-κB, and Akt (188, 196, 197).  While 
secondary bile acids themselves have not been shown to be carcinogenic (67), they produce an 
environment both in the microbiota (decreased production of protective SCFAs) and in the 
enterocytes themselves that promotes progression of CRC.  These effects on colonocytes also 
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seem to be dose-dependent, as low concentrations of bile acids and secondary bile acids appear 
to be protective, while higher concentrations have deleterious effects. 
 
Even oxidized or epimerized bile acids have differing effects on host physiology.  3-oxo-LCA 
has been shown to be the most potent agonist for the VDR (175).  Epimerization of the 7α-
hydroxyl group on CDCA yields a much more hydrophilic and therefore less toxic metabolite 
ursodeoxycholic acid, which has been shown to be protective against CRC-inducing effects of 
DCA (157).  Recent studies reported that 7-oxo-lithocholic acid acts as a competitive inhibitor of 
human hepatic 11β-HSDH-1 (198).  11β-HSDH-1 is responsible for converting 7-oxo-LCA back 
to CDCA, however it also catalyzes the activation of cortisol from cortisone (199).  When 7-oxo-
LCA is in high enough concentrations, it acts as a competitive inhibitor preventing production of 
active cortisol.  7-oxo-LCA and ursodeoxycholic acid are both less potent agonists of FXR than 
the endogenous bile acid they are formed from, CDCA (167).  Since the expression of the 
antimicrobial peptide cathelicidin is controlled by FXR in enterocytes, it follows that by 
lessening the affinity of bile acids for FXR, an otherwise susceptible microbe could increase its 
fitness in the lumen of the large intestine.  The full extent to which alteration in bile acid 
hydroxyl oxidation or epimerization effects host metabolism is a field that requires more 
significant study. 
 
The effects of bile salt biotransformations is not restricted to host-microbe interactions, as there 
are many microbe-microbe interactions that occur as a result of bile salt metabolism.  Taurine 
can be found conjugated to primary bile acids and is more prevalent in the bile acid pool of those 
eating a Western diet (78).  When liberated from bile acids through BSH activity by microbes in 
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the intestinal tract, taurine becomes a substrate for further bacterial metabolism.  Microbes are 
able to utilize taurine as an energy source via Stickland fermentation (200).  In addition, the 
formation of H2S through metabolism of taurine by Bacteroides has been shown to enhance 7α-
dehydroxylation by Clostridium sp. in germ-free mice colonized with both bacterial strains 
(201).  Addition of taurocholic acid to a low-fat diet in IL-10 deficient mice led to a bloom of 
sulfate-reducing bacteria and induced colitis (68).  These effects seem to be specific for taurine 
conjugation, as glycine liberated from bile salts has not been shown to be a source of sulfate for 
H2S production nor does it induce 7α-dehydroxylation. 
 
Bile acid 7α-dehydroxylation has recently been shown to have consequences for Clostridium 
difficile colonization and growth in the gastrointestinal tract.  C. difficile infection, the causative 
agent of antibiotic-associated diarrhea and colitis, is a significant health concern for patients 
taking broad-spectrum antibiotics (202).  An estimated 29,000 deaths are attributed to C. difficile 
infection (CDI) in the US every year (203), and the numbers are expected to increase as the 
aging population becomes more colonized.  Although rates of C. difficile colonization vary 
significantly, it has been reported that up to 90% of healthy neonates and infants, 15% of healthy 
adults, and 51% of elderly patients are asymptomatic C. difficile carriers (204).  Treatment of 
patients with broad-spectrum antibiotics, especially in hospital settings, leads to a decreased level 
of protective gut microbes which allows for the over proliferation of C. difficile which tend to be 
resistant in their spore form (205).  Once induced to germinate in the GI tract, increased C. 
difficile proliferation leads to overproduction of vegetative cells that produce toxin A and B 
causing diarrhea and severe colitis in some patients (206).  In patients with relapsing C. difficile 
infection, approximately 17% of patients do not respond to metronidazole or vancomycin 
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treatment (207).  However, fecal transplants of gut microbiota from healthy donors have been 
shown to be a successful treatment, with 81% having resolution of CDI after the first fecal 
infusion and 94% having resolution after a second fecal infusion (208).  Initial reports indicated 
an increased fecal bacterial diversity in fecal-infused CDI patients, as well as an increase in 
Bacteroidetes and Clostridium sp. as well as a decrease in Proteobacteria species (208).  A more 
directed attempt to ascertain the gut microbes that were responsible for resistance to CDI 
suggested that Clostridium scindens, the group of bacteria responsible for production of 
secondary bile acids, was strongly associated with inhibition of Clostridium difficile colonization 
and antibiotic-induced CDI in animal models and human patients (209).  Earlier work on C. 
difficile linked bile salts and bile acids to germination of spores, showing that when CA, TCA, or 
DCA were added germination of C. difficile spores occurred (210, 211).  Later work by Sorg et 
al showed C. difficile specificity for specific bile acids, as taurocholate, cholate, and 
deoxycholate induced germination in vitro but chenodeoxycholate did not (212).  It was later 
shown by the same group that chenodeoxycholate competitively inhibits taurocholate 
germination of C. difficile spores (213).  More recent work found a germinant receptor (CspC) in 
C. difficile was recognized specifically by 12α-hydroxylated bile acids (214).  Binding to this 
receptor led to the release of Ca2+ dipicolinic acid from the inside of the spore and subsequent 
influx of water, ultimately leading to growth into a vegetative cell (214).  Some recent studies 
have shown that secondary bile acids inhibit C. difficile growth in vitro (215) and that 
ursodeoxycholic acid inhibits C. difficile growth and sporulation (216).  Since C. scindens are the 
major producers of secondary bile acids, it would follow that these secondary bile acids are the 
mechanism by which C. scindens is associated with protection against CDI.  However, 
experimental proof of C. difficile growth inhibition by physiological concentrations of secondary 
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bile acids in vitro or in vivo is lacking.  Furthermore, a molecular mechanism by which DCA 
inhibits growth (as opposed to germination) is also absent.  More work to determine the interplay 
between these bacteria in the colon is necessary, but the potential for a probiotic to prevent 
against CDI is an exciting prospect.   
 
Research Objectives: 
 
The research described in this thesis is aimed at better understanding numerous mechanisms by 
which gut-associated bacteria metabolize bile acid and steroid molecules and how this 
metabolism is linked to overall microbial physiology in the anaerobic environment of the colon.   
Within this framework, three objectives were pursued.  The first objective was the 
characterization of a novel strain of Eggerthella lenta, screening and comparing its ability to 
metabolize various primary and secondary bile acids and steroid molecules, and linking its 
unique pattern of bile acid metabolites with specific gene clusters linked to acetogenesis.  The 
second objective was the discovery of a gene in Clostridium scindens ATCC 35704 responsible 
for the production of a Δ4,6-reductase that catalyzes two of the three reductive steps of the 7α-
dehydroxylation pathway.  The third objective was the utilization RNA-seq analysis to determine 
the transcriptomic changes in Clostridium scindens VPI 12708 treated with various steroid and 
bile acids, with the ultimate goal of locating the gene encoding a 17α-hydroxysteroid 
dehydrogenase responsible for production of epitestosterone from androstenedione.  The work in 
this thesis gives better insight into the 7α-dehydroxylation pathway in Clostridium scindens.  In 
addition, a unique interplay between atmospheric gases, bile acid oxidation, and 7α-
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dehydroxylation was discovered and evidence put forth to characterize Eggerthella lenta as an 
acetogen.  
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Chapter 2:  Materials and Methods 
 
Bacterial strains and materials 
 
Clostridium scindens ATCC 35704 obtained from ATCC, Clostridium scindens VPI 12708 
obtained from Virginia Polytechnic Institute, Clostridium absonum ATCC 27555 obtained from 
ATCC, and human fecal isolates C592, I10, SA14, 19BHI, KS11, SO46, SO77 from 
collaborators at Ryukyus University in Okinawa, Japan are maintained as -80°C glycerol stocks 
in our laboratory.  Eggerthella lenta ATCC 25559 was acquired commercially (ATCC).  Before 
further analysis, strains were propagated on brain heart infusion (BHI) agar plates and grown 
under anaerobic conditions in Brewer jar with AnaeroPack (Mitsubishi) for 48 hours at 37°C, 
and colonies were picked and grown individually.  Unless otherwise noted, bacterial strains were 
grown in liquid BHI broth (Becton, Dickinson) in round bottom flasks anaerobically under 100% 
N2 gas atmosphere (Airgas), supplemented with 5g/L yeast extract (Becton, Dickinson), 1g/L 
cysteine HCl (Sigma) and 40mL/L of a salt solution containing 0.2g CaCl2, 0.2g MgSO4, 1g 
K2HPO4, 1g KH2PO4, 10g NaHCO3 per liter.  When arginine (Sigma) was used, it was added 
separately to the media to a final concentration of 5g/L (0.5% wt/volume) or 10g/L (1% 
wt/volume).  Chenodeoxycholic acid (3α-, 7α- dihydroxy-5β-cholan-24-oic acid; CDCA), cholic 
acid (3α-, 7α-, 12α-trihydroxy-5β-cholan-24-oic acid; CA), and deoxycholic acid (3α-, 12α-
dihydroxy-5β-cholan-24-oic acid, DCA) were obtained from Sigma.  Allocholic acid (3α-, 7α-, 
12α-trihydroxy-5α-cholan-24-oic acid; ACA), androst-4-ene-3,17-dione (androstenedione), 
androst-4-en-17β-ol-3-one (testosterone), and androst-4-en-17α -ol-3-one (epitestosterone) were 
obtained from Steraloids.  [24-14C]-labeled CDCA and CA were obtained from American 
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Radiochemicals.  [24-14C] DCA and lithocholic acid (3α-monohydroxy-5β-cholen-24-oic acid; 
LCA) were produced biologically.  Before addition to culture, bile acids were suspended in 
methanol to a concentration of 10mM before being diluted to their final concentration in culture 
media. 
 
Production of radiolabeled secondary bile acids and bile acid metabolism screening 
 
For numerous experiments, [24C-14C]-bile acid biotransformation to secondary metabolites was 
screened.  Unless otherwise noted, bile acid biotransformation profiles were investigated in 
whole cell cultures grown at 37ºC overnight in anaerobic BHI medium under 100% N2 
atmospheric gas.  For primary bile acid biotransformation screens, cultures were grown in the 
presence of 25µM bile acids and 1µCi labeled bile acids.  For secondary bile acid metabolism 
screens, cultures were grown in the presence of 25µM secondary bile acids with varying amounts 
of analogous [24-14C]-labeled bile acids. Culture growth was monitored using UV 
spectrophotometry (BioMate 3), monitoring at 600nm.  Once adequate growth was observed, 
cultures were acidified to pH = 3.0 by adding 1N HCl (Sigma) and confirmed via pH meter.  
Cultures were then extracted with 2x volume ethyl acetate (Fischer Scientific).  The organic 
layer was isolated and concentrated under a stream of N2 gas.  Organic extracts were then 
suspended in methanol, spotted, and run on silica gel TLC plates (J.T. Baker) with a 75:20:2 
benzene:dioxane:acetic acid (Sigma) mobile phase.  Plates were exposed to MS autoradiographic 
film (Kodak) overnight and bands corresponding to bile acid metabolites were scraped off and 
quantified using liquid scintillation spectrophotometry (RPI Budget-Solve; Tri-Carb 2100TR).  
These biotransformation of [24-14C]-labeled bile acids experiments were run alongside unlabeled 
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bile acid biotransformation experiments, separated on the same TLC plates as described above, 
and the corresponding unlabeled bands were scraped and isolated for future MS analysis. 
 
Bile acid metabolite characterization 
 
For future MS analysis, 100mL C592 cultures were grown to stationary phase as stated above in 
the presence of 25µM CDCA or DCA with and without [24-14C] radiolabel.  Bile acid 
metabolites were extracted, separated, and isolated as stated above and then underwent LC-MS 
analysis.  LC-MS analysis was run on a Shimadzu UPLC coupled with a Shimadzu LCMS-IT-
TOF System (Shimadzu Corporation, Kyoto, Japan).  The LC operating conditions were as 
follows: LC column, C-18 analytical column (Capcell Pak C18, Shiseido, Japan), 250 mm × 2 
mm i.d., particle size - 3µm (C18 (RP18, ODS, Octadecyl); mobile phase, H2O containing 0.1% 
formic acid (A), and acetonitrile containing 0.1% formic acid (B); total flow rate of mobile 
phase, 0.2 ml/min; total run time including equilibration, 41 minutes.  The initial mobile phase 
composition was 70% mobile phase A and 30% mobile phase B. The percentage of mobile phase 
B was changed linearly over the next 5 minutes until 35%.  Over the next 25 minutes, the 
percentage was increased to 98% linearly.  After that the percentage was maintained for 5 
minutes, the mobile phase composition was allowed to return to the initial conditions and 
allowed to equilibrate for 5 minutes.  The injection volume was 10 µL.  The mass spectrometer 
(LCMS-IT-TOF) was operated with an electrospray ionization (ESI) source in both positive and 
negative ion mode with multiple reaction monitoring (MRM).  The nebulizer gas pressure was 
set at 150kPa with the source temperature of 200°C and the gas flow at 1.5L/min.  The detector 
voltage was 1.65kV.  High-purity nitrogen gas was used as collision cell gas. The raw 
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chromatograph and mass spectrogram data were processed with the LC solution Workstation 
software (Shimadzu).  For further characterization of C592 CDCA metabolites, as well as the 
production of 3-dehydro-DCA for putative Δ4,6-reductase screening, radiolabeled CDCA, DCA, 
putative 7-oxo-CDCA, and putative 7-oxo-isoCDCA were treated with 0.25 unit/mL purified 3α-
hydroxysteroid dehydrogenase (Sigma) for one hour in the presence of 150µM NAD+ (Sigma) in 
0.1M Tris-HCl buffer (pH 8.0).  Enzymatic reaction was quenched with ethyl acetate and 
separated on TLC as described above. 
 
Steroid metabolism screening 
 
Similar to bile acid metabolism screening, steroid metabolism screening was performed in whole 
cell cultures grown at 37ºC overnight in anaerobic BHI media under 100% N2 gas.  For whole 
cell biotransformation screening of androstenedione, testosterone, and epitestosterone 
metabolism, cultures were grown in the presence of 25µM of the steroid molecule.  Once 
adequate growth was observed, growth was quenched with the addition of 2x volume ethyl 
acetate.  The organic layer was then isolated, the solvent evaporated, and the extract suspended 
in 500µL methanol.  One hundred microliters were injected and run on high-pressure liquid 
chromatography (Agilent) using a C-18 reverse phase column (Agilent Eclipse XDB-C18), 50:50 
methanol:water mobile phase at a flow rate of 1mL/min, as adapted from previous work in (217).  
Absorbance of steroid metabolites was monitored at 240nm by UV-Vis spectroscopy.  The C. 
scindens VPI 12708 androstenedione metabolite was fractionally collected and sent for NMR 
analysis, which was performed as previously described (217).  For TLC separation of 11β-
OHAD and hydrocortisol cell culture biotransformation screens, organic extracts were run 
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similarly to described above except for the use of a different mobile phase:  5:25:0.2 isooctane; 
ethyl acetate; glacial acetic acid. 
 
Primer design, polymerase chain reaction, and plasmid construction 
 
Genomic DNA from C. scindens ATCC 35704, C. scindens VPI 12708, and C592 were isolated 
as described previously (218).  Genomic DNA was then used as template for further PCR and 
genomic sequencing.  A streptavidin tag engineered into the reverse primer (for EDS08212.1 and 
various putative 17α-HSDH candidates) or the forward primer (various putative 17α-HSDH 
candidates) and genes to test for activity were PCR amplified, restriction digested, and ligated 
into expression vectors.  Generic 16S primers (16s357F, 16s1392R) and ExTaq polymerase kit 
(Takar) were used for initial 16S screening of Eggerthella lenta strain C592.   
 
Methods for PCR amplification and plasmid construction are based on previously published 
methods (217).  The gene encoding the putative Δ4,6 reductase, EDS08212.1, was PCR 
amplified using the TITANIUM TAQ PCR Kit (Clontech) using primers designed to include the 
E. coli ribosome binding site and KpnI restriction site on the forward primer and a streptavidin-
affinity peptide encoding sequence and BamHI restriction site on the reverse primer.  The PCR 
product was purified through gel electrophoresis, underwent restriction endonuclease treatment 
(Kpn1 and BamHI), and was ligated into the pSport1 expression vector.  Recombinant plasmid 
was transformed into chemically competent E. coli DH5α cells via heat stock method, plated, 
and grown for 16 hours at 37 °C on lysogeny broth (LB) agar plates supplemented with 
ampicillin (100 µg/mL). A single colony from each transformation was inoculated into LB 
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medium (5 mL) containing ampicillin (100 µg/mL) and cultivated overnight at 37°C with 
agitation. The cells were subsequently centrifuged (3220 x g, 15 min, 4 °C) and plasmids were 
extracted from the resulting cell pellet using the QIAprep Spin Miniprep kit (Qiagen, Valencia, 
CA). The foreign DNA inserts in the recombinant plasmids were sequenced to confirm the 
correctness of the gene sequence (Virginia Commonwealth University Nucleic Acid Sequencing 
Core Facility, Eurofins Genomics).  Similar methods were used for putative 17α-HSDH genes of 
interest.  In some cases, troubleshooting changes were made via altering the streptavidin tag 
presence and location (C-terminal tag, N-terminal tag, or No strep tag), varying restriction 
endonuclease sequences, and utilization alternative expression vectors (pASK-IBA15plus and 
pASK-IBA43plus). 
 
C592 genomic sequencing 
 
Genomic DNA (1.5µg) was sheared in a gTube (Covaris, Woburn, MA) for 1 minute at 6,000 
rpm in an Eppendorf MiniSpin plus microcentrifuge (Eppendorf, Hauppauge, NY). The sheared 
DNA was converted into a Nanopore library with the Nanopore Sequencing kit SQK-NSK007 
(Oxford Nanopore, UK). The library was sequenced on a SpotON Flowcell MK I (R9) flowcell 
for 48 hours, using a MinION MK 1B sequencer. Basecalling was performed in real time with 
the software Metrichor version 2.40.17.  Poretools v-0.5.1 software (219) was used to extract 
sequences from Oxford Nanopore MinION output file folder, and then converted to fastq format.  
FastQC v-0.11.2 software was also used to further access quality scores and other attributes of 
the data set.  A Perl script was then used to trim adaptors from the raw nanopore reads. The 
adapter trimmed reads were used to blast against NCBI Ecoli_strK12_MG1655 genome.  Reads 
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with greater than 95% alignment to this genome were removed.  2,113,230 reads from the 
Illumina paired end MiSeq run and 14,023 reads from Oxford Nanopore sequencing platform 
were used for de novo hybrid assembly with SPAdes-v3.9.0 (220). The assembly produced 245 
contigs, five of which were 500 base pairs and longer. The top five contigs were selected to blast 
NCBI NT database.  Nucleotide level comparisons between Eggerthella lenta DSM 2243 
genome and the longest contig from the assembly were done with the dnadiff program from 
MUMmer v-3.23 (221).  Annotation comparisons between Eggerthella lenta DSM 2243 genome 
and the longest contig were made with Prokka v-1.11 (222).  Annotated CDS file for the longest 
C592 contig were then imported into Geneious v9.1.3 for Mauve alignment and further analysis, 
as well as utilized to form KEGG maps via BlastKOALA (223).  
 
C. scindens VPI 12708 RNA purification and Illumina sequencing 
 
After -80ºC stock of C. scindens VPI 12708 was grown overnight at 37ºC in BHI broth, a 1% 
inoculum was transferred to 100mL BHI containing 25µM of either: cholic acid, allocholic acid, 
androstenedione, cortisol, or only BHI (for uninduced control) along with relevant [24-14C]-bile 
acid.  Cells were allowed to grow to early-log phase, an additional 25µM of the inducing 
molecules were added, and then at mid-log phase cells were pelleted by centrifugation.  Pelleted 
cells were immediately suspended in RNALater (Ambion) and placed in -80ºC freezer.  
Supernatant was extracted and the metabolism of all four molecules in culture was confirmed via 
TLC and HPLC analysis, as outlined above.  
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Isolation of mRNA from C. scindens VPI 12708 follows a similar procedure to previously 
published work (Ridlon 2013). Cell pellets were suspended in 500µL lysis buffer (200mM NaCl, 
20mM EDTA, in diethylpyrocarbonate-treated water) and then transferred to 2mL bead beating 
tubes (Sarstedt).  To each tube, 1mL 5:1 acid phenol (Ambion), 200mL 20% SDS (Ambion), and 
200µL zirconium beads was added.  Cells were then disrupted on max RPM on a Mini-
BeadBeater (Biospec Products) for one-minute increments twice and placed on ice in between.  
Samples were then centrifuged to separate the aqueous and phenol phases.  The aqueous phase 
was isolated and subsequently washed with an additional 1mL of 5:1 acid phenol, and then 
separated again via centrifugation.  The nucleic acids in the purified aqueous phase were 
precipitated by addition of 2x volume of 2-propanol (Sigma), 100µL ammonium acetate 
(Ambion), and 1µL glycoblue (Ambion).  Samples were incubated at -80ºC overnight, 
centrifuged for 30 minutes, and the pellet isolated.  RNA was isolated from the nucleic acid 
samples using the Ambion “Megaclear” kit, according to the manufacturers instructions.  
Purified RNA samples were treated 2x with DNAse (Takara), following manufacturers 
instruction. Resulting RNA was checked for purity via a 1.6% denaturing gel electrophoresis (for 
16S and 23S bands) as well as via RT-PCR to check for contaminating genomic DNA following 
the Clontech manufacturer instructions. 
 
Purified total RNA then underwent mRNA enrichment protocol, following a similar procedure to 
previously published work from our lab (217). Custom biotinylated TEG-spaced 
oligonucleotides were designed against C. scindens VPI 12708 16S and 23S rRNA sequences.  
Dynabeads M-280 Streptavidin (Invitrogen) were made RNAse free and then bound to 
oligonucleotides by resuspending beads in 500uL DEPC 0.5x SSC containing 360 pmol of each 
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oligonucleotide.  Beads were captured using Promega magnetic stand (Promega).  After 
oligonucleotide beads were isolated, the rRNA capture-hybridization protocol was run using a 
Biorad C1000 thermocycler (Biorad).  Total RNA (1µg) was suspended in 35uL 6x SSC, heated 
to 70ºC for 5 minutes, cooled to 0ºC for 3 minutes, and then 150uL of oligonucleotide-bound 
beads were added.  The mixture was then incubated at 68ºC for 30 minutes.  Beads were 
magnetically captured using the Promega stand, and the supernatant containing the enriched 
mRNA was isolated and precipitated as described above.  Total RNA and enriched mRNA were 
compared using Bioanalyzer to see a distinct drop in the bands corresponding to rRNA subunits 
before RNAseq analysis. 
 
mRNA-enriched C. scindens VPI 12708 samples were then used to create libraries for Illumina 
whole transcriptome sequencing using the NEBNext Ultra RNA Library Prep Kit for Illumina, 
following manufacturer’s instructions (NEBNext).  Samples were then run using MiSeq 
instrumentation using a 2 x 300 bp recipe.  Resulting reads were then were aligned to a 
previously annotated C. scindens VPI 12708 genome using the BowTie2 algorithm. 
 
Protein overexpression and purification 
 
For the putative Δ4,6-reductase gene expression, pSport-EDS08212 plasmid was transformed 
into E. coli BL-21 CodonPlus (DE3) RIPL chemically competent cells by the heat shock method 
and grown overnight at 37 °C on LB agar plates supplemented with ampicillin (100 µg/mL). 
After 16 hours, five isolated colonies were used to inoculate 10 mL of fresh LB medium 
supplemented with antibiotics and grown at 37 °C for 6 hours with vigorous aeration. The pre-
 48 
cultures were then added to fresh LB medium (1L), supplemented with the same antibiotic at the 
same concentrations, and grown with vigorous aeration at 37 °C. At OD600 of ~0.3, isopropyl β-
D-1-thiogalactopyranoside (IPTG) inducer was added to each culture at a final concentration of 
0.1mM and the temperature was decreased to 16 °C. Following 16 hours of culturing, cells were 
pelleted by centrifugation (4,000 x g, 30 min, 4 °C).  Cells were then suspended in buffer (20mM 
sodium phosphoate buffer pH 7.0, 0.1M NaCl, 15% glycerol, 10mM 2-mercaptoethanol) and 
treated with lysozyme (5ug/mL) on ice for 1 hour.  Cell suspension was then run through a 
French press at 1,500 psi and following cell extract was centrifuged (30min, 16,000g, 4ºC). 
Recombinant EDS08212.1 gene product was then purified using Strep-Tactin® resin (IBA) as 
per manufacturing protocol. The recombinant protein was eluted using an elution buffer 
composed of 20mM Tris-HCl, 150mM NaCl, 20% glycerol, 10mM 2-mercaptoethanol pH 7.9 
and 2.5mM desthiobiotin. Protein purity was assessed using both sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting using the Strep Tag II 
antibody (IBA).  The purified protein concentration was determined via the Bradford Assay 
(BioRad).  The same methods were used for the overexpression and purification of putative 17α-
HSDH enzymes from C. scindens VPI 12708 with minor adjustments.  Constructs lacking a 
streptavidin tag were not purified on a Strep-resin column nor were visualized via Western blot 
hybridization.   
 
Δ4,6-reductase and 17α-HSDH purified enzyme reactions 
 
To test the oxidation of 3-dehydro-DCA by EDS08212.1, we used a standard buffer composed of 
20mM sodium phosphate (pH 7.0), 100mM NaCl, 20% glycerol, and 10mM 2-mercaptoethanol. 
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When utilized, pyridine nucleotides (NAD+, NADP+, NADH, NADPH) were added at 150µM 
final concentration. 3-dehydro-DCA was added at 30µM final concentration. The reaction was 
initiated by addition of 0.5µg purified rEDS08212 to 1ml reaction buffer and was terminated 
after 6 hrs at 37°C by addition of 75µl 1N HCl, and was extracted and chromatographed as 
described above. 
 
Similar methods were used for testing purified putative 17α-HSDH enzymes.  Buffers used 
included 20mM sodium phosphate (pH 7.0) or 100mM sodium acetate buffer (pH 5.5) with 
either 10mM 2-mercaptoethanol or 1mM dithiothreitol (Sigma).  When utilized, pyridine 
nucleotides (NAD+, NADP+, NADH, NADPH) were added at 150µM final concentration. 1µg 
purified recombinant putative 17α-HSDH enzymes were added to each 1mL reaction volume. In 
the case of whole cell extract assays, up to 100ug of whole cell protein extract was added per 
1mL reaction volume.  Aerobic metabolism of androstenedione and epitestosterone was tested by 
monitoring changes in pyridine nucleotide oxidation states spectrophotometrically by absorption 
at 340nm over time. Alternatively, aerobic metabolism of the steroid molecules was screened by 
extraction of reaction mixtures and separation on HPLC as described above.  Anaerobic 
metabolism used the same reaction buffers that had been made anaerobic under N2 stream.  The 
metabolism of substrates was tracked via HPLC separation, as described above.  Additionally, E. 
coli BL-21 CodonPlus (DE3) RIPL transformed with putative 17α-HSDH gene plasmid 
constructs were grown aerobically and anaerobically, induced with IPTG at early log phase, and 
inoculated with 25µM androstenedione or epitestosterone. Whole cell conversion of these 
steroids was then screened via extraction and HPLC separation, as described above. 
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Bioinformatics analysis and statistics 
 
Phylogenetic analysis of EDS08212.1 by maximum-likelihood was performed using RAxML 
8.2.0 (224), with gamma-distributed heterogeneity rates, automatically selected empirical 
substitution model, and 100 bootstrap pseudoreplicates. Selection and alignment of sequences 
from the NCBI nr database were performed as previously described (217). The resulting tree was 
drawn in Dendroscope (225) and cosmetic adjustments were performed in Inkscape. 
 
For C. scindens VPI 12708 RNAseq analysis, significance was assessed using a false discovery 
rate corrected p-values of 0.05, which were calculated and assessed using this cut-off.  RNAseq 
was utilized to make a heatmap using a distance metric of 1-(abs(pearson correlation)), and the 
“ggplot” and “heatmap.2” R packages. 
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Table 2.1:  Bacterial strains used in the present study 
 
Strain Source 
Clostridium scindens VPI 12708 VPI 
Clostridium scindens ATCC 35704 ATCC 
Clostridium absonum ATCC 27555 ATCC 
Eggerthella lenta ATCC 25559 ATCC 
Eggerthella lenta strain C592 Collaborators at Ryukyus University 
I10  Collaborators at Ryukyus University 
SA14 Collaborators at Ryukyus University 
19BHI Collaborators at Ryukyus University 
KS11 Collaborators at Ryukyus University 
SO46 Collaborators at Ryukyus University 
SO77 Collaborators at Ryukyus University 
E. coli BL21 (DE3) New England Biolabs 
E. coli Top10 Thermo Fischer 
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Table 2.2:  Primers used in the present study 
Primer Use Sequence (5’ – 3’) 
16s357F Fwd: C592 16S 
amplification 
CTCCTACGGGGAGGCAGCAA 
16s1392R Rev:  C592 16S 
amplification 
ACGGGCGGTGTGTRC 
16s35704cap1 C. scindens VPI 
12708 rRNA 
depletion 
GCGTTACTGACTCCCATGGTGTGACGG/3BioTEG/ 
16s35704cap2 C. scindens VPI 
12708 rRNA 
depletion 
CTTGCGAACGTACTCCCCAGGTGGACTA/3BioTEG/ 
16s35704cap3 C. scindens VPI 
12708 rRNA 
depletion 
GCTTCGGTCTTATGCGGTATTAGCAGCC/3BioTEG/ 
23s35704cap1 C. scindens VPI 
12708 rRNA 
depletion 
CCAGGGTAGCTTTTATCCGTTGAGCGA/3BioTEG/ 
23s35704cap2 C. scindens VPI 
12708 rRNA 
depletion 
GACAGTGCCCAAATCATTACGCCTTTCG/3BioTEG/ 
23s35704cap3 C. scindens VPI 
12708 rRNA 
depletion 
AACCTGTTGTCCATCGGCTACGGC/3BioTEG/ 
23s35704cap4 C. scindens VPI 
12708 rRNA 
depletion 
GGACATGGATAGATCACCCGGTTTCG/3BioTEG/ 
23s35704cap5 C. scindens VPI 
12708 rRNA 
depletion 
GACACCTCCGGATCAAAGGGTATTTGCC/3BioTEG/ 
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Primer Use Sequence (5’ – 3’) 
pSport112708_ 
00455NTERM 
Rnew 
Rev: Cs12708_ 
00005_00084 
w/ N-terminal 
Strep tag 
GTCGACTTATTCCTCAGCCTGCTC 
pSport112708_ 
00455NTERMF 
Fwd: Cs12708_ 
00005_00084 
w/ N-terminal 
Strep tag 
CTGCAGATTAGAGAGGTGGATAACATGTGG- 
-AGCCACCCGCAGTTCGAAAAAAATTTATTT 
CLONE12708_ 
00455F 
Fwd:  Cs12708_ 
00005_00084 
no tag 
CACTGCTCATGGTGACCTATTTCTA 
CLONE12708_ 
00455R 
Rev:  Cs12708_ 
00005_00084 
no tag 
GCTATCATCTTCACCTCTCATCATT 
pSport_00455_ 
CF 
Fwd: Cs12708_ 
00005_00084 
w/ C-terminal 
Strep tag 
TAATCTGCAGATTAGAGAGGTGGATAAC 
pSport_00455_ 
CR 
Rev: Cs12708_ 
00005_00084 
w/ C-terminal 
Strep tag 
ATATGTCGACTTATTTTTCGAACTGCGGGT- 
-GGCTCCATTCCTCAGCCTGCTC 
pASK_64_18 
Forward 
Fwd: Cs12708_ 
00064_00018 
in pASK p43 
and p15 vectors 
GGATCCAATTCATATACAGTA 
p43_68_18_R Rev: Cs12708_ 
00064_00018 
in pASK p43 
 
CCATGGCCTATTCGCTCG 
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Primer Use Sequence (5’ – 3’) 
   
p15_64_18_R Rev: Cs12708_ 
00064_00018 
in pASK p15  
ATGCATCCATGGCTCCTTATATTCGCTCG 
Cs12708_64_ 
18F 
Fwd:  Cs12708_ 
00064_00008 
in pSport1 with 
N-terminal 
Strep tag 
GTCGACGGATCCCGGAGAATGAAT- 
-TCATATACAGTA 
Cs12708_64_ 
18R 
Rev:  Cs12708_ 
00064_00008 
in pSport1 with 
N-terminal 
Strep tag 
AAGCTTCTATTTTTCGAACTGCGGGTG- 
-GCTCCATATTCGCTCGACTTTCTG 
Cs12708_114 
_9_NF 
Fwd:  Cs12708_ 
00114_00009 
in pSport1 with 
N-terminal 
Strep tag 
CTGCAGAAAAGGAAGGGGATGATAGG 
Cs12708_114 
_9_NR 
Rev:  Cs12708_ 
00114_00009 
in pSport1 with 
N-terminal 
Strep tag 
GGATCCTTATTTTTCGAACTGCGGGTGG- 
-CTCCAAACAAGCGTCCAGCC 
Cs12708_114 
_9_NoTagF 
Fwd:  Cs12708_ 
00114_00009 in 
pSport1 no tag 
GTCGACCTGCAGGATAGGATGAAGAA- 
-TTTATTTGAT 
Cs12708_114 
_9_NoTagR 
Rev:  Cs12708_ 
00114_00009 in 
pSport1 no tag 
ATGCATGGATCCAATTGTCTAAACAAG- 
-CGTCAA 
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Primer Use Sequence (5’ – 3’) 
   
Cs12708_124 
_9_NF 
Fwd:  Cs12708_ 
00124_00009 
in pSport1 with 
N-terminal  
Strep tag 
CTGCAGAAAGGAGAACAAAAAGGA 
Cs12708_124 
_9_NF 
Rev:  Cs12708_ 
00124_00009 
in pSport1 with 
N-terminal  
Strep tag 
GGATCCTTATTTTTCGAACTGCGGGTGGCT- 
-CCATATCAACGGTTCATA 
Fwd – Forward; Rev – Reverse; 3BioTEG – 3’ Biotin with triethyleneglycol (TEG) spacer 
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Table 2.3:  Plasmids used in the present study 
Plasmid Description Source 
pCRTMBlunt II-TOPO® Kanamycin resistance, 
designed for blunt-end ligation 
Thermo Fischer 
pSPORT-1 Ampicillin resistance, contains 
lac-promotor for expression in 
E. coli cells 
Thermo Fischer 
pASK-IBA43plus Ampicillin resistance, contains 
C-terminal Strep-tag, tet-
promotor expression vector 
IBA 
pASK-IBA15plus Ampicillin resistance, contains 
N-terminal Strep-tag, tet-
promotor expression vector 
IBA 
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Chapter 3:  Characterization of novel Eggerthella lenta strain C592 
 
Introduction: 
 
Significant effort is underway studying the human gut microbiome and how it impacts human 
health.  The first step in this process is to obtain a basic understanding of the makeup of this 
microbial community.  The advent of next generation sequencing, along with advances in 
computational power have provided the ability to assign functional characterization organisms 
based on clusters of orthologous groups (COG) and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) databases, allows scientists to gain insight into the effects microbes may have on each 
other and the host (226).  However, the reference genomes that guide predictive annotations of 
novel microbial strains only account for a third of the entire metagenomic data received from 
high-throughput shotgun sequencing of fecal samples (227).  A complementary approach is to 
attempt to assign strains to OTUs based on 16S DNA sequence (2).  However, in doing so it is 
very easy to miss significant differences that may exist among species within a specific OTU.  
These significant differences are evident when studying the gut “sterolbiome”, the genes 
involved in bile acid and steroid metabolism.   For example, within the same species, 
Clostridium scindens strains have been shown to have varying ability to metabolize steroids.  C. 
scindens ATCC 35704 encodes a steroid 17,20-desmolase which is absent from its sister strain 
C. scindens VPI 12708 (217).   Additionally, C. scindens VPI 12708 has been shown to have 
unique 17α−HSDH activity that is not found in C. scindens ATCC 35704 (228).  Understanding 
and characterizing the sterolbiome’s potential to biotransform these molecules in humans is 
 58 
important because even small modifications to the base structure of bile acids and steroids can 
have significant physiological effects, even at nanomolar concentrations (167, 229, 230). 
 
One bacterial strain that has garnered significant attention in the study of the human gut 
sterolbiome is Eggerthella lenta.  Within the classs Actinobacteria and the family 
Coriobacteriaceae, E. lenta is a non-motile, non-sporulating, gram-positive short rod-shaped 
bacterium usually found in pairs or chains (231).  The first isolation of what would later be 
named Eggerthella lenta was from normal adult fecal samples by Arnold H. Eggerth in 1935, 
and classified under the Bacteroides genus, although no type strain was obtained (232).  Soon 
after, the first reported type strain for Eggerthella lenta was isolated from a rectal tumor and 
added to the Prevot collection under the Eubacterium genus classification (231).  It was later 
transferred to the Eggerthella genus after further characterization and phylogenetic analysis (233, 
234). 
 
E. lenta has been proposed as an important gut microbial strain to characterize and potentially 
inhibit in patients undergoing treatment for cardiovascular disease.  Cardiac glycosides, derived 
from Digitalis purpurea, have been used for centuries to treat both heart failure and atrial 
fibrillation (235).  Approximately 10% of those treated with cardiac glycosides harbor an 
intestinal microbiota capable of reducing the α,β-unsaturated butyrolactone ring, thereby 
inactivating the drug (Figure 3.1) (236).  It has been shown that some strains of E. lenta, 
including the type strain, have the ability to reductively inactivate digitoxin (237).  Within these 
active E. lenta strains, a two-gene locus termed the “cardiac glycoside reductase operon” 
(cgrAB) was found that encodes proteins resembling bacterial cytochromes that are associated 
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Figure 3.1:  Diagram of reductive digoxin inactivation by Eggerthella lenta  
 60 
 
 
Adapted from (236) 
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with the formation of reduced digoxin products from digoxin (238), although it has yet to be 
proven that this “cgr locus” encodes a digoxin reductase.  These reduced digoxin products have 
reduced cardiac reactivity, likely due to a decreased affinity to the Na+/K+ ATPase in 
cardiomyocytes (239).  The role of E. lenta in the formation of inactivated digoxin products on 
the availability of digoxin is important because of the narrow range at which digoxin is 
therapeutically effective before it becomes toxic (240).  
 
In addition to the metabolism of cardiac glycosides, E. lenta has been shown to metabolize 
endogenous steroid molecules.  Because of their metabolism of endogenous corticosteroids, E. 
lenta has been identified as a candidate to be linked to essential hypertension, although more 
work is necessary to delineate the extent of its involvement.  The initial work of linking the gut 
microbiota to hypertension began in rats, where the development of hypertension could be 
attenuated by treatment with neomycin and vancomycin (241, 242).  However, attempts to 
delineate the specific microbes responsible for this modulation at the time were unsuccessful and 
not pursued further (243).  In the study of adults with 17-hydroxylase insufficiency, a genetic 
defect causing hypertension due to an increased level of deoxycorticosterone leading to renal 
sodium retention (244), it was found in urinary steroid analysis that 21-deoxycorticosterone was 
a major metabolite of corticosterone (245).  Radiolabeled assays showed that 21-
deoxycorticosterone was a direct metabolite of corticosterone, and that its production did not 
occur in germ free rats (245, 246).  Around the same time it was discovered that Eggerthella 
lenta produced a 21-dehydroxylase capable of converting cortisone to 11β-hydroxy-progesterone 
(247, 248). A major regulator of systemic blood pressure is aldosterone, which imparts its action 
by binding to the mineralocorticoid receptor in renal epithelial cells (249).  This leads to the 
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expression of sodium reabsorption mechanisms, ultimately increasing extracellular volume 
(249).  However, cortisol is a much more potent agonist for the mineralocorticoid receptor in 
renal epithelial cells and is in much higher concentrations in serum.  The reason that aldosterone 
is the major systemic modulator of blood pressure is that renal cells also contain 11β-
hydroxysteroid dehydrogenase-2 (11β-HSD2), which can inactivate cortisol once inside the cell, 
forming inactive cortisone (250).  Therefore, 11β-HSD2 acts as a modulator of cortisol activity.  
It has been shown that 11β-hydroxy-progesterone is a competitive inhibitor for the 11β-HSD2 
enzyme (251).  E. lenta is the only gut microbe reported to contain 21-dehydroxylase activity 
capable of converting cortisol to 11β-hydroxy-progesterone, although not all strains harbor 
activity (248).  In a model of hypertension caused by obstructive sleep apnea in rats, it was found 
that the gut microbiome of those with hypertension showed an increase in Coriobacteriaceae, 
which includes E. lenta (252).    
 
Additionally, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) found in the liver and 
responsible for converting cortisone to activated cortisol (the reverse of 11β-HSD2), has been 
shown to be competitively inhibited by oxo-bile acid derivatives of microbial bile acid 
metabolism, such as 7-oxo-lithocholic acid (198, 199), although more oxo-bile acid derivatives 
need to be screened.  E. lenta has been reported to harbor 3α-HSDH, 7α-HSDH, and 12α-HSDH 
activity, varying on the strain, which are involved in the formation of oxo-bile acids (151, 153).  
 
Metabolism of corticosterone and bile acids by E. lenta may also have implications on CRC 
formation.  11β-HSD2 is also found in colonocytes, the disruption of which has been shown to 
rescue APC knockout mice from tumor formation through a Cox-2 dependent mechanism (253).  
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Therefore, the inhibition of 11β-HSD2 activity by E. lenta-derived corticosterone derivatives 
may alter prostaglandin synthesis and reduce colonic inflammation, both factors important to 
CRC development.   
 
In addition, the metabolism of bile acids by E. lenta may lead to the formation of less toxic bile 
acid metabolites and affect CRC progression as well.  As reviewed earlier, secondary bile acids 
DCA and to a lesser degree LCA, formed from primary bile acids CA and CDCA, have been 
associated with the formation of CRC.  However, other secondary bile acids produced by gut 
microbes are less toxic.  Ursodeoxycholic acid (UDCA) is formed by the oxidation and 
subsequent epimerization of the 7α hydroxyl group of CDCA via microbial 7α-HSDH and 7β-
HSDH enzymes (125).  UDCA has been shown to be less toxic to both microbial and host cells, 
and additionally have seen some use as therapeutic agents in liver and biliary disease.  The β-
configuration of the 7-hydroxyl group leads to a more hydrophilic molecule, leading to its 
reduced toxicity (254, 255).  In addition to epimerization of the C7-hydroxyl group on CA, 
CDCA, and UDCA, the C3-hydroxyl group is also subject to isomerization by bacterial enzymes 
in the gut, including some produced by E. lenta.  E. lenta has been found to encode both a 3α-
HSDH and 3β-HSDH necessary to convert DCA to iso-DCA (150).  The same work showed that 
iso-DCA was less toxic to other gut microbes than DCA, indicating it may be a detoxification 
mechanism (150).  The effects of isomerized secondary bile acids on colonocytes remains 
unstudied, but it can be hypothesized that due to their increased hydrophilicity, iso-secondary 
bile acids would be less toxic than secondary bile acids.  What was not established in this 
previous study was whether E. lenta could convert primary bile acids to 3β-epimers.  Removal of 
the C7-hydroxyl group on primary bile acids requires the formation of a 3-oxo-Δ4-intermediate 
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and to date no 7α-dehydroxylating bacteria has been shown to encode a 3β-HSDH.  Therefore, 
we predict that isomerization of primary bile acids would lead to formation of alternate bile acid 
metabolites and prevent 7α-dehydroxylation. 
 
Studies identifying the makeup of the inhabitants of the gut microbiome have shown the two 
major represented phyla being Bacteroidetes and Firmicutes, making up on average 85% of the 
total phylotypes (256, 257).  The next most represented phylum is Actinobacteria, of which E. 
lenta is a member. Even though it is found in lower relative abundance in the gut, E. lenta still 
has significant implications to both gut microbiome and host physiology.  Studies of both germ-
free mice and hamsters have indicated that OTUs identified as or closely related to E. lenta are 
associated with increased hepatic triglycerides, increased synthesis of primary bile acids via the 
alternative pathway, and increased liver cytochrome activity (258, 259).  Interestingly, E. lenta 
and Clostridium scindens, both numerically minor constituents of the gut microbiome, which are 
nevertheless responsible for substantial metabolism of bile acids and steroid molecules, were 
shown to be associated with increased hepatic triglyceride synthesis in conventionalized ex-germ 
free mice (258).  The bile acid composition (a switch to primary bile acids produced via the 
alternative pathway) as well as increased hepatic FXR and PXR signaling, suggesting a 
significant role of E. lenta in gut microbiome-modulated energy homeostasis via bile acid 
signaling pathways (258).  A mechanism by which E. lenta may be exerting these effects is 
through activation of TGR5, leading to glucagon-like peptide-1 (GLP-1) release from 
neuroendrocrine cells, leading to increased insulin release from the pancreas, which stimulates 
production of triglycerides by hepatocytes. However, it has been shown that secondary bile acids 
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DCA and LCA are the most potent activators of TGR-5 (170, 171) and E. lenta has not been 
shown to create these molecules.  
 
Human studies have shown that diet substantially alters the structure and metabolic activity of 
the gut microbiome (226, 256).  One such quantitative study of changes to gut microbial 
diversity based on varying diets showed E. lenta levels can vary in the same individual based 
purely on diet.  A significant increase in E. lenta was observed in human subjects given a diet 
high in non-starch polysaccharides relative to other dietary polysaccharides, including resistant 
starch and a “weight loss” diet high in protein (260).  Similarly, fecal concentrations of SCFAs 
acetate, propionate, butyrate, as well as succinate, were all significantly higher in in the same 
patients eating a diet high in non-starch polysaccharides when compared to other diets (260).  
These results suggest that E. lenta thrives in an environment where anaerobic bacterial 
fermentation is occurring. 
 
Based on the previous literature, it is apparent that E. lenta impacts both gut microbial and host 
physiology.  However, a better understanding of the types of bile acid and steroid products it 
recognizes and the metabolites it creates is necessary.  Furthermore, understanding how bile 
acids and steroids play into the overall metabolism of E. lenta may give insight into why bile 
acids and steroids are utilized in the more complex gut microbial environment.  We set out to 
better understand E. lenta bile acid and steroid metabolism through characterization of a novel 
strain; C592, a human fecal isolate from a Japanese octogenarian.  Comparison of steroid 
metabolism and genome sequence between the type strain E. lenta ATCC 25559 reveals 
important strain-dependent differences in the sterolbiome among E. lenta isolates.  I discovered 
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that both these bacteria make unique patterns of oxidized bile acid and steroid metabolites, 
including a novel ability to metabolize testosterone. I show that the pattern of metabolites made 
can be altered based on the atmospheric gases present during their growth.  Based on these 
observations, the full genome sequencing/annotation of C592, and preliminary fermentative end 
product analysis, I hypothesize that Eggerthella lenta is an acetogen able to link the metabolism 
of bile acids to the formation of acetate in order to maintain intracellular redox equilibrium. In 
addition, I show that the bile acid metabolites made by E. lenta ATCC 25559 and C592 inhibit 
subsequent 7α-dehydroxylation by Clostridium scindens.  
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Results: 
 
Initial screening of C592 primary bile acid metabolism 
 
Strain C592 is a gram-positive, obligate anaerobe isolated from a human fecal sample from Dr. 
Fusae Takamine (University of Ryukyus) in Okinawa, Japan during a screen for fecal bile acid 
7α-dehydroxylating bacteria.  However, the bile acid metabolites derived from whole-cell cholic 
acid-induced 14C-cholic acid metabolism by the C592 strain had unique retardation factor (RF) 
values as compared to known metabolites synthesized by 7α-dehydroxylating bacteria (Figure 
3.2).  In comparison to both high-activity and low-activity 7α-dehydroxylating strains, C592 CA 
metabolites do not comigrate with CA, DCA, or allodeoxycholic acid (ADCA), a 5α-epimer of 
DCA (Figure 3.2).  In addition, numerous secondary metabolites were generated from CA, 
whereas the major product from other 7α-dehydroxylating strains comigrates with the DCA 
standard (Figure 3.2).    These results suggested C592 is producing unique bile acid metabolites 
from CA.  C592 CA metabolism screening was repeated, inducing with either CA or allocholic 
acid (ACA), a 5α epimer of CA. Results showed that both CA and ACA-induced C592 cultures 
metabolized [14C]-CA to secondary products unique from known 7α-dehydroxylated metabolites 
DCA and ADCA (Figure 3.3).  There was no difference in the migration of 14C-CA metabolites 
between CA and ACA-induced C592 metabolism by TLC analysis.   C592 was also screened for 
its ability to metabolize CDCA, the other primary bile acid produced by human hepatocytes.  
C592 CDCA-induced metabolism of [14C]-CDCA showed formation of three secondary products 
(Figure 3.4).  Experiments looking at C592 uninduced whole cell metabolism of [14C]-CA and 
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Figure 3.2:  TLC of whole cell extracts from various fecal bacterial strains induced by 
cholic acid to metabolize [24-14C]-cholic acid 
 
First section of TLC plate includes cholic acid, deoxycholic acid, and allodeoxycholic acid TLC 
standards.  The second section contains organic extracts from whole-cell cholic acid-induced 
[24-14C]-cholic acid metabolism.  I10, SA19, C592, 19BHI, KS11, SO96, SO77 are all human 
fecal isolates previously screened for bile acid metabolizing potential.  Cultures were grown 
overnight with 25µM cholic acid and 1µCi labeled cholic acid and separated on TLC as 
described in Materials and Methods. The major CA metabolite for I10, SA19, 19BHI, KS11, 
SO96, and SO77 comigrates with the DCA standard.  However, the C592 metabolites appear to 
migrate separately with one migrating similarly to ADCA.  
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Figure 3.3:  Conversion of [24-14C]-cholic acid by allocholic acid- and cholic acid-induced 
C592 
 
First section of TLC plate includes cholic acid, deoxycholic acid, and allodeoxycholic acid TLC 
standards.  The second section contains organic extracts from C592 whole-cell bile acid-induced 
[24-14C]-cholic acid metabolism.  C592 was grown in the presence of either 25µM cholic acid or 
25µM allocholic acid, along with 1µCi cholic acid.  Cultures were extracted and run on TLC as 
described in the Materials and Methods.  C592 metabolizes [24-14C]-cholic acid to five 
secondary metabolites, with no apparent difference in the spectrum of metabolites when induced 
with either cholic or allocholic acid.  No C592 CA metabolites comigrate with DCA or ADCA, 
suggesting they are not 7α-dehydroxylated.   
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Figure 3.4:  Conversion of [24-14C]-CDCA by CDCA-induced C592 
 
First spot on the TLC plate is the chenodeoxycholic acid TLC standard.  The second spot 
contains the organic extracts from a C592 whole-cell chenodeoxycholic acid-induced [24-14C]-
chenodeoxycholic acid metabolism.  C592 was grown in the presence of 25µM 
chenodeoxycholic acid along with 1µCi chenodeoxycholic acid.  Cultures were extracted and run 
on TLC as described in the Materials and Methods.  C592 metabolizes [24-14C]-
chenodeoxycholic acid to three secondary metabolites.   
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[14C]-CDCA as well as C592 whole cell protein extract metabolism of [14C]-CA and [14C]-
CDCA showed no significant difference from the induced samples, indicating this was not an 
inducible phenomenon (data not shown).  
 
Next C592 was compared against known bile acid 7α-dehydroxylating and epimerizing bacterial 
whole-cell cultures.  Clostridium scindens VPI 12708 is a known high-activity 7α-
dehydroxylating bacterium known to harbor a bile acid-inducible operon (bai-operon).  The 
products created from CA-induced [14C]-CA metabolism in whole cell cultures are known, 
including 3-oxo-deoxycholic acid, DCA, and 7-oxo-cholic acid (Figure 3.5).  Additionally, when 
induced with ACA, C. scindens VPI 12708 shifts its metabolic profile to create 3-oxo-
allodeoxycholic acid and allodeoxycholic acid, in addition to some trace DCA (143) (Figure 3.5).  
Both whole cell extracts of 12708 [14C]-CA metabolism were used as comparisons to help 
determine possible C592 CA metabolites, although only 7-oxo-cholic acid appeared to 
comigrate, indicating C592 CA metabolites are not 7α-dehydroxylated (Figure 3.5).  In addition, 
C592 CDCA-induced [14C]-CDCA metabolism was compared against two other bacteria known 
to metabolize CDCA.  C. scindens VPI 12708 is known to convert CDCA into several 
metabolites, including LCA, 3-oxo-lithocholic acid, 3-oxo-chenodeoxycholic acid, and 7-oxo-
lithocholic acid (7-oxo-LCA) (Figure 3.6).  Clostridium absonum was also screened, as it has 
been previously shown to harbor both a 7α-HSDH and 7β-HSDH, allowing it to epimerize 
CDCA at the 7-hydroxyl group forming ursodeoxycholic acid (146).  C. absonum whole cell 
CDCA metabolism generated 7-oxo-lithocholic acid as well as ursodeoxycholic acid (Figure 
3.6).   When these known CDCA metabolites were compared to the three C592 CDCA 
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Figure 3.5:  TLC separation of organic extracts from C. scindens VPI 12708 and C592 bile 
acid-induced whole cell conversions of [24-14C]-CA 
 
The first spot on the TLC plate is a cholic acid TLC standard.  The next three spots are organic 
extracts from whole-cell bile acid-induced [24-14C]-cholic acid metabolism screens in C. 
scindens VPI 12708 or C592.  Based on previous literature, C. scindens VPI 12708 is known to 
differentially produce deoxycholic acid or allodeoxycholic acid from cholic acid when induced 
with either cholic acid or allocholic acid, respectively (143).  In addition, C. scindens VPI 12708 
bile acid induced cultures usually generate some 7-oxo-cholic acid and 3-oxo-deoxycholic acid 
(when induced with cholic acid) or 3-oxo-allodeoxycholic acid (when induced with allocholic 
acid), based on Rf (143).  One C592 cholic acid metabolite appears to comigrate with 
allodeoxycholic acid and another with 7-oxo-cholic acid, but the rest have unique migration 
patterns.  
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Figure 3.6:  TLC separation of organic extracts from C. scindens VPI 12708, C. absonum, 
and C592 CDCA-induced whole cell conversions of [24-14C]-CDCA 
 
The first spot on the TLC plate is a chenodeoxycholic acid TLC standard.  The next three spots 
are organic extracts from whole-cell chenodeoxycholic acid-induced [24-14C]-chenodeoxycholic 
acid metabolism screens in C. scindens VPI 12708, Clostridium absonum, or C592.   Previous 
literature has determined LCA as a major product of C. scindens VPI 12708 CDCA metabolism 
(261).  Additionally, C. absonum is known to epimerize chenodeoxycholic acid to 
ursodeoxycholic acid via 7α-HSDH and 7β-HSDH reactions (146, 262).  When whole cell 
conversion of CDCA of these two known CDCA metabolizers is compared to C592, one 
metabolite (7-oxo-lithocholic acid) comigrates while the two others do not.
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metabolites, the only metabolites that shared a similar Rf was 7-oxo-LCA, indicating the other 
two compounds were unique CDCA metabolites. 
 
Determination of C592 phylogeny based on 16S sequencing 
 
C592 was confirmed to be pure through anaerobic BHI agar plate growth, colony isolation, and 
subsequent bile acid metabolism screening.  There was no growth under aerobic BHI agar 
plating.  Purified C592 was grown anaerobically in BHI broth overnight at 37ºC for genomic 
DNA isolation and purification.  Purified C592 genomic DNA was used as template for 16S 
sequence amplification using generic primers (Table 2.2).  The ~1kb PCR product was run on a 
1% agarose gel, isolated, purified, and sequenced.  The resulting C592 16S DNA fragment had 
>99% sequence similarity to the Eggerthella lenta type strain. 
 
Comparison of phenotypic similarities between C592 and E. lenta ATCC 25559 
 
E. lenta ATCC 25559 (25559) was acquired from the American Type Culture Collection, plated 
anaerobically, and colonies picked for further analysis.  Purified 25559 was grown anaerobically 
in BHI media and compared with C592 growth.  Growth of C592 and 25559 was similar 
between both strains both with and without arginine, which has been shown to be stimulatory for 
E. lenta growth in vitro (Table 3.1).  Both showed similar Gram-positive bacillus morphology 
(data not shown). 
 
Comparison of C592 and 25559 metabolism of primary and secondary bile acids 
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Table 3.1:  Overnight growth comparison between C592 and E. lenta ATCC 25559 
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Since E. lenta is known to epimerize primary and secondary bile acids, we screened the ability of 
C592 and 25559 to metabolize numerous bile acids.  Grown overnight in BHI broth under inert 
N2 gas, C592 and 25559 both metabolize 25µM CDCA into three metabolites; CDCA-A, 
CDCA-B, and CDCA-C (Figure 3.7).  CDCA-A has a similar Rf to 7-oxo-LCA, however, 
CDCA-B and CDCA-C do not share Rf values with previously described CDCA metabolites 
generated by bile acid 7α-dehydroxylating bacteria. Both strains metabolize CDCA to 
completion, leaving no remaining CDCA after 24 hours.  In a time course experiment, CDCA 
metabolism begins in early-log phase, with no detectable CDCA remaining by mid-log phase 
(data not shown).  In addition, both C592 and 25559 can grow in higher concentrations of CDCA 
(50µM and 500µM) as well as completely metabolizing the increased CDCA concentrations to 
the same three secondary metabolites (data not shown).  C592 and 25559 also completely 
metabolize CA to six metabolites (Figure 3.8).  One CA metabolite has a similar Rf value to 7-
oxo-CA, however the rest do not match known CA metabolites based on Rf values. 
 
E. lenta has been previously shown to isomerize secondary bile acids, so the ability for C592 to 
metabolize DCA and LCA was tested.  In order to test secondary bile acid metabolism, 14C-
secondary bile acids were synthesized biologically.  C. scindens VPI 12708 was grown with CA 
and 14C-CA or CDCA and 14C-CDCA overnight and the resulting bile acid metabolites were 
separated on TLC, isolated, and quantified via liquid scintillation spectrometry.  The resulting 
[14C]-secondary bile acids were used for whole cell metabolism assays.  Both C592 and 25559 
fully metabolize 25µM DCA to secondary metabolites, DCA-A and DCA-B (Figure 3.9).  C592 
also recognizes LCA, fully metabolizing it to a single secondary metabolite (data not shown).   
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Figure 3.7:  TLC separation of CDCA-induced C592 and Eggerthella lenta ATCC 25559 
whole cell metabolism of [24-14C]-CDCA 
 
The first frame is a chenodeoxycholic acid TLC standard.  The next two frames are organic 
extracts from whole-cell chenodeoxycholic acid-induced [24-14C]-chenodeoxycholic acid 
metabolism screens in C592 and E. lenta ATCC 25559.  Both C592 and E. lenta ATCC 25559 
metabolize CDCA to three metabolites; CDCA-A which comigrates with 7-oxo-lithocholic acid, 
CDCA-B and CDCA-C, which do not comigrate with known CDCA metabolites.  CDCA 
metabolites CDCA-A, CDCA-B, and CDCA-C were isolated from TLC plates and used for 
further characterization  
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Figure 3.8:  TLC separation of CA-induced C592 and Eggerthella lenta ATCC 25559 whole 
cell metabolism of [24-14C]-CA 
 
The first frame is a cholic acid TLC standard.  The next two frames are organic extracts from 
whole-cell cholic acid-induced [24-14C]-cholic acid metabolism screens in C592 and E. lenta 
ATCC 25559.  Both C592 and E. lenta ATCC 25559 metabolize CA to a similar pattern of 
metabolites.  
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Figure 3.9: TLC separation of DCA-induced C592 and Eggerthella lenta ATCC 25559 
whole cell metabolism of [24-14C]-DCA 
 
The first frame is a deoxycholic acid TLC standard.  The next two frames are organic extracts 
from whole-cell deoxycholic acid-induced [24-14C]-deoxycholic acid metabolism screens in 
C592 and E. lenta ATCC 25559.  Deoxycholic acid was made biologically via metabolism of 
CA by C. scindens VPI 12708, as described in the Materials and Methods.  Both C592 and E. 
lenta ATCC 25559 metabolize DCA to in a similar pattern to two distinct metabolites, DCA-A 
and DCA-B.  These two metabolites were isolated from the TLC plate and used for further 
analysis.  
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C592 and 25559 metabolism of CDCA was also tested in the presence of varying molecules 
which were hypothesized to alter the pattern of bile acid metabolism.  Arginine, at a 
concentration of 0.5% wt/vol, did not inhibit formation of CDCA metabolites (data not shown).  
Neither pyruvate nor glutamate (100µM final concentration) altered C592 metabolism of CDCA 
(data not shown). 
 
Mass spectrometry characterization of C592 CDCA and DCA metabolites 
 
C592 metabolism of CDCA and DCA was repeated in a larger volume in order to obtain enough 
of each metabolite to perform MS analysis. 100mL C592 BHI cultures were grown anaerobically 
overnight under inert N2 gas in the presence of 25µM CDCA.  The metabolites were separated 
on TLC alongside C592 14C-CDCA whole cell metabolism extracts and the corresponding bands 
for unlabeled CDCA-A, CDCA-B, and CDCA-C were isolated.  MS analysis on the resulting 
bands was performed.  MS analysis of authentic CDCA was performed resulting in a 
mass/charge of 392.57m/z.  CDCA-A and CDCA-B metabolites saw a loss of two mass units 
(390m/z) on MS analysis, indicating oxidation of a single hydroxyl-group (Figure 3.10).  CDCA-
C was four mass units less than CDCA (388m/z), indicating probable oxidation of two hydroxyl 
groups (Figure 3.10).  CDCA is a dihydroxy bile acid (C3, C7) and a loss of 4 AMU is consistent 
with CDCA-C being identified as 3,7-dioxo-5β-cholanoic acid.  CDCA-A has a similar Rf to 7-
oxo-LCA and shows the expected mass on MS analysis.  Additionally, when CDCA-A was 
treated with purified 3α-HSDH from Pseudomonas testosteroni in the presence of NAD+, a 
single product migrating with the same Rf value of 3,7-dioxo-5β-cholanoic acid is observed.  
Taken together, these results suggest CDCA-A is 3α-hydroxy-7-oxo-5β-cholanoic acid.
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Figure 3.10:  C592 CDCA metabolite separation and subsequent MS characterization 
 
C592 CDCA metabolites were separated as previously described on TLC both with and without 
[24-14C]-radiolabel.  Isolated unlabeled substrates then underwent MS analysis as described in 
the Materials and Methods.  Both CDCA-A and CDCA-B exhibited mass/charge ratios of 
390m/z, suggesting a loss of 2 AMU when compared to CDCA, consistent with the oxidation of 
a single hydroxyl group.  CDCA-C exhibited a loss of 4 AMU (388m/z) when compared to 
CDCA, consistent with the oxidation of two hydroxyl groups.  Correlating this data with TLC 
and 3α-HSDH treatment data, the putative identities of these metabolites are:  CDCA-A - 3α-
hydroxy-7-oxo-5β-cholanoic acid, CDCA-B - 3β-hydroxy-7-oxo-5β-cholanoic acid, CDCA-C - 
3,7-dioxo-5β-cholanoic acid.  
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CDCA-B has the same mass as CDCA-A. However, the Rf matches neither 7-oxo-LCA nor 3-
oxo-CDCA.  In addition, when treated with purified 3α-HSDH in the presence of NAD+, there is 
no product formed.  These results suggest that CDCA-B is 3β-hydroxy-7-oxo-5β-cholanoic acid. 
 
The same procedure was used to perform MS analysis on the C592 DCA metabolites.  MS 
analysis for DCA has been performed previously with a resulting mass of 392.57m/z.  When 
compared to the mass of DCA, C592 DCA metabolite DCA-A shows a loss of two mass units 
(390m/z), indicating the oxidation of a single hydroxyl group (Figure 3.11).  DCA-B shows a 
loss of four mass units (388m/z), indicating the oxidation of two hydroxyl groups (Figure 3.10).  
Similarly to CDCA, DCA only contains two hydroxyl groups, one at the 3rd and 12th carbons.  
Therefore, DCA-B can be identified as 3,12-dioxo-5β-cholanoic acid.  DCA-A is likely either 3-
oxo-DCA or 12-oxo-DCA, the specific oxidized hydroxyl group was not determined. 
 
Comparison of steroid metabolism by C592 and 25559 
 
Since E. lenta type strain has previously been shown to metabolize neutral steroids such as 
deoxycortisone, deoxycortisol, and dehydrocorticosterone (248), we determined substrate 
specificity for C592 and 25559 metabolism of numerous compounds sharing the steroid 
backbone.  C592 and 25559 were grown overnight anaerobically in BHI broth in the presence of 
25µM androstenedione and its 17α/β-reduced end products, epitestosterone and testosterone, 
respectively.  Cultures were extracted and the metabolites separated on reverse phase column 
HPLC and monitored at 240nm. Neither androstenedione nor epitestosterone were metabolized 
to a secondary metabolite (data not shown).  However, both C592 and 25559 metabolized
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Figure 3.11: C592 DCA metabolite separation and subsequent MS characterization 
 
C592 DCA metabolites were separated as previously described on TLC both with and without 
[24-14C]-radiolabel.  Isolated unlabeled substrates then underwent MS analysis as described in 
the Materials and Methods. DCA-A exhibited mass/charge ratio of 390m/z, suggesting a loss of 
2 AMU when compared to DCA, consistent with the oxidation of a single hydroxyl group.  
DCA-B exhibited a loss of 4 AMU (388m/z) when compared to DCA, consistent with the 
oxidation of two hydroxyl groups. DCA-A is hypothesized to be either- 3α-hydroxy-12-oxo-5β-
cholanoic acid or 12α-hydroxy-3-oxo-5β-cholanoic acid. DCA-B is predicted to be 3,12-dioxo-
5β-cholanoic acid.  
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testosterone to a secondary metabolite that comigrated with androstenedione (Figure 3.12).  The 
data indicates that C592 and 25559 recognize the 17β-hydroxyl group on testosterone and 
preferentially oxidize it.  This is the first report of 17β-HSDH activity in E. lenta.  C592 and 
25559 were also tested for their ability to metabolize hydrocortisone and cholesterol, however no 
products were detected under N2 gas (data not shown).  Taken together, it appears that under 
inert N2 anaerobic growth, both C592 and 25559 preferentially oxidize bile acid and steroid 
hydroxyl groups (Figure 3.13). 
 
Whole genomic sequencing of C592 and comparison to E. lenta type strain 
 
In order to get a more comprehensive comparison of novel strain C592 and E. lenta 25559, the 
genome C592 was sequenced.  Genomic DNA was isolated from C592 was sheared and 
converted to a Nanopore library.  The library was then sequenced on SpotON Flowcell MK 1 for 
48 hours using a MinION MK 1B sequencer.  Poretools and FastQC was used to determine 
quality scores of the data set and reads from E. coli were removed via a Perl script.  SPAdes-
v3.9.0 was then used for de novo hybrid assembly of the reads.  This resulted in five contigs 
>500bp, the top five of which were blasted to the NCBI NT database (Table 3.2).  NODE_1 
indicates the C592 genomic DNA, while four smaller contigs were also picked up likely 
indicating the presence of plasmids (Table 3.2). MUMmer v-3.23 was used to perform nucleotide 
level comparisons between the C592 NODE_1 contig and the E. lenta type strain closed genome 
(Table 3.3).  This comparison showed that C592 and 25559 share approximately 88% base pair 
identity, however over 400k base pairs (>10%) were unaligned (Table 3.3).  Mauve alignment
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Figure 3.12:  C592 metabolizes testosterone to androstenedione under inert N2 gas 
 
C592 was grown the presence of 25mM testosterone and then extracted as described in the 
Materials and Methods.  The organic extract was run on HPLC, monitoring at 240nm for 
absorption via UV-Vis.  Based on both androstenedione and testosterone controls, C592 
metabolizes testosterone to a product that comigrates with the androstenedione control yet 
maintains the 4-ene-3-oxo moiety required for 240nm absorption.  This suggests the 17β-
hydroxyl group on testosterone is being oxidized by C592.  Similar experiments run with 
epitestosterone did not show production of a secondary metabolite, suggesting this activity is 
specific to the β-configuration of the C17-hydroxyl group.  
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Figure 3.13:  Summary of C592 and 25559 bile acid and neutral steroid metabolic potential 
 
This diagram shows C592 bile acid and steroid metabolic potential.  Based on the data presented 
so far, C592 has shown the potential for numerous biotransformations of the three hydroxyl 
groups found on primary and secondary bile acids, including 3α-, 3β-, 7α-, 12α-HSDH activity.  
Additionally, C592 has been shown to exhibit 17β-HSDH activity.  
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Table 3.2:  De novo hybrid assembly of the five largest contigs from C592 genomic 
sequencing 
 
SPAdes-v3.9.0 Hybrid Assembly 
Contig Name Length Coverage BLAST Top Hits (NT database) 
NODE_1 3,593,230 71x Eggerthella lenta DSM 2243, complete genome 
NODE_2 45,419 148x Gordonibacter pamelaeae 7-10-1-b draft genome 
NODE_3 3,947 864x 
Uncultured prokaryote from Rat gut metagenome 
metamobilome, plasmid pRGRH0595  
 
NODE_4 2,749 1663x 
Uncultured prokaryote from Rat gut metagenome 
metamobilome, plasmid pRGRH0074  
 
NODE_5 2,231 1780.77 
Uncultured prokaryote from Rat gut metagenome 
metamobilome, plasmid pRGRH0074  
 
Total 3,647,576   
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Table 3.3: Nucleotide level comparisons between C592 NODE_1 contig and the E. lenta 
type strain closed genome 
 
                    Eggerthella lenta DSM 2243 
genome 
C592 NODE_1 
Sequences   
TotalSeqs 1 1 
AlignedSeqs 1(100.00%) 1(100.00%) 
TotalBases 3,632,260 3,593,230 
AlignedBases 3,196,021(87.99%) 3,188,117(88.73%) 
UnalignedBases 436,239(12.01%) 405,113(11.27%) 
Alignments   
1-to-1  220 220 
TotalLength 3,172,629 3,172,428 
AvgIdentity 98.66 98.66 
[Feature Estimates]   
Breakpoints 554 554 
Relocations 26 35 
Translocations 0 0 
Inversions 14 14 
InsertionSum  466,071 434,221 
InsertionAvg 2,118.50 1,929.87 
TandemIns 0 2 
TandemInsSum 0 255 
TandemInsAvg 0.00 127.50 
[SNPs]   
TotalSNPs 35,383 35,383 
TotalGSNPs 8,237 8,237 
TotalIndels 4,555 4,555 
TotalGIndels 99 99 
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of the C592 and 25559 genomes was performed, showing significant rearrangement but high 
similarity between the two genomes (Figure 3.14).  Comparison of annotations were performed 
between C592 and the E. lenta type strain and showed that C592 encodes 3047 proteins, while 
25559 encodes 3110 proteins (Table 3.4).  Taken together, although C592 and 25559 appear to 
have similar bile acid metabolic profiles and highly conserved genomic regions, their genomes 
also harbor significant differences. 
 
Searching the C592 genome for an explanation for the production of oxo-bile acid 
derivatives under anaerobic conditions 
 
The production of oxo-bile acids under anaerobic condition is unique, since most anaerobic 
bacteria scavenge for electron accepters to regenerate their oxidized metabolic cofactors, such as 
pyridine nucleotides and ferredoxin.  Conversely, the oxidation of bile acids would generate 
reduced pyridine nucleotides.  Therefore, we sought to determine a reason C592 would be 
carrying out such a reaction in an anaerobic environment.  Using the genetic information gained 
from C592 genomic sequencing, KEGG maps were populated with enzymes annotated to be 
present in C592 based on KEGG gene ontology using BlastKOALA and pathway mapping tools.  
Of the entirety of encoding sequences in C592, only 1340 (42%) matched KEGG annotations 
(Figure 3.15).  Sixty-one enzymes were annotated to be involved in carbon metabolism.  C592 
contains genes for the glycolysis pathway, an incomplete TCA cycle (missing succinyl-CoA 
synthetase), and a pyruvate:ferredoxin oxidoreductase capable of creating acetyl-CoA from 
pyruvate.  Interestingly, annotation of the complete genome sequence of C592 and comparative 
genomics against E. lenta ATCC 25559 suggests that both
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Figure 3.14:  Mauve alignment of C592 and E. lenta type strain genomes 
 
Mauve gene alignment was performed between the longest C592 contig from sequencing and the 
E. lenta type strain closed genome and visualized using Circos as described in the Materials and 
Methods.  There are some gaps in this alignment both within the localized collinear blocks 
(LCB) and in between LCBs.   
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Table 3.4:  CDS protein annotation comparison between C592 and Eggerthella lenta type 
strain 
  
 
Eggerthella_lenta_DSM_2243	 New	Assembly	
contig	 contigs:	1	 contigs:	1	
bases:	 3,632,260	 3,593,230	
tmRNA:	 1 1	
tRNA:	 54	 54	
rRNA:	 6	 6	
Repeat	region:	 1	 1	
CDS:		 3110	 3047	
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Figure 3.15:  Overall C592 BlastKOALA results 
 
Annotated sequences from the C592 genomic data in FASTA format were further analyzed using 
the KEGG Orthology and Links Annotation (BlastKOALA) (223).  C592 KEGG maps were 
generated using KEGG mapping software.  42.1% of the total C592 annotated genes were 
recognized by the BlastKOALA algorithm and populated to relevant KEGG maps.  Overall 
breakdown of the recognized C592 sequences shows that the two largest groups represented by 
KEGG maps were environmental information processing and genetic information processing, 
with numerous other groups represented as well.  
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 strains encode a near complete Wood-Ljungdahl pathway for generation of acetate from CO2 
(Figure 3.16).  Of the nine enzymes in this pathway, KEGG annotation located six of the genes 
in C592.  Further searching of C592 genomic data showed putative genes for two of the 
remaining three genes in the pathway (Table 3.5).  These results gave a possible explanation for 
the requirement of reducing equivalents from bile acids, as the fixation of CO2 to acetate requires 
multiple reducing equivalents. 
 
In addition to carbon metabolism, C592 was shown to have numerous other metabolic pathways 
of interest.  Of note, it contains genes required for the metabolism of arginine, as the E. lenta 
type strain is reported to have (263).  C592 is annotated to have genes allowing it to convert 
arginine to form ornithine, ammonia, and CO2 while generating ATP from ADP (Figure 3.16).  
In addition, it has genes allowing it to interconvert arginine and fumarate, likely depending on its 
energetic needs (Figure 3.17).  This shows energy conservation gene pathways in E. lenta are 
maintained in C592. 
 
Identifying gene clusters of interest in C592 and 25559 
 
Work on the characterization of genes in the E. lenta type strain encoding bile acid isomerization 
enzymes has been done previously (150).  Devlin et al. screened numerous E. lenta short-chain 
dehydrogenase/reductase enzymes (SDR) for bile acid 3α-HSDH and 3β-HSDH activity, 
focusing on their ability to isomerize DCA.  However, of all ten genes tested, only three were 
found to be active.  Six of the seven tested were found in high homology in C592, including the 
two confirmed 3β-HSDH and one 3α-HSDH (Table 3.6).  Additional SDR, oxidoreductases,
 108 
Figure 3.16: C592 encodes genes annotated to be involved in the Wood Ljungdahl pathway  
 
C592 KEGG annotated data generated from BlastKOALA was used with the KEGG Mapper 
Reconstruct Pathway tool, utilizing data from the KEGG Atlas (264).  Green lines indicate genes 
present in C592 that match the relevant annotation in the pathway.  C592 has genes annotated to 
be part of the Wood-Ljungdahl pathway.  These include formate dehydrogenase, formyl-
tetrahydrofolate synthetase, formyl-tetrahydrofolate cyclohydrolase, methylene-tetrahydrofolate 
reductase, phosphotransacetylase, and acetate kinase.  Three genes in this pathway were not 
annotated via KEGG mapping, but two had similar candidates found through searching the C592 
genome for similar enzymes.  These include a methylene-tetrahydrofolate reductase, and the 
carbon monoxide dehydrogenase.  A methyltransferase/acetyl-CoA synthase was not located in 
the C592 genome.  All of these identified C592 genes are also highly conserved in the E. lenta 
ATCC 25559 type strain.  Table 3.6 contains the ascension numbers for the relevant Wood-
Ljungdahl pathway genes in C592 and their corresponding genes in E. lenta ATCC 25559.   
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Table 3.5:  Wood Ljungdahl Pathway Homologous Genes in C592 and E. lenta ATCC 25559 
 
Wood-Ljungdahl	Pathway	Homologous	Genes	
Formate-tetrahydrofolate	synthetase	
C592:	 Type	Strain:	
Name	 db_xref	 Length	 Name	 db_xref	 Length	
Formate--tetrahydrofolate	ligase	(EC	6.3.4.3)	CDS	 SEED:fig|6666666.209054.peg.396	 1,668	
formate--tetrahydrofolate	
ligase	CDS	 GI:506241661	 1,668	
Formyl-tetrahydrofolate	cyclohydrolase	/	methylene-tetrahydrofolate	dehydrogenase	
C592:	
	 	
Type	Strain:	
	 	Name	 db_xref	 Length	 Name	 db_xref	 Length	
Methylenetetrahydrofolate	dehydrogenase	(NADP+)	
(EC	1.5.1.5)	/	Methenyltetrahydrofolate	
cyclohydrolase	(EC	3.5.4.9)	CDS	 SEED:fig|6666666.209054.peg.400	 870	
tetrahydrofolate	
dehydrogenase	CDS	 GI:497294816	 870	
Methylene-tetrahydrofolate	reductase	
C592:	
	 	
Type	Strain:	
	 	Name	 db_xref	 Length	 Name	 db_xref	 Length	
bifunctional	homocysteine	S-methyltransferase/5,10-
methylenetetrahydrofolate	reductase	protein	CDS	 SEED:fig|6666666.209054.peg.677	 903	 methionine	synthase	CDS	 GI:497295229	 903	
Carbon	monoxide	dehydrogenase	
C592:	
	 	
Type	Strain:	
	 	Name	 db_xref	 Length	
	 	 	Xanthine	dehydrogenase,	molybdenum	binding	
subunit	(EC	1.17.1.4)	CDS	 SEED:fig|6666666.209054.peg.1780	 2,298	 (Did	not	show	up	in	Mauve	alignment)	
	Phosphate	acetyltransferase	and	acetate	kinase	
C592:	
	 	
Type	Strain:	
	 	Name	 db_xref	 Length	 Name	 db_xref	 Length	
Phosphate	acetyltransferase	(EC	2.3.1.8)	CDS	 SEED:fig|6666666.209054.peg.1464	 999	
phosphate	acetyltransferase	
CDS	 GI:496664653	 999	
Acetate	kinase	(EC	2.7.2.1)	CDS	 SEED:fig|6666666.209054.peg.1463	 1,215	 acetate	kinase	CDS	 GI:496664654	 1,215	
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Figure 3.17:  KEGG map of C592 arginine metabolism genes and the link to Kreb’s cycle 
 
C592 KEGG annotated data generated from BlastKOALA was used with the KEGG Mapper 
Reconstruct Pathway tool, utilizing data from the KEGG Atlas (264).  Green lines indicate genes 
present in C592 that match the relevant annotation in the pathway.  C592 encodes genes allowing 
it to metabolize arginine to ammonia while generating ATP, CO2, and ornithine.  This pathway 
of ATP generation in the E. lenta type strain, outlined in the box, was first described by Sperry et 
al and was described as necessary for optimal E. lenta growth (263).  C592 additionally encodes 
enzymes that allow it to generate fumarate from arginine, which can then be utilized as an 
electron acceptor to form succinate.  C592 encodes numerous redundant fumarate reductases 
throughout its genome.  
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Table 3.6:  Annotated reductases in C592 and E. lenta ATCC 25559 genomes 
 
Reductase	genes	tested	in	Devlin	et.	al	2015	
C592:	 E.	lenta	type	strain:	
Name	 db_xref	 Name	 db_xref	
Confirmed	
activity?	
3-oxoacyl-[acyl-carrier	protein]	reductase	
(EC	1.1.1.100)	CDS	
SEED:fig|6666666.
209054.peg.735	 short-chain	dehydrogenase	CDS	 GI:496664150	 Elen_2515	
	Sorbitol-6-phosphate	2-dehydrogenase	(EC	
1.1.1.140)	CDS	
SEED:fig|6666666.
209054.peg.1846	 3-ketoacyl-ACP	reductase	CDS	 GI:506240750	 Elen_1325	 3β-HSDH	
Dehydrogenases	with	different	specificities	
(related	to	short-chain	alcohol	
dehydrogenases)	CDS	
SEED:fig|6666666.
209054.peg.1011	 short-chain	dehydrogenase	CDS	 GI:496663880	 Elen_2188	
	3-oxoacyl-[acyl-carrier	protein]	reductase	
(EC	1.1.1.100)	CDS	
SEED:fig|6666666.
209054.peg.879	 short-chain	dehydrogenase	CDS	 GI:496663981	 Elen_0690	 3α-HSDH	
3-oxoacyl-[acyl-carrier	protein]	reductase	
(EC	1.1.1.100)	CDS	
SEED:fig|6666666.
209054.peg.1230	 beta-ketoacyl-ACP	reductase	CDS	 GI:496661655	 Elen_1987	
	
Glucose	1-dehydrogenase	(EC	1.1.1.47)	CDS	
SEED:fig|6666666.
209054.peg.3084	 glucose-1-dehydrogenase	CDS	 GI:506240102	 Elen_0198	 3β-HSDH	
?	Gap	in	Mauve	Alignment	
	
short-chain	
dehydrogenase/reductase	SDR	CDS	 GI:506240693	 Elen_1208	
	Other	reductases	in	C592	and	E.	lenta	type	strain	genome	
C592:	 E.	lenta	type	strain:	
Name	 db_xref	 Name	 db_xref	
2,4-dienoyl-CoA	reductase	[NADPH]	(EC	1.3.1.34)	CDS	 SEED:fig|6666666.209054.peg.377	 NADH:flavin	oxidoreductase	CDS	 GI:497294813	
putative	Fe-S	oxidoreductase	CDS	 SEED:fig|6666666.209054.peg.412	 hypothetical	protein	CDS	 GI:506241657	
oxidoreductase	FAD/NAD(P)-binding	CDS	 SEED:fig|6666666.209054.peg.516	
ferredoxin-NADP+	reductase	subunit	
alpha	CDS	 GI:506241633	
3-oxoacyl-[acyl-carrier	protein]	reductase	(EC	1.1.1.100)	
CDS	 SEED:fig|6666666.209054.peg.735	 short-chain	dehydrogenase	CDS	 GI:496664150	
Short-chain	dehydrogenase/reductase	SDR	CDS	 SEED:fig|6666666.209054.peg.851	 short-chain	dehydrogenase	CDS	 GI:496664009	
oxidoreductase	of	aldo/keto	reductase	family,	subgroup	
1	CDS	
SEED:fig|6666666.209054.peg.149
2	
2,5-diketo-D-gluconic	acid	reductase	
CDS	 GI:506240950	
FIG00624394:	hypothetical	protein	CDS	
SEED:fig|6666666.209054.peg.169
2	 FAD-dependent	oxidoreductase	CDS	 GI:497294359	
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Periplasmic	aromatic	aldehyde	oxidoreductase,	FAD	
binding	subunit	YagS	CDS	
SEED:fig|6666666.209054.peg.177
9	 Gap	in	Mauve	Alignment	
Xanthine	dehydrogenase,	molybdenum	binding	subunit	
(EC	1.17.1.4)	CDS	
SEED:fig|6666666.209054.peg.178
0	 Gap	in	Mauve	Alignment	
Periplasmic	aromatic	aldehyde	oxidoreductase,	iron-
sulfur	subunit	YagT	CDS	
SEED:fig|6666666.209054.peg.178
1	 Gap	in	Mauve	Alignment	
Fe-S	oxidoreductase,	related	to	NifB/MoaA	family	with	
PDZ	N-terminal	domain	CDS	
SEED:fig|6666666.209054.peg.183
5	 hypothetical	protein	CDS	 GI:506240759	
predicted	NADPH-dependent	reductase	CDS	
SEED:fig|6666666.209054.peg.189
8	 FMN	reductase	CDS	 GI:496662103	
FIG092679:	Fe-S	oxidoreductase	CDS	
SEED:fig|6666666.209054.peg.191
4	
B12-binding	domain-containing	
radical	SAM	protein	CDS	 GI:506240718	
Heterodisulfide	reductase,	cytochrome	reductase	subunit	
CDS	
SEED:fig|6666666.209054.peg.192
3	 oxidoreductase	CDS	 GI:496662126	
Sarcosine	oxidase	alpha	subunit	(EC	1.5.3.1)	CDS	
SEED:fig|6666666.209054.peg.194
4	 FAD-dependent	oxidoreductase	CDS	 GI:497294180	
Flavin	reductase-like,	FMN-binding:Rubredoxin-type	
Fe(Cys)4	protein	CDS	
SEED:fig|6666666.209054.peg.205
2	 flavin	reductase	CDS	 GI:496662252	
Aldo/keto	reductase:4Fe-4S	ferredoxin,	iron-sulfur	
binding	CDS	
SEED:fig|6666666.209054.peg.212
2	 Fe-S	oxidoreductase	CDS	 GI:506240601	
NAD(FAD)-utilizing	dehydrogenase,	sll0175	homolog	CDS	
SEED:fig|6666666.209054.peg.216
4	 FAD-dependent	oxidoreductase	CDS	 GI:506240573	
Fe-S	OXIDOREDUCTASE	(1.8.-.-)	CDS	
SEED:fig|6666666.209054.peg.242
4	 YgiQ	family	radical	SAM	protein	CDS	 GI:506241324	
Fe-S	oxidoreductase	CDS	
SEED:fig|6666666.209054.peg.265
4	 radical	SAM	protein	CDS	 GI:497295255	
putative	NADH-dependent	flavin	oxidoreductase	CDS	
SEED:fig|6666666.209054.peg.282
3	 NADH:flavin	oxidoreductase	CDS	 GI:506240206	
FMN-dependent	NADH-azoreductase	CDS	
SEED:fig|6666666.209054.peg.288
3	
NAD(P)H	dehydrogenase	(quinone)	
CDS	 GI:496663491	
Aldo/keto	reductase:4Fe-4S	ferredoxin,	iron-sulfur	
binding	CDS	
SEED:fig|6666666.209054.peg.305
7	 Fe-S	oxidoreductase	CDS	 GI:497293772	
Gap	in	Mauve	Alignment	
	
oxidoreductase	CDS	 GI:496664037	
Gap	in	Mauve	Alignment	
	
FAD-dependent	oxidoreductase	CDS	 GI:496661933	
Gap	in	Mauve	Alignment	
	
NADH:flavin	oxidoreductase	CDS	 GI:496661830	
Gap	in	Mauve	Alignment	
	
short-chain	dehydrogenase	CDS	 GI:506240690	
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and dehydrogenases were identified in both C592 and 25559, totaling 26, although not all are 
identified in both genomes via the Mauve alignment (Table 3.6).  Of interest, Devlin et al. 
identified a “bai-like” operon in the E. lenta type strain containing numerous SDR enzymes 
reductases in an operon (150). C592 contains the same operon in high homology, but is missing a 
key enzyme in the pathway, directly downstream of the three SDR enzymes (Figure 3.18).   It 
has been hypothesized that this missing gene directly downstream of three SDR enzymes is the 
gene for the 21-dehydroxylase enzyme, indicating that C592 may not 21-dehydroxylate 
corticoids. 
 
In the determination of cardiac glycoside reductase activity in the E. lenta type strain, a putative 
gene cluster responsible for this activity was identified based on RNAseq results (238).  
However, when searching the aligned genome of C592, this two-gene cluster is absent (Figure 
3.19).  This suggests that C592 should not exhibit digoxin reductase activity.  Alternatively, if 
digoxin reductase activity is measured, it is likely this two-gene cluster in the type strain is not 
responsible for producing the enzymes responsible. 
 
When searching the KEGG maps based on C592, it was found that many genes in the Wood-
Ljungdahl acetogenesis pathway are present.  These same genes are also present in the E. lenta 
type strain genome.  In addition, both genomes encode membrane-energization gene clusters 
responsible for producing multi-subunit hydrogenases capable of functioning as an electron 
transport chain while generating a proton or Na+ gradient.  A Rhodocbacter nitrogen fixation 
(RNF) complex, found in acetogens as a means of coupling ATP generation to the Wood-
Ljungdahl pathway (95-97), is also found in both C592 and 25559 (Figure 3.20).  Not all
 116 
Figure 3.18:  Gene cluster alignment of “bai-like” operon from C592 and 25559 
 
A. Alignment of a gene cluster in C592 and 25559 that contains numerous reductases.  Within 
this series of reductases in the type strain is a gene annotated as a scytalone dehydratase.  It 
shares that annotation to the 7α-dehydratase from C. scindens (265).   We hypothesize that this 
gene encodes the enzyme responsible for the 21-dehydroxylase enzyme.  B.  E. lenta type strain 
has been reported to have 21-dehydroxylase activity previously (247, 248).  Interestingly, this 
putative gene is missing from C592 while the two flanking genes remain with high homology.  
C592 is currently being tested for its ability to 21-dehydroxylate deoxycortisone.  
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Figure 3.19:  Gene cluster alignment of the putative cardiac glycoside reductase operon 
from C592 and 25559 
 
Gene cluster identified by Haiser et al to encode the cardiac glycoside reductase in Eggerthella 
lenta ATCC 25559 is missing from C592. Homologous genes are not found elsewhere in the 
genome.  C592 is currently being tested for cardiac glycoside reductase activity, although based 
on the absence of the genes predicted to encode activity, it is hypothesized it will not exhibit the 
phenotype.  
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Figure 3.20:  Gene cluster alignment of RNF complex operon from C592 and 25559 
 
Gene clusters in C592 and 25559 annotated to encode an RNF complex are similar to those 
found in acetogens (95-97).  Green bar above the mauve alignment indicates level of homology.  
Green indicates >90% homology, yellow indicates 30-90% homology, red indicates >30% 
homology.  The operon encoding the RNF complex is highly conserved between the two strains. 
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acetogens harbor genes for an RNF complex, others instead encode “energy conserving 
hydrogenase” (Ech) complexes that similarly generate a proton gradient while generating H2 
from reduced ferredoxin (266).  Both C592 and 25559 also harbor a putative Ech gene cluster 
(Figure 3.21).  In addition, both strains harbor ATP synthase transmembrane complexes, able to 
utilize this proton gradient generated from RNF and Ech complexes to generate ATP from ADP 
(Figure 3.22).  Taken together, these results strongly suggest that both C592 and 25559 share 
many genetic similarities to acetogens, especially with regard to redox balancing and ATP 
generating processes. 
 
One important molecule for acetogenesis is CO2, which can be quickly utilized in anaerobic 
environments.  Therefore, the ability to form CO2 independently would be evolutionarily 
advantageous for an acetogen.  C592 has genes to metabolize arginine and agmatine to form a 
carbamoyl phosphate intermediate and carbamate kinases to ultimately generate ATP, CO2, and 
ammonia (Table 3.7).  In addition, C592 appears to harbor multiple amino acid decarboxylases.  
A gene encoding a putative glutamate decarboxylase was located next to a glutamate/gamma-
aminobutyric acid (GABA) antiporter, indicating C592 could metabolize glutamate to GABA + 
CO2 and then use CO2 as an electron acceptor (Table 3.8).  In addition, C592 is annotated to 
have a histidine decarboxylase, which would yield histamine and CO2 from histidine (Table 3.8).  
Taken together, it is apparent that C592 has numerous avenues for generating its own CO2 via 
intracellular processes, depending on substrate availability.  Additionally, C592 appears to have 
the ability to make biogenic amines, such as GABA and histamine, which could have significant 
effects on host physiology. 
 
 123 
Figure 3.21:  Gene cluster alignment of energy-conserving hydrogenase operon from C592 
and 25559 
 
Gene clusters in C592 and 25559 annotated to encode an Ech complex are similar to those found 
in acetogens not harboring an RNF complex (98, 266).  Green bar above the mauve alignment 
indicates level of homology.  Green indicates >90% homology, yellow indicates 30-90% 
homology, red indicates >30% homology.  The operon encoding the Ech complex is highly 
conserved between the two strains. 
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Type 
C592 
Consensus	identity 
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Figure 3.22:  Gene cluster alignment of ATP synthase operon from E. lenta strains C592 
and 25559 
 
Gene clusters in C592 and 25559 annotated to encode an ATP synthase operon. This 
transmembrane protein would be able to utilize a putative proton gradient generated from either 
Ech- or RNF-complexes to generate ATP (93, 266). 
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Table 3.7: Annotated arginine and agmatine metabolism genes in E. lenta strain C592 
 
Name	 db_xref	
Arginine	deiminase	(EC	3.5.3.6)	CDS	 SEED:fig|6666666.209054.peg.3131	
Agmatine	deiminase	(EC	3.5.3.12)	CDS	 SEED:fig|6666666.209054.peg.2844	
Arginine	deiminase	(EC	3.5.3.6)	CDS	 SEED:fig|6666666.209054.peg.1265	
Agmatine	deiminase	(EC	3.5.3.12)	CDS	 SEED:fig|6666666.209054.peg.866	
Agmatine	deiminase	(EC	3.5.3.12)	CDS	 SEED:fig|6666666.209054.peg.857	
Ornithine	carbamoyltransferase	(EC	2.1.3.3)	CDS	 SEED:fig|6666666.209054.peg.2843	
Aspartate	carbamoyltransferase	(EC	2.1.3.2)	CDS	 SEED:fig|6666666.209054.peg.1518	
Ornithine	carbamoyltransferase	(EC	2.1.3.3)	CDS	 SEED:fig|6666666.209054.peg.1266	
Putrescine	carbamoyltransferase	(EC	2.1.3.6)	CDS	 SEED:fig|6666666.209054.peg.864	
Putrescine	carbamoyltransferase	(EC	2.1.3.6)	CDS	 SEED:fig|6666666.209054.peg.855	
Ornithine	carbamoyltransferase	(EC	2.1.3.3)	CDS	 SEED:fig|6666666.209054.peg.593	
Carbamate	kinase	(EC	2.7.2.2)	CDS	 SEED:fig|6666666.209054.peg.1267	
Carbamate	kinase	(EC	2.7.2.2)	CDS	 SEED:fig|6666666.209054.peg.867	
Carbamate	kinase	(EC	2.7.2.2)	CDS	 SEED:fig|6666666.209054.peg.858	
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Table 3.8: Annotated glutamate and histidine decarboxylationg genes in E. lenta strain 
C592 
 
Name db_xref 
Probable glutamate/gamma-aminobutyrate 
antiporter CDS SEED:fig|6666666.209054.peg.3136 
Glutamate decarboxylase (EC 4.1.1.15) CDS SEED:fig|6666666.209054.peg.3135 
histidine decarboxylase, pyruvoyl type( 
EC:4.1.1.22 ) CDS 
SEED:fig|6666666.209054.peg.753 
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Within the realm of carbon metabolism, C592 has genes encoding an incomplete TCA cycle 
(Table 3.9).  Of particular interest, C592 appears to encode duplicate genes for fumarate 
reductase, a mechanism by which anaerobic bacteria are able to deposit reducing equivalents 
onto fumarate to generate succinate.  Additionally, the C592 genome encodes genes for 
generating fumarate from arginine, including an arginosuccinate synthase and arginosuccinate 
lyase (Table 3.10).  Fumarate is widely utilized anaerobically as a potential electron acceptor, 
leading to the formation of succinate (36).  Previous work with the type strain of E. lenta as well 
as preliminary fermentative end product analysis (data not shown) suggest that both C592 and 
25559 generate succinate as well as acetate as their major fermentative end products.  The 
incomplete TCA cycle of C592 (ending at succinate), the multitude of fumarate reductases, and 
the ability to shift arginine to fumarate, suggests fumarate is a major electron acceptor in E. 
lenta.  C592 also has genes that encode various other electron-accepting reactions, such as 
dimethyl sulfoxide reduction and nitrogen reduction (data not shown).  Acetogens are described 
as being a heterogenous group of organisms, specifically with regard to their utilization of 
various electron donors and electron acceptors (93).  These results correlate with those findings 
in other acetogenic bacteria, as both C592 and E. lenta appear to utilize numerous bile acids and 
steroids as electron donors and various other molecules as electron acceptors. 
 
  Varying atmospheric gases changes C592 and 25559 bile acid and steroid metabolism 
 
Since both 25559 and C592 appear to be acetogens based on genetic composition and previous 
fermentative end product analysis, next we tested the effects altered atmospheric gases would 
have on bile acid metabolism.  It was hypothesized since hydroxyl groups on bile acids were 
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Table 3.9: Annotated genes from the Kreb’s cycle in E. lenta strain C592 
 
Gene	Name	 db_xref	
Citrate	synthase	(si)	(EC	2.3.3.1)	CDS	 SEED:fig|6666666.209054.peg.20	
Aconitate	hydratase	(EC	4.2.1.3)	CDS	 SEED:fig|6666666.209054.peg.2429	
Isocitrate	dehydrogenase	[NAD]	(EC	1.1.1.41)	
CDS	 SEED:fig|6666666.209054.peg.2430	
Isocitrate	dehydrogenase	[NADP]	(EC	1.1.1.42)	
CDS	 SEED:fig|6666666.209054.peg.1697	
2-oxoglutarate	oxidoreductase,	gamma	subunit	
(EC	1.2.7.3)	CDS	 SEED:fig|6666666.209054.peg.1488	
2-oxoglutarate	oxidoreductase,	beta	subunit	
(EC	1.2.7.3)	CDS	 SEED:fig|6666666.209054.peg.1487	
2-oxoglutarate	oxidoreductase,	alpha	subunit	
(EC	1.2.7.3)	CDS	 SEED:fig|6666666.209054.peg.1486	
2-oxoglutarate	oxidoreductase,	delta	subunit,	
putative	(EC	1.2.7.3)	CDS	 SEED:fig|6666666.209054.peg.1485	
Malate	dehydrogenase	(EC	1.1.1.37)	CDS	 SEED:fig|6666666.209054.peg.2038	
fumarate	hydratase	CDS	 SEED:fig|6666666.209054.peg.2035	
Fumarate	hydratase	class	I,	aerobic	(EC	
4.2.1.2);	L(+)-tartrate	dehydratase	beta	subunit	
(EC	4.2.1.32)	CDS	 SEED:fig|6666666.209054.peg.2034	
Succinate	dehydrogenase	flavoprotein	subunit	
(EC	1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3027	
Succinate	dehydrogenase	iron-sulfur	protein	
(EC	1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3026	
fumarate	reductase/succinate	dehydrogenase	
flavoprotein	domain	protein	CDS	 SEED:fig|6666666.209054.peg.2659	
Succinate	dehydrogenase	flavoprotein	subunit	
(EC	1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.36	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3180	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3162	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3118	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3101	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3100	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.3074	
Fumarate	reductase	flavoprotein	subunit	(EC	 SEED:fig|6666666.209054.peg.2904	
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1.3.99.1)	CDS	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2860	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2775	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2772	
putative	fumarate	reductase	flavoprotein	
subunit	CDS	 SEED:fig|6666666.209054.peg.2742	
putative	fumarate	reductase	flavoprotein	
subunit	CDS	 SEED:fig|6666666.209054.peg.2736	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2731	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2727	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2679	
fumarate	reductase/succinate	dehydrogenase	
flavoprotein	domain	protein	CDS	 SEED:fig|6666666.209054.peg.2659	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2633	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2449	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2385	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2353	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2301	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2227	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.2195	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.1967	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.1768	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.1642	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.1095	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.1084	
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putative	fumarate	reductase	flavoprotein	
subunit	CDS	 SEED:fig|6666666.209054.peg.875	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.695	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.656	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.613	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.606	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.561	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.545	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.522	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.480	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.472	
putative	fumarate	reductase	flavoprotein	
subunit	CDS	 SEED:fig|6666666.209054.peg.471	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.364	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.243	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.217	
Fumarate	reductase	flavoprotein	subunit	(EC	
1.3.99.1)	CDS	 SEED:fig|6666666.209054.peg.19	
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Table 3.10:  Annotated genes for arginine biosynthesis in E. lenta strain C592  
 
Name	 db_xref	
Argininosuccinate	synthase	(EC	6.3.4.5)	CDS	 SEED:fig|6666666.209054.peg.2435	
Argininosuccinate	lyase	(EC	4.3.2.1)	CDS	 SEED:fig|6666666.209054.peg.2434	
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being used as electron donors, if a more energetically favorable electron donor was present then 
C592 and 25559 would shift to utilizing that electron donor and the oxidation of bile acids would 
be inhibited.  Both C592 and 25559 encode membrane-associated and cytoplasmic ferredoxin 
hydrogenases (including and Ech complex described above) capable of utilizing hydrogen to 
reduce oxidized ferredoxin.  The RNF complex, as well as other electron-bifurcating enzymes 
not yet identified in C592 or E. lenta, can then move electrons from reduced ferredoxin to 
oxidized NAD+, thereby generating reduced NADH, which would ultimately inhibit bile acid 
oxidation. C592 and 25559 metabolism of CDCA was tested under inert nitrogen, carbon 
dioxide, and hydrogen gas to mimic gases that might be present to varying degrees in the human 
intestinal tract to see if any changes in bile acid or steroid metabolism occurred. Under inert N2 
gas, C592 and 25559 completely metabolize CDCA into mostly CDCA-A and CDCA-C, 
although the relative amount is different between strains (Figure 3.23).  When grown in the 
presence of CO2 gas, CDCA was completely metabolized to the same three CDCA metabolites 
found under N2 gas culture conditions, although CDCA-A is the major metabolite for both strains 
(Figure 3.24).  When grown in the presence of H2 gas, CDCA metabolism by both C592 and 
25559 is significantly inhibited (Figure 3.25).  While there was some production of 7-oxo-CDCA 
and 3-oxo-CDCA, the majority of the CDCA remains unutilized in the cell cultures.  These 
experiments were repeated for both C592 and 25559 metabolism of testosterone.  Under H2, both 
C592 and 25559 have their metabolism of testosterone completely inhibited (data not shown). 
These results show that C592 and 25559 are able to shift their electron donors, and ultimately 
bile acid and steroid metabolism, based on substrate availability, preferring to use the most 
energetically favorable substrate possible.  Such an ability to be flexible with redox balancing is 
beneficial for any microbe living in the competitive environment of the human intestinal tract.  
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Figure 3.23:  Quantitation of C592 and 25559 metabolites of CDCA when grown overnight 
under inert N2 gas 
 
C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and 
1µCi [24-14C]-CDCA under inert N2, extracted, and run on TLC as previously described.  Bands 
corresponding to CDCA metabolites were scraped and the relative amounts of each were 
determined through liquid scintillation spectrometry.  Representative TLC on left.  Top right 
indicates relative amount of each of the metabolites with pie charts to show amounts relative to 
total radioactivity detected from lane, experiment run in triplicate.  The major product for 25559 
under N2 is 7-oxo-3α-chenodeoxycholic acid, whereas for C592 it is 3,7-dioxo-
chenodeoxycholic acid.    
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Figure 3.24:  Quantitation of C592 and 25559 metabolites of CDCA when grown overnight 
under CO2 gas 
 
C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and 
1µCi [24-14C]-CDCA under CO2, extracted, and run on TLC as previously described.  Bands 
corresponding to CDCA metabolites were scraped and the relative amounts of each were 
determined through liquid scintillation spectrometry.  Representative TLC on left.  Top right 
indicates relative amount of each of the metabolites with pie charts to show amounts relative to 
total radioactivity detected from lane, experiment run in triplicate.  The major product for 25559 
and C592 CDCA metabolism under CO2 is 7-oxo-3α-chenodeoxycholic acid. 
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Figure 3.25:  Quantitation of C592 and 25559 metabolites of CDCA when grown overnight 
under H2 gas 
 
C592 and E. lenta ATCC 25559 were grown overnight in the presence of 25µM CDCA and 
1µCi [24-14C]-CDCA under CO2, extracted, and run on TLC as previously described.  Bands 
corresponding to CDCA metabolites were scraped and the relative amounts of each were 
determined through liquid scintillation spectrometry.  Representative TLC on left.  Top right 
indicates relative amount of each of the metabolites with pie charts to show amounts relative to 
total radioactivity detected from lane, experiment run in triplicate.  The major product for 25559 
and C592 CDCA metabolism under CO2 is 7-oxo-3α-chenodeoxycholic acid. 
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C592 oxo-bile acid derivatives inhibit 7α-dehydroxylation in vitro 
 
Since C592 and 25559 both exhibited significant changes in bile acid metabolism based on 
atmospheric gas composition, we first wanted to test if a similar effect occurred with 7a-
dehydroxylating bacteria.  We performed the same bile acid metabolism test as above using the 
7α-dehydroxylating bacteria Clostridium scindens VPI 12708 (12708).  There was no significant 
effect of CO2 or H2 gas atmosphere on CA or CDCA 7a-dehydroxylation by 12708 (Figure 
3.26).  Next we tested the impact of the formation of oxo-bile acids on the 7α-dehydroxylation 
of primary bile acids by 12708.  We isolated [14C]-labeled CDCA metabolites (CDCA-A, 
CDCA-B, CDCA-C) and introduced them into a growing culture of 12708.  After 24 hours, 
12708 was able to reduce CDCA-A back to CDCA and subsequently 7α-dehydroxylate a portion 
of the newly formed CDCA (Figure 3.27).  Over the same time course, 12708 metabolized 7-
oxo-3β-chenodeoxycholic acid (CDCA-B) to a product whose Rf matched iso-CDCA (3β-
CDCA), but was unable to subsequently 7α-dehydroxylate (Figure 3.26). C. scindens VPI 12708 
is known to have 3α-HSDH and 7α-HSDH activity (148) but has never reported to have 3β-
HSDH activity, possibly explaining the lack of 7α-dehydroxylation of the 3β CDCA-B 
metabolite.  When CDCA-C was added to growing cultures of 12708, it was only partially 
reduced back to a mixture of CDCA and 3-oxo-CDCA (Figure 3.27).  These results suggest in 
vitro, two of the three major bile acid products from C592 and 25559 metabolism of CDCA 
prevent effective 7α-dehydroxylation by 12708.  When C592 and 12708 were grown in a mixed 
culture containing CDCA, the pattern of CDCA metabolites suggested a significant decrease in 
7α-dehydroxylation when compared to the results of a 12708 pure culture (Figure 3.28).  Likely  
 
 142 
Figure 3.26:  C. scindens VPI 12708 metabolism of CA and CDCA does not change under 
anaerobic CO2 or H2 atmospheric gas 
 
Clostridium scindens VPI 12708 was grown overnight in anaerobic BHI in the presence of 
25mM CA or CDCA and 1µCi CA or CDCA under varying atmospheric conditions (N2, CO2, or 
H2).  Cultures were extracted and run on TLC plates as described in Materials and Methods.  C. 
scindens VPI 12708 did not alter its metabolism of CA or CDCA under any of the varying 
atmospheric gases.  
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Figure 3.27:  C. scindens VPI 12708 recognizes C592 CDCA metabolites but is unable to 
effectively 7α-dehydroxylate 
 
A.  First spot is a CDCA TLC standard.  Next two spots are C592/12708 overnight cell culture 
conversions of CDCA.  C592 generates three products as described above.  12708 generates one 
major metabolite, lithocholic acid (LCA), indicated by the black star.  B.  The three CDCA 
metabolites were isolated, concentrated, and added to 12708 overnight cultures at approximately 
25µM final concentration. 7-oxo-3α-CDCA (red star) was reduced back to CDCA by 12708.  
Some trace LCA is formed, but not as significant as 12708 + CDCA cell culture.  C.  12708 
reduces 7-oxo-3β-CDCA (green star) to a band that does not comigrate with CDCA.  This band 
has a similar Rf to 3β-CDCA (iso-CDCA), suggesting 12708 reduces this metabolite back to iso-
CDCA.  However, 7α-dehydroxylation does not appear to occur, suggesting 12708 is unable to 
7α-dehydroxylate the 3β-epimer.  D.  12708 recognizes 3,7-dioxo-CDCA (yellow star) and 
produces two major metabolites.  One metabolite comigrates with CDCA, while the other 
comigrates with 3-oxo-CDCA.  There does not appear to be any metabolite formed that 
comigrates with LCA.  
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Figure 3.28:  Coculture of C. scindens VPI 12708 and C592 inhibits 7α-dehydroxylation of 
CDCA 
 
A.  C. scindens VPI 12708 whole cell conversion of CDCA.  B.  C592 whole cell conversion of 
CDCA.  C.  10mL anaerobic BHI broth under N2 was inoculated with 1% overnight culture of 
both 12708 and C592 along with 25mM CDCA and 1mCi [24-14C]-CDCA.  This coculture was 
grown overnight at 37ºC and then extracted and run on TLC as described above.  The coculture 
CDCA pattern of metabolites matches neither the C592 nor 12708 patterns.  A significant 
amount of CDCA remains, while the other major product comigrates with 7-oxo-3α-CDCA.  
This suggests that in coculture, C592 and 12708 cycle CDCA back and forth between an 
oxidized and 3α-reduced C7-oxo group.  
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these two gut bacteria cycle between oxidation and reduction of hydroxyl groups on the bile 
acids regulating secondary bile acid formation. 
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Discussion: 
 
E. lenta is a normal inhabitant of the human intestinal microbiome.  It has been studied due to its 
propensity to metabolize bile acids and steroids, including the isomerization of primary and 
secondary bile acids at the 3-hydroxyl group (150) and the 21-dehydroxylation of corticoids 
(248).  The effects of these biotransformations are significant for both the gut microbiome as a 
whole and the host. E. lenta-derived glucocorticoid metabolites can inhibit renal cells ability to 
modulate response to cortisol, ultimately leading to fluid retention and hypertension (251).  
Isomerized secondary bile acids, such as iso-DCA, have been shown to be less toxic to other 
members of the gut microbiome at physiological concentrations (150).  Additionally, isomerized 
secondary bile acids have been hypothesized to be less toxic to colonocytes.  However, the 
pattern of isomerization requires what would at the surface appear to be an energetically 
unfavorable oxidation of a hydroxyl group in an anaerobic environment.  Oxidized bile acids 
(oxo-BA), or bile acids with a ketone hydroxyl moiety, were thought to be intermediates in the 
ultimate bile acid metabolism profile. However, oxidized bile acids are known to be present in 
significant amounts in serum, portal blood, fecal water, and fecal pellets (158-163, 267).  
Cholecystectomized patients are reported to have increased oxo-BA in portal circulation, likely 
due to more primary bile acids escaping into the large intestine and undergoing metabolism by 
gut microbes (165).  Oxo-BA have been shown to have differing agonistic properties than their 
fully reduced counterparts for host nuclear and G-protein coupled receptors.  For instance, 3-
oxo-LCA is the most potent bile acid VDR receptor agonist (175).  However, oxo-BA receptor 
activation remains to be fully tested for other known receptors that respond to bile acids.  
Additionally, how the oxidation of the hydroxyl groups of bile acids by E. lenta plays into its 
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general host metabolism is not known, instead the studies focused on the effects of the fully 
reduced end products.  Additionally, the effects of oxidation or epimerization of hydroxyl groups 
on other gut microbes, specifically those that are known to metabolize bile acids, had not been 
previously studied. 
 
In the current study, a novel strain of Eggerthella lenta, C592, was characterized, with an 
emphasis on the composition of its genome as well as its steroid and bile acid metabolism 
profile.  C592 was originally isolated from the fecal sample from Okinawa, Japan. Initially 
suspected to be a 7α-dehydroxylating bacterium, C592 was shown to create both mono- and di-
keto bile acid metabolites from CDCA.  Additionally, it was shown to completely metabolize 
secondary bile acids DCA and LCA to numerous secondary metabolites.  When compared to 
high activity and low activity 7α-dehydroxylating bacteria, most are not able to completely 
convert CA and CDCA to secondary metabolites.  Conversely, C592 was shown to convert 
concentrations of CDCA that can inhibit the growth of other bacteria (500µM) to secondary 
metabolites.  This pattern of metabolites initially suggested an irreversible conversion of primary 
bile acids, such as 7α-dehydroxylation.  However, MS analysis confirmed the CDCA and DCA 
C592 metabolites lost two or four mass units, indicating oxidation of one or two hydroxyl 
groups, respectively. 
 
C592 was subsequently determined to have high 16S sequence similarity to the Eggerthella lenta 
type strain.  Various E. lenta strains had been shown previously to have 3α-HSDH, 7α-HSDH, 
and 12α-HSDH activity (151, 153).  However, complete oxidation of primary and secondary bile 
acids by E. lenta was not noted in the literature.  Additionally, the accumulation of dioxo-
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primary or secondary bile acids in E. lenta whole cell extracts, such as 3,7-dioxo-CDCA or 3,12-
oxo-DCA, was not reported.  This study also shows that both C592 and the E. lenta type strain 
have 17β-HSDH activity, capable of converting testosterone to its precursor, androstenedione.  
While E. lenta has been reported to metabolize some steroids, 17β-HSDH activity has never 
before been reported.  Testosterone and other androgens are known to be excreted in the bile and 
become substrates for metabolism by gut microbes (268). Additionally, androgens may undergo 
passive diffusion across colonocytes.  The effects of bacterial inactivation of androgens on host 
physiology is not known, however the conservation of these genes in numerous strains of E. 
lenta indicate they give some evolutionary advantage. 
 
In this study, a full, closed genomic sequence for the novel C592 E. lenta strain was determined.  
Impressively, it maintains high genomic and metabolic similarities to the Eggerthella lenta type 
strain isolated from a patient in Europe in the 1930s.  This strong homology over both temporal 
and geographical differences emphasizes the importance of its set of genes, especially those for 
bile acid metabolism, in its ability to grow in the niche environment of the human intestinal tract.  
However, some differences between C592 and the type strain arose.  For instance, the cgr gene 
locus reported to encode the gene for digoxin reductase was not found in C592.  Current testing 
of C592 is underway in order to ascertain its ability to reduce digoxin in vitro.  The results of 
these future experiments will be important, as the clear lack of the described “cgr locus” from the 
type strain should indicate C592 would not have the ability to reduce digoxin.  However, if it is 
able to successfully reduce digoxin, it is likely this gene cluster does not in fact encode the 
enzymes responsible for catalyzing this reaction 
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Additionally, a bai-like operon in E. lenta was identified in the Devlin et al. study describing the 
enzymes responsible for 3α-hydroxyl epimerization of bile acids (150).  Within this operon and 
downstream of three SDR family enzymes is a gene that is currently being analyzed by 
collaborators as the putative 21-dehydroxylase, the enzyme responsible for 21-dehydroxylation 
of glucocorticoids.  The gene responsible for the production of this enzyme has not been 
previously reported.  However, this gene is conspicuously absent from C592.  In fact, both genes 
flanking this putative 21-dehydroxylase are there with high similarity.  This suggests that C592 
may not have 21-dehydroxylase activity in vitro.  Experiments to ascertain C592’s ability to 
perform the 21-dehydroxylase reaction are ongoing, although preliminary results suggest it does 
not have the activity (data not shown). 
 
Whole genome sequencing of C592 allowed for better determination of the reasoning behind the 
formation of these oxo-bile acid derivatives.  The anaerobic environment in the colon has a very 
low redox potential, therefore the oxidation of bile acid hydroxyl groups would appear to be 
energetically unfavorable.  However, numerous previous observations gave us direction, 
including E. lenta production of acetate and succinate as its only fermentative end products (VPI 
Anaerobe Laboratory Manual) and its propensity to utilize CO2 gas from its headspace during 
growth (VPI Anaerobe Laboratory Manual, past laboratory observations).  It was found that 
C592, along with the type strain, harbor genes encoding the majority of the enzymes in the 
Wood-Ljungdahl pathway.  This pathway of fixing CO2 to produce acetate requires 
numerousreducing equivalents, including reduced ferredoxin and NADH (93) and is an 
explanation as to why C592 was preferentially oxidizing bile acids (Figure 3.29). Under inert 
nitrogen gas, C592/25559 oxidation of bile acids would generate reduced pyridine nucleotides.
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Figure 3.29:  Illustration of C592 whole cell redox balancing with bile acids under low H2 
partial pressure 
 
C592, under low H2 partial pressure, preferentially oxidizes bile acids.  This would lead to an 
increased level of reduced pyridine nucleotides, which could either be cycled through the RNF 
complex to generate reduced ferredoxin or be used in other metabolic processes, such as the 
Wood-Ljungdahl pathway.    
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These reduced pyridine nucleotides could then be transferred to oxidized ferredoxin while 
utilizing a H+ or Na+ gradient via the putative RNF complex, also located in C592 and E. lenta 
type strain. Reduced ferredoxin could then be used in the Wood-Ljundahl pathway to generate 
acetate.  Additionally, the reduced ferredoxin could be used to generate a H+ gradient via the 
putative Ech complex located in both C592 and E. lenta type strain genome.  Ultimately, under 
inert gas, C592 and 25559 use bile acids as electron donors for various other metabolic 
pathways. 
 
This study showed that the tendency of E. lenta strains to oxidize bile acids is sensitive to the 
atmospheric gases present.  When the atmospheric gas in the headspace was changed to 100% 
hydrogen, oxidation of bile acids was significantly inhibited.  The reasoning behind this shift 
gives further insight into why C592 and 25559 oxidize bile acids.  C592 and 25559 encode 
numerous genes annotated to be ferredoxin oxidoreductases.  This family of enzymes is able to 
utilize H2 to reduce ferredoxin.  Additionally, the membrane-bound Ech complex, also present in 
both C592 and 25559, can perform a similar reaction while utilizing a proton gradient.  The RNF 
complex can utilize reduced ferredoxin to generate a proton gradient and reduced NADH.  
Reduced NADH can be utilized in various metabolic pathways, including the Wood-Ljungdahl 
pathway to create acetate.  The proton gradient generated from the RNF complex can be used to 
generate ATP via ATP synthase.  Energetically, the oxidation of H2 to form reduced ferredoxin 
is a more favorable reaction than the oxidation of bile acid hydroxyl groups, as H2 has a redox 
potential (Eº’) of -0.421 V while NADH is -0.315 V (41).  Therefore, when H2 is abundant, C592 
is able to switch to the higher energy electron donor to regenerate both reduced ferredoxin and 
NADH, while generating a H+ gradient for ATP generation (Figure 3.29).  More 
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experimentation about this putative link between bile acid metabolism and acetogenesis in E. 
lenta should be performed, including the confirmation of acetate generation from CO2 utilizing 
radiolabeled CO2 gas.  Collaborators are currently testing the fermentative end products 
produced by both C592 and 25559 under the various gas atmospheres used to screen bile acid 
metabolism.  Additionally, the presence or absence of bile acids will be tested to see its impacts 
on the amount of fermentative end products, as we hypothesize if E. lenta has more access to 
electron donors, then it will produce quantitatively more acetate. 
 
Another important observation was the effect that oxo-bile acid production by E. lenta strains 
has on other bacteria that metabolize bile acids.  The ability for high-activity 7α-dehydroxylating 
bacteria to produce LCA from oxo-CDCA metabolites was impaired.  Additionally, co-culturing 
of C592 and 12708 prevented formation of LCA, even though in pure cultures C592 grows to 
only two tenths the optical density of 12708 in the same time frame (data not shown).  The two 
major bands from the coculture assay were CDCA and 7-oxo-CDCA, indicating both strains 
cycle the bile acid hydroxyl groups between oxidation and reduction.  Taken together, these 
results suggest that in the human colon, under conditions of low available H2, that E. lenta strains 
could prevent 7α-dehydroxylation of primary bile acids (Figure 3.29).  
 
This has significant implications for C592 and E. lenta bile acid metabolism in vivo.  The 
composition of gas in the colon, specifically with regard to H2, can vary significantly.  Both 
methanogens and sulfidogens utilize H2 and have higher affinity to H2 than acetogens. However, 
the amount of methanogens found in colonic samples can vary on individuals to be undetectable 
to over 109 CFU/g stool (47). Additionally, even if hydrogen sulfide producing bacteria are 
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present, sulfidogenesis requires the presence of sulfate or sulfite to occur.  Some patients who 
have a very high level of bacterial fermentation occurring in their colon, such as native Africans 
eating a diet rich in complex carbohydrates, can have additional H2 in their colon above what is 
already being utilized by methanogens and sulfidogens (14, 269).  Therefore, E. lenta strains’ 
ability to oxidize bile acids, if solely determined by availability of H2, could be altered based on 
the amount of bacterial fermentation, presence of methanogens, presence of sulfidogens, and 
presence of sulfate/sulfite in the colon (Figure 3.30).  This ability to metabolize primary bile 
acids would then affect the ability for 7α-dehydroxylating bacteria to product more toxic 
secondary bile acids.   
 
Current metrics for measuring the “metabolic potential” of an individual’s gut microbiome relies 
on OTUs, or groups of bacteria able to carry out specific metabolic reactions.  However, this 
method lacks the resolution to see both differences between members of the same OTUs, such as 
C592 vs. other strains of E. lenta.  Additionally, it cannot adequately take into account other 
variables that may affect microbial metabolism in vivo more than whether or not the genes are 
present, demonstrated by C592 and E. lenta bile acid oxidation reliance on a lack of available 
higher-energy electron donors. 
 
Since secondary bile acids have been shown to be toxic molecules involved in many 
pathophysiological gastrointestinal disorders, E. lenta may turn out to be a very desirable 
bacterium in the colon, under the right circumstances.  However, not all E. lenta strains were 
created equal.  A strain such as C592, which does not contain the cardiac glycoside reductase 
operon nor the putative 21-dehydroxylase gene, may be a better probiotic candidate.  
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Figure 3.30:  Illustration of C592 whole cell redox balancing with bile acids under high H2 
partial pressure 
 
C592, under high H2 partial pressure, significantly cuts back on its metabolism of bile acids.  
This is likely due to the fact that H2 is able to directly reduce oxidized ferredoxin via cytoplasmic 
and membrane bound ferredoxin oxidoreductases.  Reduced ferredoxin could then either be 
cycled through the RNF complex to generate reduced pyridine nucleotides or be used in other 
metabolic processes, such as the Wood-Ljungdahl pathway.  Increased concentration of 
intracellular reduced pyridine nucleotides would inhibit the oxidation of bile acids.  
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Additionally, it has been shown that metabolism of primary bile acids has been associated with a 
resistance to antibiotic-induced C. difficile infection (209).  However, the effects of oxo-bile acid 
derivatives have not been studied.  Future experiments are warranted to look at the possible 
protective effects oxo-bile acids could have to prevent C. difficile spore germination. 
 
The major products of C592 and E. lenta bile acid metabolism determined in this study, oxo-bile 
acids, may be the explanation behind previous studies involving E. lenta.  In a study of 
conventionalized ex-germ free mice, Claus et al. found that both the C. scindens and E. lenta 
OTUs were correlated with significant increases in hepatic triglyeride levels.  The authors 
hypothesized that secondary bile acids DCA and LCA, produced by gut microbes such as C. 
scindens, were responsible for this increase since they are the most potent bile acid activators for 
TGR-5, which can ultimately lead to GLP-1 production, pancreatic insulin release, and hepatic 
triglyceride synthesis.  However, E. lenta is not shown to make secondary bile acids DCA or 
LCA, which was also confirmed by this study.  This suggests that other bile acid derivatives 
made by E. lenta, such as oxo-bile acids, have a significant role in modulating host physiology.  
More studies are needed to see the effects of varying oxidation states of the various hydroxyl 
groups on primary bile acids CA and CDCA to further understand this interaction.   
 
The studies described in this report give insight into how E. lenta and novel strain C592 are able 
to link bile acid metabolism to redox balancing.  It is the first report of acetogenic gene clusters 
in E. lenta and asserts its role as an acetogen in the gut microbiome.  The formation of oxo-bile 
acid derivatives is also shown to inhibit microbial 7α-dehydroxylation.  More studies, like those 
outlined above, are needed to understand the complex interactions between E. lenta, other gut 
 161 
microbes, and the host under varying conditions which might alter its bile acid and steroid 
metabolic profile.  However, it is apparent that oxo-bile acids, often overlooked as metabolic 
intermediates, are important molecules both for gut microbial physiology and for host 
physiology. 
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Chapter 4:  Clostridium scindens ATCC 35704 Δ4,6 reductase gene discovery 
 
Introduction: 
 
The human liver synthesizes two primary bile acids from cholesterol, cholic acid (3α, 7α, 12α-
trihydroxy-5β-cholan-24-oic acid; CA) and chenodeoxycholic acid (3α, 7α-dihydroxy-5β-cholen-
24-oic acid; CDCA). Bile acids are conjugated to either taurine or glycine and secreted into the 
gallbladder where they form a major constituent of bile. Meal induced hormonal stimulation of 
the gallbladder results in secretion of bile into the small bowel where bile salts function to 
solubilize lipids and lipid-soluble vitamins. When bile salts reach the terminal ileum, they are 
actively transported across the epithelium and return to the liver in the portal circulation. This 
process is termed the enterohepatic circulation and is 95% efficient (113). However, roughly 
400-800 mg of bile salts escape into the large bowel where they encounter a population of 
microbes whose functional gene capacity dwarfs that of the host. Indeed, 99% of functional 
genes in the human are microbial and most of these reside in the gut microbiome (132).  Of these 
functional genes, there are two classes of enzymes that have the capacity to alter bile salt 
structure and thereby change the composition of the bile acid pool (270). 
 
When bile salts encounter the gut microbiome, they are rapidly deconjugated to free bile acids 
and taurine or glycine by an enzyme encoded by the bile salt hydrolase (BSH) gene. BSH is 
widespread among members of the gut microbiome (116). Once the free bile acid is liberated, it 
becomes a substrate for bile acid 7α-dehydroxylation (BA7). BA7 is a multi-enzyme biochemical 
pathway that results in the removal of the 7α-hydroxy group through a series of oxidation 
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reactions (Figure 4.1). Unlike BSH, BA7 is found in only a few species within the genus 
Clostridium (125).  Studies in numerous Clostridia strains led to the discovery of an eight-gene 
operon that was upregulated in the presence of primary unconjugated bile acids (262, 265, 271-
277).  Work on determining the enzymes in this bile acid-induced operon (bai operon) and the 
genes responsible for their production has yielded significant insight into the inner workings of 
this process (Figure 4.2).  Primary bile acids are transported into the bacterial cell by a proton-
dependent bile acid transporter encoded by the baiG gene (275).  Once inside the cell, the first 
step of BA7 of primary bile acids is their ligation to CoA in an ATP-dependent fashion (273, 
274, 276).  After CoA ligation, the C3-hydroxyl group undergoes oxidation via the baiA gene 
(278), which is specific for CoA conjugates.  Next, a C=C bond is formed between the fourth 
and fifth carbon by a NADH:flavin-dependent oxidoreductase encoded by the baiCD gene (262).  
The rate-limiting, non-reversible step of the reaction occurs next, the bile acid 7a-dehydration. 
The gene encoding the enzyme for the 7α-dehydratase is baiE (265), and the resulting bile acid 
products are 3-dehydro-Δ4,6-deoxycholyl-CoA or 3-dehydro-Δ4,6-lithocholyl-CoA, based on the 
starting metabolite (279).  The 3-dehydro-Δ4,6 bile acid intermediates then undergo three 
successive reductive steps leading to LCA or DCA.  The genes responsible for the production of 
these enzymes have yet to be determined.  Secondary bile acids are then exported from the cell, 
although the gene encoding the bile acid exporter has not yet been identified. 
 
Our lab recently reported the structure and catalytic mechanism of the rate-limiting enzyme, the 
bile acid 7α-dehydroxylase, encoded by the baiE gene, that converts 7α,12α-dihydroxy-5β-3- 
dehydro-chol-4-en-24-oic acid to 12α-dihydroxy-5β-3-dehydro-chol-4,6 dien-24-oic acid (279). 
The bile acid reaction product of the BaiE undergoes three reductions at C4- C5, C6-C7 and 
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Figure 4.1:  Schematic of 7α-dehydroxylation pathway in Clostridium scindens ATCC 
35704. 
 
This multi-step enzymatic process to remove the C7α-hydroxyl group contains an oxidative arm, 
an irreversible 7α-dehydration step, and a reductive arm that ultimately forms deoxycholic acid 
from cholic acid.  The enzymes that constitute the reductive arm of this pathway are currently 
unidentified, although a Δ4 and a Δ6 reduction are two of the three proposed reaction steps in the 
pathway.  
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finally the 3-oxo-group is converted to a 3α-hydroxy forming DCA, a major secondary bile acid 
produced in the vertebrate gut. Genes in the “oxidative” arm have been identified and 
characterized (113), while genes in the “reductive” arm have yet to be identified. Here, we report 
the identification and initial characterization of a recombinant flavoprotein involved in the 
metabolism of 3-dehydro-DCA. Our phylogenetic analysis identified this gene in other bile acid 
BA7 bacteria. Mass spectrometric analysis of the product revealed a loss of four atomic mass 
units (amu) suggesting the formation of two double bonds. We suggest likely end products 
generated by this novel enzyme.
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Results 
 
Previous work in our laboratory identified bile acid intermediates in the “reductive arm” of the 
bile acid pathway including a 3-oxo-4 and a 3-oxo-4,6-intermediate (143). We also showed that 
oxidation of 3-dehydro-CDCA (7α-hydroxy) and 3-dehydro-UDCA (7β-hydroxy) prior to bile 
acid 7α-dehydroxylation is catalyzed by stereo-specific NAD-dependent flavin oxidoreductases 
encoded by the baiCD and baiH genes, respectively (262). Therefore, we searched the annotated 
genome of C. scindens ATCC 35704 for “flavin oxidoreductase”. Our search identified 24 genes 
annotated as containing flavin-binding domains (Table 4.1). The BaiCD and BaiH proteins were 
identified in the search, previously demonstrated to oxidize the C4-C5 of primary bile acids prior 
to 7α-dehydration (262). One ORF in particular, EDS08212.1, was selected for further analysis. 
The deduced amino acid sequence is in the HpnE squalene-associated FAD-dependent 
desaturase domain family, an enzyme involved in the mammalian cholesterol biosynthesis 
pathway (Figure 4.2). Taken together, this suggests that EDS08212.1 is a flavoprotein similar to 
those that metabolize sterols and may be involved in bile acid metabolism.  
 
We overexpressed EDS08212.1 as a C-terminal streptavidin-tagged recombinant protein 
(rEDS08212) in E. coli BL21 (DE3) RIL. The predicted amino acid sequence is 44.5 kDa, and 
we observed a single band by SDS-PAGE after streptactin affinity chromatography at 46.5±2 
kDa (Figure 4.3). After binding crude E. coli extracts overexpressing rEDS08212.1 and washing 
with binding buffer (see Materials and Methods), we observed a bright yellow protein that eluted 
during the desthiobiotin elution step (Figure 4.3). The rEDS08212.1 was stable only for <12 hrs 
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Table 4.1:  Flavin reductases identified in the genome of Clostridium scindens ATCC 35704 
 
  
EDS06786.1 flavin reductase-like protein Pyridoxine 5'-phosphate oxidase-like and flavin reductase-like proteins 24.2 
EDS08212.1 flavoprotein family protein squalene-associated FAD-dependent desaturase 45.5 
EDS07700.1 flavin reductase-like protein NADH-FMN oxidoreductase RutF, flavin reductase(DIM6/NTAB) family 21.1 
EDS08305.1 flavin reductase Multimeric flavodoxin WrbA 28.7 
EDS06663.1 flavin reductase NAD(P)H dehydrogenase, quinone family 19.8 
EDS08737.1 pyridine nucleotide-disulfide oxidoreductase  Uncharacterized NAD(FAD)-dependent dehydrogenases 70.8 
EDS08749.1 rubredoxin rubredoxin 23.7 
EDS07050.1 Nitroreductase Nitro_FMN_reductase 20.3 
EDS06718.1 rubredoxin rubredoxin_SM 79 
EDS06682.1 
oxidoreductase, 2-nitropropane dioxygenase family 
protein Dioxygenases related to 2-nitropropane dioxygenase 38.4 
EDS05114.1 4Fe-4S binding domain protein NAD(P)H-flavin oxidoreductase 30.1 
EDS08567.1 Rubrerythrin rubredoxin_SM 23.4 
EDS08382.1 pyridine nucleotide-disulfide oxidoreductase Uncharacterized NAD(FAD)-dependent dehydrogenases 69.5 
EDS08369.1 nitroreductase family protein NAD(P)H-flavin oxidoreductase 21.7 
EDS07342.1 hypothetical protein NADH-FMN oxidoreductase RutF, flavin reductase(DIM6/NTAB) family 19.7 
EDS07048.1 hypothetical protein Nitroimidazol reductase NimA or a related FMN-containing flavoprotein 19.6 
EDS06690.1 putative enoyl-[acyl-carrier-protein] reductase II  Dioxygenases related to 2-nitropropane dioxygenase 33.2 
EDS06281.1 rubredoxin Rubrerythrin 19.8 
EDS06280.1 Rubrerythrin Rubrerythrin 22.2 
EDS06153.1 NADH oxidase OYE_like_FMN_family 70.1 
EDS05767.1 pyridine nucleotide-disulfide oxidoreductase (BaiCD) ADH oxidase (NoxB-2) 70.1 [13] 
EDS05762.1 pyridine nucleotide-disulfide oxidoreductase (BaiH) noxB-1; NADH oxidase 72 [13] 
WP_004604785.1 flavin reductase rubredoxin 23.6 
WP_039909174.1 2,4-dienoyl-CoA reductase OYE_like_FMN_family 72.5 
Table&1:&Flavin&Reductases&iden3ﬁed&in&the&genome&of&Clostridium+scindens&ATCC&35704&&
Accession 
Number Annotation  Regions/folds 
Deduced Mr 
(kDa) Reference 
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Figure 4.2:  Schematic representation of the reaction catalyzed by squalene-desaturase and 
the oxidation of 3-dehydro-4-DCA to 3-dehydro-DCA in the 7α-dehydroxylation pathway. 
 
A gene encoding a putative flavoprotein (EDS08212.1) in the FAD-dependent squalene-
desaturase family is hypothesized to be involved in the “reductive arm” of the bile acid 7α-
dehydroxylating pathway.  
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Figure 4.3:  Overexpression and purification of rEDS08212.1 from C. scindens ATCC 
35704 
 
 A: Lane “M” is the protein marker, lane “1” is the soluble crude extract (30 µg), lane “2” is the 
eluent following streptavidin affinity chromatography (2 µg). B: rEDS08212.1 bound to 
streptavidin column after thorough washing displaying distinctive yellow pigmentation.   
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after which visible precipitation was evident. Storage at -20°C in 50% glycerol did not improve 
solubility. 
 
We detected formation of a single product on TLC after incubation with rEDS08212.1 (0.5 µg) 
in the presence of 3-dehydro-DCA, but not DCA, at pH 7.0 (Figure 4.4). We did not observe 
formation of this product with heat-killed enzyme (70°C 1 min). This reaction occurred in the 
presence or absence of pyridine nucleotides (NAD+, NADH, NADP+, NADPH), suggesting that 
this reaction proceeds by bile acid-dependent flavin reduction followed by regeneration of FAD+ 
via chemical oxidation via molecular oxygen (data not shown).  
 
Next, the reaction substrate (Rf =0.78) and product (Rf =0.40) were scraped from the TLC plate, 
extracted from the silica gel by ethyl acetate, and dried under nitrogen gas for mass spectrometry 
analysis. The substrate had a retention time of 25 minutes and a major mass ion was detected in 
positive mode at 391.2878 m/z and 389.2559 m/z in negative mode, as predicted (Figure 4.5). 
The product retention time was 22.5 minutes with a major mass ion in positive mode of 387.1681 
m/z and 385.1739 m/z in negative mode. These data suggest that the substrate lost four atomic 
mass units (amu) and may potentially be involved in the metabolism of two carbon-carbon 
double bonds. This observation was repeated in three separate reactions and confirmed.  
 
In order to investigate the most likely origin of the C. scindens ATCC 35704 EDS08212.1 gene, 
we have performed a wide-scale maximum-likelihood phylogenetic analysis involving all protein 
sequences from the public databases displaying a reasonable level of similarity to the protein 
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Figure 4.4:  Autoradiograph of thin layer chromatography separation of rEDS08212.1 
reaction products from [24-14C] 3-dehydro-DCA. 
 
A. [24-14C] DCA TLC standard, B. [24-14C] 3-dehydro-DCA TLC standard, C. [24-14C] 3-
dehydro-DCA + rEDS08212.1 +150µM NAD+ , D. 3-dehydro-DCA + rEDS08212.1 + 150 µM 
NAD+ biological replicate, E. [24-14C] DCA standard, F. [24-14C] 3-dehydro-DCA + heat-killed 
rEDS08212.1, G. [24-14C] 3-dehydro-DCA + heat-killed rEDS08212.1 + 150 µM NAD+.  
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Figure 4.5:  LCMS-IT-TOF analysis of rEDS08212.1 reaction products. 
 
Substrate and product were separated from TLC, scraped and bile acids extracted from silica, 
concentrated and analyzed by LCMS. A. From top-bottom, UPLC profile with major peak 
identified at RT 25 minutes (substrate), Positive mode analysis of RT 25 minutes peak, Negative 
mode analysis of RT 25 minutes peak. B. From top-bottom, UPLC profile with major peak 
identified at RT 22.5 minutes (product), Positive mode analysis of RT 25 minutes peak, Negative 
mode analysis of RT 22.5 minutes peak.   
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characterized herein. Our final alignment involved 1,273 protein sequences from a diverse 
assemblage of bacterial groups, as well as some eukaryotic sequences. 
 
A previously determined sequence, from Clostridiales bacterium VE202-26 (280), is identical to 
the one for C. scindens VPI 12708, at the nucleotide as well as the amino acid level. Thus, as 
expected, they group in the tree with branch lengths of zero and bootstrap support of 100. The 
sequence for C. scindens ATCC 35704 clusters very closely to these two other sequences, also 
with the highest bootstrap support. The other Clostridium sequence nearest in the tree belongs to 
C. hylemonae DSM 15053, a bacterium previously shown to harbor the bai pathway (272). 
 
The EDS08212.1 gene and homologous genes from the strains analyzed here grouped deep 
within a large group of Firmicutes bacteria (Figure 4.6) and, as seen in Figure 4.6-B, group with 
a number of bacteria from the Lachnospiraceae and Ruminococcaceae families, as seen 
previously in a phylogenomic analysis of 20 single-copy protein-coding genes that were present 
in 99 Firmicutes genomes (217). Thus, the EDS08212.1 gene in C. scindens strains does not 
seem to have been derived from a horizontal gene transfer event, since its phylogeny agrees 
closely with the species phylogeny. 
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Figure 4.6:  Maximum likelihood phylogenic tree of EDS08212.1 from Clostridium scindens 
ATCC 35704. 
 
A. Wide-scale phylogeny (1,273 protein sequences). B. Details of the region of the tree 
containing EDS08212.1. Values on nodes represent bootstrap support (only 50 or higher shown).   
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Discussion: 
 
The conversion of primary to secondary bile acids such as DCA and LCA is implicated in 
diseases of the GI tract, including liver (179) and colorectal cancer (67, 281). The bile acid 7α-
dehydroxylation pathway has only been reported in a few species of intestinal clostridia, 
including C. scindens (113, 125). The genes encoding the enzymes for the oxidative half of the 
pathway have been delineated in numerous Clostridium species (113). However, the enzymes 
catalyzing the final three reductive reactions have not yet been identified (Figure 4.1).  
 
In the current study, we identified a likely candidate for the first two reductive steps following 
7α-dehydration. The gene encoding EDS08212.1 in C. scindens ATCC 35704 is predicted to 
encode a flavin-dependent squalene desaturase, a reaction that is analogous to the 
oxidation/reduction of secondary bile acids. We cloned and overexpressed rEDS08212.1 in E. 
coli and purified the enzyme to apparent electrophoretic homogeneity. The enzyme yielded a 
bright yellow color, indicative of flavin-binding. The enzyme was active against 3-dehydro-DCA 
but not DCA, suggesting specificity for the A-ring. We observed a loss of 4 amu from the 
substrate after purification of the reaction products by TLC and then UPLC-IT-TOF-MS. This 
suggests that two oxidations are occurring, strongly indicating the formation of the 3-dehydro-
4,6-DCA intermediate. Alternatively, the aerobic degradation of cholic acid to carbon dioxide by 
soil microorganisms, particularly by Comamonas testosteroni, results in the formation of a 3-
dehydro-1,4-intermediate, which also requires two oxidations (282).  
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Further work is underway to confirm the specific activity of EDS08212.1, although the lack of 
commercial availability of substrates makes this further characterization difficult. However, we 
are currently testing the utilization of 3-dehydro-Δ4,6-LCA by EDS08212.1 as a substrate for 
reduction under anaerobic conditions.  If EDS08212.1 is confirmed to make 3-dehydro-LCA 
from this substrate, it will confirm the enzyme acts on the Δ4,6 double bonds in bile acids 
formed during the 7α-dehydroxylation pathway.  Additionally, EDS08212.1 is being tested for 
its pyridine nucleotide specificity, as we predict that under anaerobic conditions, NADH would 
be required to reduce the bound FAD/FMN. 
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Chapter 5:  Clostridium scindens VPI 12708 RNAseq and 17α-HSDH gene discovery 
 
Introduction: 
 
Bile acids are not the only steroidal compounds excreted by the liver that undergo enterohepatic 
circulation.  Sharing the same four cycloalkane rings as bile acids, endogenously produced 
steroid hormones are conjugated to glucuronate or sulfate and then can be excreted into bile 
(283).  The levels of excreted steroid hormones in bile are higher in females, as estrogen 
secretion into bile is a major mechanism used to modulate host serum levels (284). Once inside 
the lumen of the intestines, conjugated steroid hormones are deconjugated via hydrolysis by both 
host epithelial and bacterial deconjugating enzymes, such as glucuronidases and sulfatases, and 
deconjugated hormones can then be reabsorbed or enter the large intestine (268).  Glucuronidase 
activity is found in some of the most abundant microbes in the gut microbiome, including 
Bacteroides species (285).  After deconjugation, most steroid hormones reenter the circulation 
where they are eventually permanently excreted in urine.  Studies have shown that treatment 
with broad-spectrum antibiotics increased fecal secretion of steroid hormones and decreased 
renal excretion, likely due to the lack of deconjugation and subsequently increased loss of steroid 
hormones in the feces (286). Interestingly, dietary changes such as increased fiber or decreased 
dietary fat have also been associated with increased fecal excretion and decreased levels of 
circulating androgenic steroid hormones (284).  Both increased fiber and a vegetarian diet low in 
fat have been shown to be associated with reduced fecal bacteria β-glucuronidase activity, which 
would results in a decreased reuptake of excreted steroid hormones (287, 288).   
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Once deconjugated, steroid hormones that escape reabsorption in the intestines, similarly to bile 
acids, become substrates for various bacterial biotransformations.  In the anaerobic environment 
of the large intestine, the majority of bacterial steroid conversions are hydrolytic and reductive in 
nature.  On C21 and C17 steroid hormones, the 4-ene-3-keto moiety can be reduced to either 
3α/β and 5α/β, leading to a variety of differing metabolites (289-291).  The reduction of this 
moiety generally leads to less biologically active molecules (268).  The majority of bacteria 
shown to have this activity are within the Clostridium genus. 
 
Other bacterial conversions target the side-chain of glucocorticoids (Figure 5.1).  As discussed 
previously, Eggerthella lenta has been shown to have 21-dehydroxylase activity (247, 248, 292).  
This bacterium is able to convert deoxycortisone to progesterone.   Other bacterial species within 
the genus Clostridia have been shown to have 17,20 desmolase activity capable of performing 
side-chain cleavage of glucocorticoids to form androgens.  A recent study identified a gene 
cluster in Clostridium scindens ATCC 35704 encoding the steroid-17,20-desmolase, which is 
inducible by cortisol (217).  In C. scindens, it was shown through RNAseq analysis that the 
17,20-desmolase may feed the two carbons released from cortisol into the pentose-phosphate 
pathway for cellular growth and maintenance (217). 
 
The product of 17,20-desmolase metabolism of cortisol, 11β-hydroxy-androstenedione, and 
endogenously produced androgens such as testosterone and its precursor androstenedione harbor 
a C17-hydroxyl group that can undergo bacterial metabolism in the colon. The C17-keto group 
of androstenedione and 11β-hydroxy-androstenedione can be reduced by Bacteroides fragilis to 
testosterone and 11β-hydroxy-testosterone, respectively (291).  Additionally, the same C17-keto
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Figure 5.1:  Biotransformations of cortisol by gut microbes. 
 
Cortisol can undergo numerous biotransformations.  Numerous strains of bacteria have been 
shown to 3α/β and 5α/β reduce the 4-ene-3-keto moiety of cortisol.  Clostridium scindens ATCC 
35704 has been shown to harbor 20α-HSDH activity on cortisol.  Eggerthella lenta has been 
shown to have 21-dehydroxylase activity on cortisol.  Clostridium scindens ATCC 35704 
encodes a 17,20 desmolase able to convert cortisol to 11β-hydroxy-androstenedione.  
Clostridium scindens VPI 12708 has been shown to have 17α-HSDH activity on C17 steroid 
molecules.  Bacteroides fragilis and, in this work, Eggerthella lenta has been shown to have 
17β-HSDH activity on C17 steroids.
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Adapted from (217)  
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group on androstenedione can be reduced to epitestosterone by Clostridium scindens VPI 12708 
(228).  Unpublished results from our lab have also shown that C. scindens VPI 12708 recognizes 
11β-hydroxy-androstenedione.  Since both of these bacterial strains are present in the colon, it is 
possible that strains would be able to epimerize the C17-hydroxyl group on these molecules, 
interconverting these molecules between androgenically active (testosterone) and inactive 
(epitestosterone) compounds.  The physiological purpose behind these biotransformation 
reactions is still unknown, but both interkingdom signaling and microbe-microbe signaling are 
valid hypotheses for why the enzymatic potential to interconvert these androgenic compounds 
persists in the colon. 
 
The androgenic steroid molecules that are excreted in bile, become unconjugated and substrates 
for further bacterial metabolism can be physiologically active on host tissue even at nanomolar 
concentrations.  This physiological activity can vary based on the presence, stereospecificity, and 
reductive state of the functional groups on the steroid core (293). It is important therefore to find 
the genes responsible for encoding enzymes that recognize androgens in the microbes that are 
known members of the gut microbiome.  Clostridium scindens VPI 12708 has been shown to 
have 17α-hydroxysteroid dehydrogenase activity, but the gene responsible for its production has 
never been found (de Prada 1994). Additionally, a very similar strain, Clostridium scindens 
ATCC 35704 was recently shown to metabolize endogenous steroid compounds, but not have 
17α-HSDH activity (217).  I therefore set out to locate the gene in Clostridium scindens VPI 
12708 responsible for the production of the 17α-HSDH enzyme. 
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Results: 
 
Previous work in Clostridium scindens VPI 12708 suggested that its 17α-hydroxysteroid 
dehydrogenase activity was inducible by androstenedione (228).  We therefore set out to confirm 
that C. scindens 12708 had androstenedione-inducible 17α-HSDH activity.  C. scindens VPI 
12708 was grown overnight and induced with 100µM androstenedione.  Overnight cultures were 
then centrifuged, the pellets washed with buffer, and then incubated with radiolabeled 11β-
hydroxy-androstenedione (11β-OHAD).  Results showed that over the course of two hours, 
androstenedione-induced C. scindens VPI 12708 generated reduced 11β-OHAD (Figure 5.2). 
Uninduced C. scindens VPI 12708 did not form a product from 11β-OHAD over the same time 
period (Figure 5.2).  This suggested that metabolism of androstenedione was an inducible trait in 
this bacterium. 
 
We also wanted to confirm that the product of androstenedione metabolism was epitestosterone, 
a 17α-reduced compound.  Overnight cultures of C. scindens VPI 12708 were inoculated with 
100µM androstenedione and allowed to grow overnight.  Cultures were then extracted with ethyl 
acetate and the resulting organic layer was concentrated and run on HPLC using a reverse-phase 
C18 column.  The formation of a secondary product was monitored at 240nm and fractionally 
collected (Figure 5.3).  This isolated metabolite of androstenedione was then sent for NMR 
analysis.  The resulting NMR structure confirmed that C. scindens VPI 12708 produced 
epitestosterone from androstenedione (Figure 5.4).
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Figure 5.2:  Clostridium scindens VPI 12708 exhibits inducible 17α-HSDH activity 
 
 
Clostridium scindens VPI 12708 was grown in the presence of 100µM androstenedione 
(induced) or without androstenedione (uninduced) overnight and then cells pelleted, washed, and 
exposed to fresh radiolabeled 11b-hydroxyl-androstenedione.  Conversion was tracked overtime 
with 1mL aliquots taken out and quenched with ethyl acetate.  Organic extracts were run on TLC 
and the formation of a secondary metabolite was visualized over time only in the induced whole 
cell samples.  
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Figure 5.3:  Clostridium scindens VPI 12708 produces a secondary metabolite from 
androstenedione that maintains the 4-ene-3-keto moiety 
 
Clostridium scindens VPI 12708 was grown overnight in 10mL BHI in the presence of 100mM 
androstenedione and then extracted with ethyl acetate.  20% of the total organic extract was run 
on HPLC to separate androstenedione from its metabolite.  Other than the injection peak, which 
is visible on all injections and corresponds with an influx of 100% methanol, the two peaks 
absorbing at 240nm correspond to the two steroids.   Androstenedione, based on control data, 
elutes around 30 minutes.  The secondary metabolite eluted at approximately 52 minutes.  This 
elution also matched that of commercially obtained epitestosterone.  The collected sample was 
subsequently sent for NMR analysis.  
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Figure 5.4:  NMR analysis of the Clostridium scindens VPI 12708 androstenedione 
metabolite confirms epitestosterone formation 
 
NMR analysis confirmed epitestosterone was being formed by Clostridium scindens VPI 12708. 
NMR analysis was performed on the fractionally collected C. scindens VPI 12708 
androstenedione metabolite (see Figure 5.3).  NMR analysis was performed as described 
previously (217).  Table on left denotes hydrogen positioning.  Table on right compares chemical 
shift, in ppm, as compared to two previous NMR spectrums of epitestosterone from literature 
(294, 295).  Both findings are congruent with the C. scindens VPI 12708 metabolite being 
identified as epitestosterone.  
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After confirming C. scindens VPI 12708 has inducible 17α-HSDH activity, we next set out to 
find the gene encoding the respective enzyme.  RNA-seq had been used previously to great effect 
in identifying the cortisol-induced 17,20 desmolase operon in a highly similar strain of 
Clostridium scindens (ATCC 35704) (217).  Therefore, we set out to use the same technique for 
the identifying the C. scindens VPI 12708 17α-HSDH. Additionally, RNAseq could be used 
simultaneously to study the changes in the overall transcriptome when certain steroid hormones 
and bile acids are present.  In this aim, C. scindens VPI 12708 cultures were grown to mid-log 
phase under varying inducing conditions, including cortisol, androstenedione, cholic acid, and 
allocholic acid.  The cells were pelleted and frozen at -80ºC and the supernatants were extracted 
and run on TLC to confirm substrate metabolism (data not shown).  Total RNA was then isolated 
from cell pellets following methods derived from Ridlon et al., including the enrichment of 
mRNA using custom designed biotinylated polynucleotides (217). rRNA depleted samples were 
used to generate libraries for sequencing using NEBNext Ultra RNA Library Prep Kit for 
Illumina and sequenced using the MiSeq 2 x 300 bp protocol.  Reads were then populated to a 
previously sequenced Clostridium scindens VPI 12708 genome (unpublished).  Results indicated 
that in the cholic acid-induced and allocholic acid-induced samples, the bile acid operon (bai-
operon) was significantly induced versus uninduced control (Table 5.1).  These results 
functioned as a positive internal control, showing the quality of the RNA in these samples was 
high enough to determine induction of various genes against uninduced controls.  Interestingly, 
although cortisol, androstenedione, cholic acid, and allocholic acid all share a similar steroidal 
backbone, their effects on the overall transcriptomic pattern in C. scindens VPI 12708 are 
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Table 5.1:  Induction of bile acid inducible operon in Clostridium scindens VPI 12708 by cholic acid (CA) and allocholic acid 
(ACA) 
 
  
Cholic acid-induced vs. uninduced “bai operon” Illumina MiSeq Reads 
locus 
Uninduced 
Reads CA-induced reads log2(fold_change) p_value q_value significant 
Cs12708_c00003_00018 8.28709 924.929 6.80233 0.0167 0.0894583 no 
Cs12708_c00003_00019 8.4592 1268.97 7.22892 0.0018 0.0176897 yes 
Cs12708_c00003_00020 0 1624.22 inf 5.00E-05 0.000844444 yes 
Cs12708_c00003_00021 12.077 1433.27 6.8909 0.0654 0.210908 no 
Cs12708_c00003_00022 12.5373 1431.1 6.83476 0.0167 0.0894583 no 
Cs12708_c00003_00024 8.97984 1240.13 7.10958 0.0167 0.0894583 no 
Cs12708_c00003_00026 12.2184 1535.93 6.97392 0.00025 0.00367742 yes 
Cs12708_c00003_00027 42.0197 2020.16 5.58726 0.0167 0.0894583 no 
Allocholic acid-induced vs. uninduced “bai operon” Illumina MiSeq Reads 
locus 
Uninduced 
Reads ACA-induced reads log2(fold_change) p_value q_value significant 
Cs12708_c00003_00018 8.31544 140.121 4.07474 0.0019 0.0156222 yes 
Cs12708_c00003_00019 8.48946 135.107 3.99229 0.00035 0.00390943 yes 
Cs12708_c00003_00020 0 174.78 inf 5.00E-05 0.000700592 yes 
Cs12708_c00003_00021 12.1164 109.976 3.18216 0.11395 0.283439 no 
Cs12708_c00003_00022 12.5816 132.8 3.39987 0.001 0.00935968 yes 
Cs12708_c00003_00024 9.01056 89.4478 3.31136 0.00625 0.0396766 yes 
Cs12708_c00003_00026 12.2606 119.024 3.27915 5.00E-05 0.000700592 yes 
Cs12708_c00003_00027 42.1566 133.286 1.6607 0.0541 0.17104 no 
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striking (Figure 5.5).  Cholic acid-induced C. scindens VPI 12708 transcriptomic pattern appears 
to cluster separately from allocholic, androstenedione, and cortisol induced transcriptomic 
patterns (Figure 5.5).  This observation is interesting, as the only difference between cholic acid 
and its epimer allocholic acid is the position of the hydrogen on the fifth carbon.  With hydrogen 
in the α-configuration, the steroid backbone of allocholic acid more closely resembles a planar 
steroid hormone than a bile acid.  Therefore, it appears that because of this change, C. scindens 
VPI 12708 responds to it more as a steroid hormone than a bile acid, although the bai-operon is 
still induced, although to a lower level than what is seen from cholic acid induction (Figure 5.4). 
 
From previous studies and unpublished data, we knew that the 17α-HSDH should have the 
following characteristics:  be annotated to be within the SDR family or alcohol polyol 
dehydrogenase family; encode a polypeptide sequence around 40kDa; be induced by 
androstenedione and cholic acid; should have a metal binding and pyridine nucleotide binding 
site; not be found in similar strain Clostridium scindens ATCC 35704 (de Prada 1994).  In 
contrast to the cholic acid-induced sample, there were not very many significantly induced genes 
in the androstenedione-induced sample (Table 5.2).  Putative genes that matched the 17α-HSDH 
criteria were chosen for further analysis (Table 5.3). 
 
Genes that were chosen based on the RNAseq analysis were successfully cloned into expression 
vectors, overexpressed in E. coli, purified, and tested for their 17α-HSDH activity.  Constructs 
were made with either a C- or N-terminal streptavidin tag for column purification, or no tag in 
the case of whole cell extract assays, and constructs were checked for nucleotide fidelity by 
sequencing.  Purified enzymes, whole cell extracts, and induced whole cell transformed E. coli
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Table 5.2:  Genes upregulated in Clostridium scindens VPI 12708 in response to 
androstenedione induction 
Locus	
Uninduced	
Reads	
Androstenedione	
induced	reads	
log2	(fold	
change)	 p	value	 q	value	 significant	
Cs12708_c00002
_00026:0-663	 225.526	 969.11	 2.10337	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00043
_00034:0-1050	 114.12	 391.381	 1.77803	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00073
_00017:0-1962	 180.598	 393.201	 1.12249	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00056
_00017:0-1014	 222.157	 460.616	 1.05198	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00163
_00001:0-657	 2456.39	 4786.56	 0.962446	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00001
_00068:0-1086	 211.009	 409.538	 0.956696	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00117
_00003:0-840	 641.622	 1184.81	 0.884863	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00060
_00011:0-888	 3375.83	 6031.37	 0.837242	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00002
_00029:0-543	 12527.7	 21981.3	 0.811153	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00064
_00002:0-2043	 354.865	 622.498	 0.810802	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00022
_00007:0-1275	 257.052	 449.644	 0.806724	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00005
_00015:0-1062	 442.204	 760.787	 0.782782	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00005
_00016:0-1014	 411.663	 705.56	 0.777307	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00005
_00013:0-759	 555.471	 951.575	 0.776607	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00065
_00020:0-1551	 628.777	 1056.69	 0.748936	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00119
_00005:0-1446	 273.459	 459.123	 0.747557	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00039
_00001:2-2760	 94.0148	 157.74	 0.746587	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00060
_00013:0-657	 603.456	 1004.75	 0.735521	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00038
_00001:0-1506	 2022.81	 3350.23	 0.727895	 5.00E-05	
0.0011
0607	 yes	
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Cs12708_c00214
_00001:0-555	 1403.85	 2300.25	 0.712406	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00043
_00033:0-1422	 242.143	 383.461	 0.663222	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00002
_00028:0-537	 5594.94	 8752.84	 0.645628	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00131
_00003:0-1344	 405.984	 628.224	 0.629855	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00060
_00010:0-771	 2460.73	 3740.22	 0.604038	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00144
_00011:0-627	 1277.69	 1914.51	 0.583437	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00146
_00003:0-1326	 766.735	 1145.99	 0.57979	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00007
_00064:0-2184	 1370.67	 2031.96	 0.567989	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00075
_00015:0-936	 717.297	 1050.21	 0.550039	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00001
_00016:0-1740	 886.114	 1295.91	 0.548396	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00103
_00014:0-2139	 1801.65	 2626.09	 0.543598	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00060
_00012:0-1533	 583.929	 850.414	 0.542371	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00202
_00002:0-1311	 661.761	 963.585	 0.542102	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00149
_00007:0-1335	 444.439	 643.149	 0.533168	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00195
_00007:0-828	 658.498	 936.879	 0.508683	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00076
_00015:0-1035	 5197.37	 7209.73	 0.472162	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00023
_00037:0-657	 4351.25	 5896.36	 0.438396	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00013
_00036:0-1314	 642.023	 860.493	 0.422539	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00059
_00020:0-375	 32471.2	 43056.3	 0.407062	 5.00E-05	
0.0011
0607	 yes	
Cs12708_c00114
_00009:0-768	 32.2213	 422.962	 3.71444	 0.0001	
0.0019
8908	 yes	
Cs12708_c00194
_00002:0-489	 233.608	 598.168	 1.35646	 0.00015	
0.0027
9567	 yes	
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Cs12708_c00064
_00017:0-1359	 44.4706	 112.038	 1.33307	 0.00015	
0.0027
9567	 yes	
Cs12708_c00008
_00038:0-396	 1091.75	 1948.95	 0.836058	 0.0002	
0.0035
594	 yes	
Cs12708_c00058
_00001:0-492	 271.411	 517.127	 0.93004	 0.0031	
0.0320
424	 yes	
Cs12708_c00166
_00003:0-786	 124.227	 229.998	 0.888637	 0.00405	
0.0389
689	 yes	
Cs12708_c00151
_00009:0-924	 101.621	 182.081	 0.841384	 0.00405	
0.0389
689	 yes	
Cs12708_c00022
_00038:0-501	 199.674	 412.743	 1.0476	 0.00465	
0.0435
042	 yes	
Cs12708_c00081
_00005:0-624	 83.9893	 208.062	 1.30874	 0.00495	
0.0457
682	 yes	
Cs12708_c00005
_00027:0-1767	 26.5059	 55.6576	 1.07027	 0.005	
0.0460
506	 yes	
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Figure 5.5:  Overall transcriptomic heatmap of Clostridium scindens VPI 12708 induced 
with numerous bile acid and steroid molecules 
 
C. scindens VPI 12708 was grown in the presence of 50µM cortisol, androstenedione, allocholic 
acid, or cholic acid.  mRNA was isolated, purified, and then sequenced for each sample.  
RNAseq results were used to generate heat maps of induction using a distance metric of 1-
(abs(pearson correlation)).  Results show that the C. scindens VPI 12708 transcriptomic pattern 
in response to cortisol, androstenedione, and allocholic acid cluster together and separately from 
the cholic acid induced transcriptomic pattern. 
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Table 5.3:  Putative 17α-HSDH genes from Clostridium scindens VPI 12708 screened for activity 
 
Locus Annotation 
based on blastp 
results 
Size Presence 
in 35704 
strain 
Metal 
binding 
site 
NAD(P) 
binding site 
Induction by 
androstene-
dione 
Induction by 
cholic acid 
17α-
HSDH 
activity 
Other information 
of interest 
Cs12708
_00064_
00018 
Glycerol 
dehydrogenase 
39.1 
kDa 
No Yes Yes Yes Yes No Part of operon, 
including 
membrane-
spanning protein, 
that is upregulated 
by androstenedione 
and cholic acid 
Cs12708
_00005_
00084 
“Old yellow 
enzyme”, 
NADH flavin 
oxidoreductase 
70.5 
kDa 
No Not 
annotated 
Yes Yes No No Alignment with 
previously 
characterized 12708 
baiCD (262) shows 
conservation of 
catalytically 
necessary cysteine 
residues 
Cs12708
_00124_
00009 
Short chain 
dehydrogenase
/reductase 
(SDR) 
31.3 
kDa 
No Not 
annotated 
Yes Yes No No Has bacterial 3α-
HSDH conserved 
domain (via NCBI 
protein blast, 
ascension = 
cd05328) 
Cs12708
_00114_
00009 
Short chain 
dehydrogenase
/reductase 
(SDR) 
27.6 
kDa 
No Not 
annotated 
Yes Yes No No  
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cultures were tested for 17α-HSDH activity.  Assays were performed both aerobically and 
anaerobically (under N2 stream). Reduction of androstenedione or oxidation of epitestosterone 
was measured spectrophotometrically for the change in NAD+/NADH oxidation state or via 
organic extraction and HPLC separation of products.  Under all these experimental conditions, 
none of the tested enzymes exhibited 17α-HSDH activity.  At this point, there were no more 
candidate genes left from the RNAseq analysis. 
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Discussion: 
 
Gaining a better understanding of our gut microbiome’s ability to metabolize numerous 
endogenous and exogenous molecules to secondary molecules of varying physiological 
relevance is an important area of study.  Bacterial bile acid and steroid metabolites have been 
shown on numerous occasions to have important physiological effects on the host.  Finding the 
genes responsible for the production of genes that encode steroid/bile acid metabolizing enzymes 
is important in order to get a better understanding of why microbes utilize these substrates in 
vivo. Of equal importance, as the era of “personalized medicine” approaches, it is becoming 
more important to be able to predict metabolic potential of an individual’s gut microbiome as it 
may pertain to other pathophysiological disorders.  In this aim, it is important to have more a 
more robust understanding of specific enzymes in the “sterolbiome”, as it makes predictive 
annotation and therefore the prediction of an individual’s gut microbiome’s “metabolic 
potential” more accurate.  Therefore, we set out to find the gene in Clostridium scindens VPI 
12708 responsible for the synthesis of a 17α-HSDH enzyme able to interconvert 
androstenedione and epitestosterone.  In concert with other bacteria known to have 17β-activity 
such as B. fragilis (291), this would allow the gut microbiota to interconvert active testosterone 
to anti-antrogenic epitestosterone, and vice versa.   
 
We were able to confirm that C. scindens VPI 12708 has inducible 17α-HSDH activity, able to 
convert androstenedione to epitestosterone in vitro.  We performed RNAseq analysis on 
differentially induced C. scindens VPI 12708 samples and showed interesting differences in 
whole transcriptomic changes under these varying conditions.  After finding candidate genes, we 
 206 
tested them for their 17α-HSDH activity using numerous experimental conditions.  Ultimately 
the gene responsible for the production of the C. scindens VPI 12708 17α-HSDH was not found.   
 
There are numerous potential explanations for this outcome.  One explanation is that the C. 
scindens VPI 12708 genomic data used as reference for the RNAseq data was not a closed 
genome.  Therefore, if the gene for the 17α-HSDH was not sequenced in the genomic 
sequencing, it would not have been identified through RNAseq analysis. Alternatively, it is 
possible that any of the putative 17α-HSDH purified enzymes lost activity at some stage in their 
production or purification.  However, we took every precaution to prevent this including using 
various expression vectors, confirming fidelity of the inserts, confirming production of protein, 
testing whole cell extracts and transformed cell cultures for activity, testing enzymes activity 
aerobically and anaerobically using two separate metrics for screening, and testing both the 
oxidation of epitestosterone and reduction of androstenedione.  
 
It is possible that in producing these Clostridial proteins in a different genus (Escherichia) that 
an additional component, such as differing molecular chaperones, are necessary for the proper 
maturation of the 17α-HSDH.  A way of getting around this difficulty would be to knock out 
genes of interest directly in C. scindens.  Unfortunately, a mechanism for directly knocking out 
genes in Clostridium scindens has not been developed, however not for a lack of effort.  Most 
recently, work on developing a Crispr-Cas9 knockout system in Clostridium scindens is 
underway in a collaborating lab.  Such a system in Clostridium scindens would be a huge 
accomplishment and widely utilized.  The production of secondary bile acids by Clostridium 
scindens have been differentially implicated to be associated with CRC (67, 281) as well as with 
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protection against post-antibiotic Clostridium difficile infection (209).  If one was able to knock 
out the bai-operon responsible for producing secondary bile acids in Clostridium scindens, the 
contributions of secondary bile acids to these disease processes could be more accurately 
determined. 
 
Until either more cost-effective means of screening transcriptomic data for prokaryotes or a 
genetic knockout system for Clostridium scindens is developed, the gene encoding 17α-HSDH 
will continue to elude us.  A future direction may be to screen other fecal isolates for 17α-HSDH 
activity on androstenedione and then comparing the genomic data to more accurately search for a 
putative gene.  This experiment would be interesting, as the prevalence of microbial 17α-HSDH 
activity in human fecal samples is unknown.   
 
The work on identifying the 17α-HSDH gene in C. scindens VPI 12708 did provide some 
interesting results.  It showed how differently C. scindens VPI 12708 recognizes steroid 
compounds with the same steroidal backbone.  Additionally, based on the clustering of heat 
maps of the four treatment groups, C. scindens VPI 12708 appears to recognize cholic acid 
differently from allocholic acid, androstenedione, and cortisol (Figure 5.4).  Since allocholic acid 
is a 5α-epimer of cholic acid, these results suggest that the planar orientation of the A ring on the 
steroid backbone on these molecules is an important regulator of its molecular function.  To 
make better use of this data, I recommend the resequencing of C. scindens VPI 12708 genome 
using more up to date annotation techniques.  That way, the transcriptomic data from the 
RNAseq analysis we performed can give more insight into how these steroid molecules impact 
the overall cell metabolism.  Additionally, it could test one of the possible reasons for the 
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inability to identify the 17α-HSDH gene.  Ultimately, this work gives interesting preliminary 
data for future studies, as well as a list of genes not to screen for 17α-HSDH activity in 
subsequent studies. 
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Chapter 6:  Summary and Perspectives 
 
The human gut microbiome is a diverse ecosystem of microbial organisms that inhabit our 
gastrointestinal tract.  The concentration of living cells, approximately 1011/g feces, is of the 
highest density found in nature.  The study of the human gut microbiome has undergone a 
renaissance in the past decade with the advent of next-generation sequencing techniques (2).  
High-throughput analysis of the constituents of the gut microbiome has given significant insights 
into human health and changed how we study the general makeup of the gut microbiome.  
Changes to certain characteristics of the gut microbiome, such as the quantities of specific 
bacterial species or changes in the presence and levels of microbial-derived metabolites, have 
been associated with a wide range of pathophysiological conditions.  Obesity (226, 256, 296), 
cardiovascular disease (297), hypertension (242, 252), inflammatory bowel disease (66, 84), 
colorectal cancer (67, 281), liver cancer (179), cirrhosis (298, 299), and post-antibiotic C. 
difficile infection (209) have all been associated with changes to the gut microbiome or the 
various metabolites it produces.  There are, however, limitations to the conclusions we can draw 
from 16S, COG, and KEGG DNA and transcriptomic analysis.  16S screens of fecal bacteria do 
not delineate differences that may exist within different strains of the same species.  The 
reference genomes that guide the predictive annotation for shotgun sequencing, such as COG and 
KEGG, account for only a third of all genomic data that is obtained (227).   
 
This problem is evident when looking at specific aspects of gut microbial metabolism such as the 
“sterolbiome”, or the prokaryotic genes that encode enzymes metabolizing bile acids within the 
gut microbiome.  Numerous bacterial strains within the Firmicutes and Actinobacteria phyla, two 
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of the three most prevalent phyla present in the GI tract, encode enzymes responsible for 
biotransformations of both bile acids and other steroid molecules.  A small subset of bacteria 
within the Clostridium genus have been shown to have genes encoding enzymes in a multi-step 
7α-dehydroxylation pathway, making them capable of turning endogenously produced primary 
bile acids CA and CDCA into secondary bile acids DCA and LCA, respectively (113).  
Production of secondary bile acids have been reported to be qualitatively the most common 
bioconversion of bile acids in the colon, as the majority of primary bile acids that escape 
enterohepatic circulation end up 7α-dehydroxylated in the large intestine (133). The genes 
encoding enzymes in the oxidative arm of the 7α-dehydroxylation pathway have been 
characterized in numerous Clostridium species (113).  However, the genes encoding the enzymes 
for the three successive reductive steps have not been identified.  In the current study, evidence is 
presented that the Clostridium scindens ATCC 35704 gene EDS08212.1 encodes a Δ4,6 
reductase that catalyzes the two reductive steps immediately following 7α-dehydration.  This 
gene is closely related to genes found in other 7α-dehydroxylating strains.  It is unique in its 
ability to catalyze two reductive reactions on both the A and B ring of bile acids (both the C4=C5 
and C6=C7 bonds).  Ultimately this work helps to further characterize a very important 
biochemical pathway within the “sterolbiome” and will ultimately serve to help us better 
understand the entirety of the 7α-dehydroxylation pathway. 
 
While 7α-dehydroxylation of primary bile acids is the most studied bacterial bile acid metabolic 
pathway, other biotransformations do occur.  One such set of reactions is the oxidation and 
epimerization of bile acid hydroxyl groups.  Oxidation of the α-hydroxyl groups on the 3rd, 7th, 
and 12th carbon of bile acids leads to the formation of an oxo-moiety.  Microbial oxidation of 
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bile acids occurs regularly in the large intestine, as previous analysis of fecal samples and portal 
circulation show the accumulation of oxo-bile acids to varying degrees (158-163, 165, 267)  
 
Once epimerized, these oxo-bile acids can undergo further biotransformations.  They can be 
reduced back to an α-configuration by bacterial or host hepatic α−HSDHs.  Alternatively, they 
can be epimerized to the β-configuration.  Numerous gut-associated microbes have been shown 
to harbor bile acid C3- and C7-hydroxyl-β-HSDHs (146, 150, 157).  Epimerized bile acids have 
been shown to be less toxic to other gut microbes that inhabit the large intestine (150).  As such, 
if an individual harbors gut microbes that can epimerize bile acids, the makeup of their gut 
microbiome may be different from an individual who does not, although that has not been 
experimentally proven.  Additionally, epimerized bile acids pose a problem for bacteria that 
otherwise utilize primary bile acids.  These 7α-dehydroxylating bacteria were not induced to 7α-
dehydroxylate primary bile acids by ursodeoxycholic acid, although they are capable of 7β-
dehydroxylation if induced by 7α-bile acids (261).  Additionally, urosdeoxycholic acid has been 
shown to inhibit the germination and vegetative growth of Clostridium difficile spores and be 
protective against recurrent infection (216).  It is clear that the epimerization of bile acids forms 
less toxic secondary metabolites.  However, the role of oxo-bile acids, the “intermediate” 
molecule in this process, is less well characterized. 
 
In the current study, we show evidence that 7α-dehydroxylation can be inhibited by the 
formation of oxo-bile acid derivatives.  Clostridium scindens VPI 12708 (12708) was unable to 
effectively 7α-dehydroxylate the three CDCA metabolites produced by E. lenta C592.  Two of 
the metabolites (7-oxo-3α-hydroxy-CDCA and 3,7-dioxo-CDCA) were partially reduced back to 
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CDCA, although 7α-dehydroxylation did not occur to the same extent as fully reduced CDCA.  
Additionally, the 7-oxo-3β-hydroxy-CDCA metabolite was reduced by C. scindens VPI 12708 
back to isoCDCA, but was not 7α-dehydroxylated. Taken together, this shows that C. scindens 
VPI 12708 does not recognize isoCDCA as a substrate for 7α-dehydroxylation, possibly due to 
the absence of a 3β-HSDH.  Additionally, the oxidation of hydroxyl groups appears to inhibit the 
7α-dehydroxylation of primary bile acids, even if C. scindens is able to reduce the oxo-bile acid 
metabolites back to the original primary bile acid.  One potential explanation for these findings is 
that oxo-bile acids do not induce the “bai” operon, similar to ursodeoxycholic acid (261).  
Therefore, in the C. scindens VPI 12708 oxo-bile acid metabolism analysis, the oxo-bile acids 
are reduced but 7α-dehydroxylated products do not form because they require induction of the 
bai operon. Further experimentation should be done to test C. scindens “bai” gene expression via 
qPCR when induced with the various oxo-bile acid derivatives made by C592.   
 
In coculture experiments, E. lenta C592 and C. scindens 12708 appear to cycle CDCA back and 
forth between 7α-CDCA and 7-oxo-CDCA, but LCA does not appear to accumulate. This 
experiment gives insight into what might happen if both C. scindens 12708 and E. lenta C592 
were in the large intestine under low H2 partial pressure and suggests a mechanism by which 
secondary bile acid formation may be inhibited in vivo by another member of the gut 
microbiome (Figure 6.1). Future experimentation on this point is warranted.  In vivo experiments 
of humanized mice (mice designed to have a humanized gut microbiome), could be designed to 
include supplementation with E. lenta strains to see if secondary bile acid formation is inhibited.  
Additionally, the effect of diet, such as the supplementation of complex carbohydrates that could 
lead to an excess of H2 gas in the colon and thus inhibit E. lenta bile acid metabolism, could be  
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Figure 6.1:  Model of Eggerthella lenta C592 bile acid metabolism in vivo. 
 
 
In the lumen of the large intestine, both Clostridium scindens and Eggerthella lenta would be 
competing for the same pool of primary bile acids.  C. scindens preferentially 7α-dehydroxylates 
primary bile acids to secondary bile acids.  At the same time, E. lenta would be competing for 
the same primary bile acids to use as electron donors.  These oxidized bile acids would be 
reduced by C. scindens back to primary bile acids, leading to a cycle of oxidation-reduction 
between the two strains.  This cycle would inhibit the build up of secondary bile acids in the 
colon.  However, the ability for E. lenta to oxidize bile acids would be dependent on the 
availability of H2 gas.  The availability of H2 gas in the lumen of the colon is dependent on two 
factors; the rate of production via anaerobic fermentation and the rate of utilization by H2 
utilizers.  Other gut microbial H2 utilizers, sulfidogens and methanogens, have higher affinity to 
H2 than acetogens.  Therefore if sulfidogens or methanogens were present and their preferred 
substrates for reduction were available, the amount of H2 for utilization by E. lenta would be 
low.  With a paucity of available H2, E. lenta would use bile acids as electron donors, leading to 
the formation of oxo-bile acids.  Alternatively, if H2 production outpaces the H2 utilization or if 
methanogenesis and sulfidogenesis are not occurring, E. lenta would switch to utilizing H2 as an 
electron donor and cease to oxidize bile acids.  This would allow C. scindens to properly 7α-
dehydroxylate primary bile acids, leading to an accumulation of secondary bile acids.   
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tested in this model.  Within this framework, other strains could be added as well, such as 
hydrogen sulfide gas producing bacteria (both with and without sulfate substrates) or 
methanogens, to see if their presence with E. lenta impacts the formation of secondary bile acids.  
Given the in vitro data generated in this work, it would be expected that E. lenta might inhibit 
7α-dehydroxylation by C. scindens strains and that excess H2 formation could counteract this 
inhibition.  However, given recent studies showing that secondary bile acids are directly linked 
to resistance against post-antibiotic CDI, the question arises as to whether limiting the formation 
of secondary bile acids should be viewed as a therapeutic target. 
 
Recent literature has suggested that C. scindens, specifically the formation of secondary bile 
acids, is protective against post-AB CDI in both human patients and animal models (209).  
However, little data is available showing a mechanism linking secondary bile acids to the 
inhibition of either C. difficile spore germination or vegetative growth.  Perhaps the most 
promising link is the study identifying the C. difficile germination receptor CspC is specifically 
activated by 12α-hydroxyl bile acids (214).  Work presented in this study shows that the 
12α−hydroxyl group on DCA is oxidized during E. lenta C592 DCA metabolism.  Future 
experimentation should look to the effects that 12-oxo-DCA has on both C. difficile growth and 
spore germination, as well as its ability to be recognized by the CspC receptor.   
 
The effects these oxo-bile acid metabolites have are not limited to other members of the gut 
microbiome.  Host tissues are significantly affected by numerous bacterial metabolites, 
particularly bile acids.  Oxo-bile acid derivatives have been shown to have varying effects, 
although they have not been thoroughly tested as well as their fully reduced counterparts.  7-oxo-
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CDCA, coincidentally a major product of E. lenta C592 CDCA metabolism, has been shown 
previously to be a competitive inhibitor for hepatic 11β−HSDH1 (198, 199).  This inhibition 
prevents effective reduction of inactive cortisone to cortisol.  The extent to which this inhibition 
affects overall host physiology has not been tested.  Additionally, bile acids are known to 
activate host G-protein coupled and nuclear receptors to varying extents based on the regio and 
stereo positioning of the functional groups attached to their steroid cores and side chains.  3-oxo-
LCA, the most likely product of E. lenta C592 LCA metabolism, has been shown to be the most 
potent vitamin D receptor agonist (175).  Additionally, 7-oxo-CDCA and 3,7-oxo-CDCA have 
both been shown to be less potent agonists for FXR than their α-reduced counterparts, but more 
potent than β-reduced epimers (167).  Oxo-bile acids, therefore, already have an established role 
in host physiology unique from their α- and β-reduced sister molecules.  However, the full 
spectrum of primary and secondary oxo-bile acid derivatives has not been tested for agonist 
properties on various bile acid-sensitive receptors.  Of particular interest would be to determine 
oxo-bile acids’ ability to activate TGR-5, as this is implicated in significantly altering host 
metabolism.  Previous literature has suggested C. scindens is associated with increased hepatic 
triglyceride levels (258), which is a downstream effect of secondary bile acid activation of TGR-
5 (173). Secondary bile acids DCA and LCA are the most potent activators of TGR-5 (170).  E. 
lenta was also shown to be associated with increased hepatic triglyceride levels (258), but they 
do not perform 7α-dehydroxylation. Therefore, this suggests that oxo-bile acid derivatives made 
by E. lenta are performing similar activities to secondary bile acids, potentially through the 
activation of TGR-5. 
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Epimerized bile acids, such as ursodeoxycholic acid, have been shown to be less toxic to 
colonocytes (254, 255).  The toxicity of oxo-bile acid derivatives has not been studied, but would 
likely be different from fully reduced bile acids.  Previous studies have shown that varying the 
configuration of hydroxyl groups on bile acids directly affects their hydrophobicity (254), which 
is a major contributor to bile acid toxicity.  However, the hydrophobicity of oxo-bile acid 
derivatives has not been assessed. 
 
The formation of oxo-bile acids by E. lenta strains could have many effects, both to other gut 
microbes and to various host tissues.  The extent of these effects have yet to be fully elucidated, 
likely owing to the fact that oxo-bile acids have been seen as intermediates in the epimerization 
of bile acids.  However recent published studies, as well as the work presented here, suggest that 
oxo-bile acids could be key actors in modulating host and gut microbial physiology.  Evidence 
has been presented that E. lenta strains share many qualities with acetogens, and how bile acid 
oxidation play into their whole cell redox balancing and energy production.  Additionally, our 
studies show that atmospheric gases play a key role in determining the extent of E. lenta bile acid 
metabolism.  Both the E. lenta strains and oxo-bile acids warrant further exploration as possible 
therapeutic agents.  However, this comes with a warning, since recent studies have suggested an 
important role of secondary bile acids in the prevention of CDI.  Therefore, it is important to 
acquire a better understanding of the mechanism by which secondary bile acids prevent CDI 
before suggesting for their diminution in patients.  Ultimately, this work makes a case for E. 
lenta strains to be considered acetogens, for the formation of oxo-bile acids as a means to 
prevent 7α-dehydroxylation, and serves as a baseline to direct future study of oxo-bile acid 
formation in vivo.  
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